"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,A1,US 2021/0253216 A1,070-052-956-881-732,2021-08-19,2021,US 202117178161 A,2021-02-17,US 202117178161 A;;US 202029732741 F;;US 202062977638 P,2020-02-17,Hands-Free Kayak Steering System,"A hands-free kayak steering system is a system that enables users to maneuver small watercrafts without requiring physical steering by the user. The system may include a bridging base, a first maneuvering mechanism, a second maneuvering mechanism, a user controller, and a portable power source. The bridging base supports the user controller for the user to steer the watercraft using the feet. The first maneuvering mechanism and the second maneuvering mechanism enable the system to adjust to fit on the watercraft. In addition, the first maneuvering mechanism and the second maneuvering mechanism generate thrust to propel the watercraft in the desired direction. The user controller enables the user to selectively engage the first maneuvering mechanism and the second maneuvering mechanism to steer the watercraft in the desired direction. Finally, the portable power source provides the voltage necessary to power both the first maneuvering mechanism and the second maneuvering mechanism.",COVINGTON CHRISTOPHER,COVINGTON CHRISTOPHER,,https://lens.org/070-052-956-881-732,Patent Application,yes,3,1,2,2,0,B63B34/26;;B63B34/05;;B63H25/02;;B63H2025/465;;B63H25/48;;B63B34/10;;B63H5/125;;B63B2209/00;;B63H21/17;;B63B79/10;;B63B79/40;;B63H25/02,B63H25/48;;B63B34/10;;B63B79/10;;B63B79/40;;B63H5/125;;B63H21/17;;B63H25/02,,0,0,,,,ACTIVE
2,US,B2,US 11827330 B2,066-108-231-394-764,2023-11-28,2023,US 202117178161 A,2021-02-17,US 202117178161 A;;US 202029732741 F;;US 202062977638 P,2020-02-17,Hands-free kayak steering system,"A hands-free kayak steering system is a system that enables users to maneuver small watercrafts without requiring physical steering by the user. The system may include a bridging base, a first maneuvering mechanism, a second maneuvering mechanism, a user controller, and a portable power source. The bridging base supports the user controller for the user to steer the watercraft using the feet. The first maneuvering mechanism and the second maneuvering mechanism enable the system to adjust to fit on the watercraft. In addition, the first maneuvering mechanism and the second maneuvering mechanism generate thrust to propel the watercraft in the desired direction. The user controller enables the user to selectively engage the first maneuvering mechanism and the second maneuvering mechanism to steer the watercraft in the desired direction. Finally, the portable power source provides the voltage necessary to power both the first maneuvering mechanism and the second maneuvering mechanism.",COVINGTON CHRISTOPHER,COVINGTON CHRISTOPHER,,https://lens.org/066-108-231-394-764,Granted Patent,yes,9,0,2,2,0,B63B34/26;;B63B34/05;;B63H25/02;;B63H2025/465;;B63H25/48;;B63B34/10;;B63H5/125;;B63B2209/00;;B63H21/17;;B63B79/10;;B63B79/40;;B63H25/02,B63H25/48;;B63B34/10;;B63B79/10;;B63B79/40;;B63H5/125;;B63H21/17;;B63H25/02,,0,0,,,,ACTIVE
3,BR,B1,BR 102013027355 B1,085-687-101-736-648,2022-03-22,2022,BR 102013027355 A,2013-10-24,US 201213661971 A,2012-10-26,Aparelho e processo para exibir um meio físico virtual,"sistema de exibição de realidade virtual. a presente invenção refere-se a um processo e um aparelho para exibir um meio físico virtual (204). as informações de posição do primeiro olho (226) para um primeiro olho (234), em um computador (236) de uma pessoa (206), e as informações de posição do segundo olho (228) para um segundo olho (240), na cabeça (236) da pessoa (206), são recebidas. uma primeira imagem (252) do meio físico virtual (204) para o primeiro olho (234) é gerada com base nas informações de posição do primeiro olho (22). uma segunda imagem (254) do meio físico virtual (204) para o segundo olho (240) é gerada com base nas informações de posição do segundo olho (228) para o segundo olho (240). a primeira imagem (252) e a segunda imagem (254), para exibição, são enviadas para a pessoa (206).",BOEING CO,CHRISTOPHER LEONARD COVINGTON,,https://lens.org/085-687-101-736-648,Granted Patent,no,0,0,19,19,0,G06F3/013;;G06F3/012;;G02B27/017;;G02B2027/0134;;G02B27/0093;;G02B5/30;;G02B2027/0138;;G02B2027/014;;G02B2027/0187;;H04N13/344;;H04N13/144;;H04N13/366;;G06F3/011;;G02B27/01;;G02B30/00;;G16Z99/00;;G06T13/00;;G09G5/00;;G06F3/013;;G02B2027/0134;;G02B27/017;;G02B27/0093;;G02B2027/0138;;G02B2027/014;;G06F3/012;;G02B5/30;;G02B2027/0187;;H04N13/344;;H04N13/144;;H04N13/366;;G06F3/011,G06F3/14;;G06T19/00,,0,0,,,,ACTIVE
4,US,A1,US 2017/0107708 A1,154-947-977-596-546,2017-04-20,2017,US 201615294216 A,2016-10-14,US 201615294216 A;;US 201562241377 P,2015-10-14,PROTECTOR,"The present disclosure includes a protector configured to cooperate with a toilet having a bowl with an upper surface and a seat that can be selectively raised and lowered. The protector includes a body and a flange member extending outwardly from the body. The flange member is configured to removeably cooperate with the upper surface of the bowl and the upper surface of the seat depending on whether the seat is raise or lowered. The distal portion of the body of the protector is disposed below the flange member while the proximal portion of the body extends generally upwardly above the flange member. In addition, the distal portion of the body is configured to extend into a bowl of a toilet while the flange member rests on the upper surface of the bowl or the upper surface of the seat.",COVINGTON CHRISTOPHER ALLEN,COVINGTON CHRISTOPHER ALLEN,,https://lens.org/154-947-977-596-546,Patent Application,yes,6,1,1,1,0,A47K13/02;;A47K13/14;;E03D9/00;;A47K13/02;;A47K13/14,E03D9/00;;A47K13/02;;A47K13/14,,0,0,,,,DISCONTINUED
5,JP,A,JP 2014086091 A,054-446-799-515-561,2014-05-12,2014,JP 2013221877 A,2013-10-25,US 201213661971 A,2012-10-26,VIRTUAL REALITY DISPLAY SYSTEM,PROBLEM TO BE SOLVED: To provide a method and apparatus for displaying a virtual environment.SOLUTION: First eye position information 226 for a first eye 234 in a head 236 of a person 206 and second eye position information 228 for a second eye 240 in the head 236 of the person 206 are received. A first image 252 of the virtual environment 204 to be shown to the first eye 234 is generated based on the first eye position information 226. A second image 254 of the virtual environment 204 to be shown to the second eye 240 is generated based on the second eye position information 228 for the second eye 240. The first image 252 and the second image 254 for display are sent to the person 206.,BOEING CO,CHRISTOPHER LEONARD COVINGTON,,https://lens.org/054-446-799-515-561,Patent Application,no,4,5,19,19,0,G06F3/013;;G06F3/012;;G02B27/017;;G02B2027/0134;;G02B27/0093;;G02B5/30;;G02B2027/0138;;G02B2027/014;;G02B2027/0187;;H04N13/344;;H04N13/144;;H04N13/366;;G06F3/011;;G02B27/01;;G02B30/00;;G16Z99/00;;G06T13/00;;G09G5/00;;G06F3/013;;G02B2027/0134;;G02B27/017;;G02B27/0093;;G02B2027/0138;;G02B2027/014;;G06F3/012;;G02B5/30;;G02B2027/0187;;H04N13/344;;H04N13/144;;H04N13/366;;G06F3/011,G06T19/00;;G06F3/048;;G06F3/14;;H04N5/64;;H04N13/04,,1,0,,,"鈴木 耕: ""遠隔作業支援用立体映像システムの開発 −表示立体映像への運動視差付加−"", 映像情報メディア学会技術報告 ＶＯＬ．３０ ＮＯ．５２, vol. IDY2006-85, HI2006-125 (Oct.2006), JPN6017023452, 18 October 2006 (2006-10-18), JP, pages 13 - 16, ISSN: 0003586024",ACTIVE
6,BR,A2,BR 102013027355 A2,153-546-670-319-823,2014-10-21,2014,BR 102013027355 A,2013-10-24,US 201213661971 A,2012-10-26,SISTEMA DE EXIBIÇÃO DE REALIDADE VIRTUAL,"RESUMO Patente de Invenção: ""SISTEMA DE EXIBIÇÃO DE REALIDADE VIRTUAL"". A presente invenção refere-se a um processo e um aparelho para exibir um meio físico virtual (204). As informações de posição do primeiro olho (226) para um primeiro olho (234), em um computador (236) de uma pessoa (206), e as informações de posição do segundo olho (228) para um segundo olho (240), na cabeça (236) da pessoa (206), são recebidas. Uma primeira imagem (252) do meio físico virtual (204) para o primeiro olho (234) é gerada com base nas informações de posição do primeiro olho (22). Uma segunda imagem (254) do meio físico virtual (204) para o segundo olho (240) é gerada com base nas informações de posição do segundo olho (228) para o segundo olho (240). A primeira imagem (252) e a segunda imagem (254), para exibição, são enviadas para a pessoa (206).",BOEING CO,COVINGTON CHRISTOPHER LEONARD,,https://lens.org/153-546-670-319-823,Patent Application,no,0,0,19,19,0,G06F3/013;;G06F3/012;;G02B27/017;;G02B2027/0134;;G02B27/0093;;G02B5/30;;G02B2027/0138;;G02B2027/014;;G02B2027/0187;;H04N13/344;;H04N13/144;;H04N13/366;;G06F3/011;;G02B27/01;;G02B30/00;;G16Z99/00;;G06T13/00;;G09G5/00;;G06F3/013;;G02B2027/0134;;G02B27/017;;G02B27/0093;;G02B2027/0138;;G02B2027/014;;G06F3/012;;G02B5/30;;G02B2027/0187;;H04N13/344;;H04N13/144;;H04N13/366;;G06F3/011,G06T19/00;;G06F3/14,,0,0,,,,ACTIVE
7,AU,A1,AU 2013/224653 A1,064-350-639-041-500,2014-05-15,2014,AU 2013/224653 A,2013-09-04,US 201213661971 A,2012-10-26,Virtual reality display system,VIRTUAL REALITY DISPLAY SYSTEM A method and apparatus for displaying a virtual environment (204). First eye position information (226) for a first eye (234) in a head (236) of a person (206) and second eye position information (228) for a second eye (240) in the head (236) of the person (206) is received. A first image (252) of the virtual environment (204) for the first eye (234) is generated based on the first eye position information (226). A second image (254) of the virtual environment (204) for the second eye (240) is generated based on the second eye position information (228) for the second eye (240). The first image (252) and the second image (254) for display are sent to the person (206).,BOEING CO,COVINGTON CHRISTOPHER LEONARD,,https://lens.org/064-350-639-041-500,Patent Application,no,0,0,19,19,0,G06F3/013;;G06F3/012;;G02B27/017;;G02B2027/0134;;G02B27/0093;;G02B5/30;;G02B2027/0138;;G02B2027/014;;G02B2027/0187;;H04N13/344;;H04N13/144;;H04N13/366;;G06F3/011;;G02B27/01;;G02B30/00;;G16Z99/00;;G06T13/00;;G09G5/00;;G06F3/013;;G02B2027/0134;;G02B27/017;;G02B27/0093;;G02B2027/0138;;G02B2027/014;;G06F3/012;;G02B5/30;;G02B2027/0187;;H04N13/344;;H04N13/144;;H04N13/366;;G06F3/011,G06T13/00;;G06F15/00;;H04N13/04,,0,0,,,,ACTIVE
8,CN,A,CN 103793049 A,089-231-088-752-706,2014-05-14,2014,CN 201310516866 A,2013-10-28,US 201213661971 A,2012-10-26,Virtual reality display system,The present invention relates to a virtual reality display system. A method and apparatus for displaying a virtual environment (204) is provided. First eye position information (226) for a first eye (234) in a head (236) of a person (206) and second eye position information (228) for a second eye (240) in the head (236) of the person (206) is received. A first image (252) of the virtual environment (204) for the first eye (234) is generated based on the first eye position information (226). A second image (254) of the virtual environment (204) for the second eye (240) is generated based on the second eye position information (228) for the second eye (240). The first image (252) and the second image (254) for display are sent to the person (206).,BOEING CO,COVINGTON CHRISTOPHER LEONARD,,https://lens.org/089-231-088-752-706,Patent Application,no,4,13,19,19,0,G06F3/013;;G06F3/012;;G02B27/017;;G02B2027/0134;;G02B27/0093;;G02B5/30;;G02B2027/0138;;G02B2027/014;;G02B2027/0187;;H04N13/344;;H04N13/144;;H04N13/366;;G06F3/011;;G02B27/01;;G02B30/00;;G16Z99/00;;G06T13/00;;G09G5/00;;G06F3/013;;G02B2027/0134;;G02B27/017;;G02B27/0093;;G02B2027/0138;;G02B2027/014;;G06F3/012;;G02B5/30;;G02B2027/0187;;H04N13/344;;H04N13/144;;H04N13/366;;G06F3/011,G06F3/01,,0,0,,,,ACTIVE
9,KR,A,KR 20140053765 A,111-099-320-527-053,2014-05-08,2014,KR 20130114282 A,2013-09-26,US 201213661971 A,2012-10-26,VIRTUAL REALITY DISPLAY SYSTEM,A method and an apparatus for displaying a virtual environment (204) are provided. A first eye position information (226) for a first eye (234) in a head (236) of a person (206) and a second eye position information (228) for a second eye (240) in the head (236) of the person (206) are received. A first image (252) in the virtual environment (205) for the first eye (234) is generated based on the first eye position information (226). A second image (254) of the virtual environment (204) for the second eye (240) is generated based on the second eye position information (228) for the second eye (240). The first image (252) and the second image (254) for display are transmitted to the person (206).,BOEING CO,CHRISTOPHER LEONARD COVINGTON,,https://lens.org/111-099-320-527-053,Patent Application,no,1,1,19,19,0,G06F3/013;;G06F3/012;;G02B27/017;;G02B2027/0134;;G02B27/0093;;G02B5/30;;G02B2027/0138;;G02B2027/014;;G02B2027/0187;;H04N13/344;;H04N13/144;;H04N13/366;;G06F3/011;;G02B27/01;;G02B30/00;;G16Z99/00;;G06T13/00;;G09G5/00;;G06F3/013;;G02B2027/0134;;G02B27/017;;G02B27/0093;;G02B2027/0138;;G02B2027/014;;G06F3/012;;G02B5/30;;G02B2027/0187;;H04N13/344;;H04N13/144;;H04N13/366;;G06F3/011,H04N13/04;;G02B27/01;;G02B27/22,,0,0,,,,ACTIVE
10,US,A1,US 2014/0118357 A1,123-617-761-142-59X,2014-05-01,2014,US 201213661971 A,2012-10-26,US 201213661971 A,2012-10-26,Virtual Reality Display System,A method and apparatus for displaying a virtual environment. First eye position information for a first eye in a head of a person and second eye position information for a second eye in the head of the person is received. A first image of the virtual environment for the first eye is generated based on the first eye position information. A second image of the virtual environment for the second eye is generated based on the second eye position information for the second eye. The first image and the second image for display are sent to the person.,BOEING CO;;BOEING CO,COVINGTON CHRISTOPHER LEONARD,THE BOEING COMPANY (2012-10-26),https://lens.org/123-617-761-142-59X,Patent Application,yes,2,31,19,19,0,G06F3/013;;G06F3/012;;G02B27/017;;G02B2027/0134;;G02B27/0093;;G02B5/30;;G02B2027/0138;;G02B2027/014;;G02B2027/0187;;H04N13/344;;H04N13/144;;H04N13/366;;G06F3/011;;G02B27/01;;G02B30/00;;G16Z99/00;;G06T13/00;;G09G5/00;;G06F3/013;;G02B2027/0134;;G02B27/017;;G02B27/0093;;G02B2027/0138;;G02B2027/014;;G06F3/012;;G02B5/30;;G02B2027/0187;;H04N13/344;;H04N13/144;;H04N13/366;;G06F3/011,G06T13/00;;G09G5/00,345/473;;345/8,0,0,,,,ACTIVE
11,EP,A3,EP 2725457 A3,038-918-001-256-728,2016-08-17,2016,EP 13189587 A,2013-10-21,US 201213661971 A,2012-10-26,Virtual reality display system,"A method and apparatus for displaying a virtual environment (204). First eye position information (226) for a first eye (234) in a head (236) of a person (206) and second eye position information (228) for a second eye (240) in the head (236) of the person (206) is received. A first image (252) of the virtual environment (204) for the first eye (234) is generated based on the first eye position information (226). A second image (254) of the virtual environment (204) for the second eye (240) is generated based on the second eye position information (228) for the second eye (240). The first image (252) and the second image (254) for display are sent to the person (206).
",BOEING CO,COVINGTON CHRISTOPHER LEONARD,,https://lens.org/038-918-001-256-728,Search Report,yes,3,0,19,19,0,G06F3/013;;G06F3/012;;G02B27/017;;G02B2027/0134;;G02B27/0093;;G02B5/30;;G02B2027/0138;;G02B2027/014;;G02B2027/0187;;H04N13/344;;H04N13/144;;H04N13/366;;G06F3/011;;G02B27/01;;G02B30/00;;G16Z99/00;;G06T13/00;;G09G5/00;;G06F3/013;;G02B2027/0134;;G02B27/017;;G02B27/0093;;G02B2027/0138;;G02B2027/014;;G06F3/012;;G02B5/30;;G02B2027/0187;;H04N13/344;;H04N13/144;;H04N13/366;;G06F3/011,G06F3/01;;G02B27/00;;G02B27/01;;H04N13/00,,0,0,,,,ACTIVE
12,AU,B2,AU 2013/224653 B2,049-144-713-644-780,2019-05-02,2019,AU 2013/224653 A,2013-09-04,US 201213661971 A,2012-10-26,Virtual reality display system,VIRTUAL REALITY DISPLAY SYSTEM A method and apparatus for displaying a virtual environment (204). First eye position information (226) for a first eye (234) in a head (236) of a person (206) and second eye position information (228) for a second eye (240) in the head (236) of the person (206) is received. A first image (252) of the virtual environment (204) for the first eye (234) is generated based on the first eye position information (226). A second image (254) of the virtual environment (204) for the second eye (240) is generated based on the second eye position information (228) for the second eye (240). The first image (252) and the second image (254) for display are sent to the person (206).,BOEING CO,COVINGTON CHRISTOPHER LEONARD,,https://lens.org/049-144-713-644-780,Granted Patent,no,2,0,19,19,0,G06F3/013;;G06F3/012;;G02B27/017;;G02B2027/0134;;G02B27/0093;;G02B5/30;;G02B2027/0138;;G02B2027/014;;G02B2027/0187;;H04N13/344;;H04N13/144;;H04N13/366;;G06F3/011;;G02B27/01;;G02B30/00;;G16Z99/00;;G06T13/00;;G09G5/00;;G06F3/013;;G02B2027/0134;;G02B27/017;;G02B27/0093;;G02B2027/0138;;G02B2027/014;;G06F3/012;;G02B5/30;;G02B2027/0187;;H04N13/344;;H04N13/144;;H04N13/366;;G06F3/011,G06T13/00;;G06F15/00,,2,1,005-519-248-057-493,10.1109/tbme.2005.863952;;16761839,"MORIMOTO, C. et al., 'Detecting Eye Position and Gaze from a Single Camera and 2 Light Sources', International Conference on Pattern Recognition, IEEE, August, 2002.;;GUESTRIN, E. et al., 'General Theory of Remote Gaze Estimation Using the Pupil Center and Corneal Reflections', IEEE Transactions on biomedical engineering, IEEE, 2006, Vol. 53, No. 6, pages 1124-1133.",ACTIVE
13,EP,B1,EP 2725457 B1,101-710-782-304-007,2019-07-03,2019,EP 13189587 A,2013-10-21,US 201213661971 A,2012-10-26,Virtual reality display system,,BOEING CO,COVINGTON CHRISTOPHER LEONARD,,https://lens.org/101-710-782-304-007,Granted Patent,yes,3,1,19,19,0,G06F3/013;;G06F3/012;;G02B27/017;;G02B2027/0134;;G02B27/0093;;G02B5/30;;G02B2027/0138;;G02B2027/014;;G02B2027/0187;;H04N13/344;;H04N13/144;;H04N13/366;;G06F3/011;;G02B27/01;;G02B30/00;;G16Z99/00;;G06T13/00;;G09G5/00;;G06F3/013;;G02B2027/0134;;G02B27/017;;G02B27/0093;;G02B2027/0138;;G02B2027/014;;G06F3/012;;G02B5/30;;G02B2027/0187;;H04N13/344;;H04N13/144;;H04N13/366;;G06F3/011,G02B5/30;;G06F3/01;;G02B27/00;;G02B27/01;;H04N13/144;;H04N13/344;;H04N13/366,,0,0,,,,ACTIVE
14,EP,A2,EP 2725457 A2,162-005-274-936-760,2014-04-30,2014,EP 13189587 A,2013-10-21,US 201213661971 A,2012-10-26,Virtual reality display system,"A method and apparatus for displaying a virtual environment (204). First eye position information (226) for a first eye (234) in a head (236) of a person (206) and second eye position information (228) for a second eye (240) in the head (236) of the person (206) is received. A first image (252) of the virtual environment (204) for the first eye (234) is generated based on the first eye position information (226). A second image (254) of the virtual environment (204) for the second eye (240) is generated based on the second eye position information (228) for the second eye (240). The first image (252) and the second image (254) for display are sent to the person (206).
",BOEING CO,COVINGTON CHRISTOPHER LEONARD,,https://lens.org/162-005-274-936-760,Patent Application,yes,0,1,19,19,0,G06F3/013;;G06F3/012;;G02B27/017;;G02B2027/0134;;G02B27/0093;;G02B5/30;;G02B2027/0138;;G02B2027/014;;G02B2027/0187;;H04N13/344;;H04N13/144;;H04N13/366;;G06F3/011;;G02B27/01;;G02B30/00;;G16Z99/00;;G06T13/00;;G09G5/00;;G06F3/013;;G02B2027/0134;;G02B27/017;;G02B27/0093;;G02B2027/0138;;G02B2027/014;;G06F3/012;;G02B5/30;;G02B2027/0187;;H04N13/344;;H04N13/144;;H04N13/366;;G06F3/011,G06F3/01;;G02B27/00;;G02B27/01;;H04N13/00,,0,0,,,,ACTIVE
15,US,S,US D0852337 S,016-158-776-542-490,2019-06-25,2019,US 201629576348 F,2016-09-01,US 201629576348 F,2016-09-01,Protector,,COVINGTON CHRISTOPHER ALLEN,COVINGTON CHRISTOPHER ALLEN,,https://lens.org/016-158-776-542-490,Design Right,no,17,2,1,1,0,,,2302;;D23/310,1,0,,,"Website: www.pottytrainingconcepts.com; The Splatter Shield Easily Converts Toilet to Urinal for Boys; Mar. 21, 2016.",ACTIVE
16,CA,A1,CA 2825563 A1,072-722-680-065-517,2014-04-26,2014,CA 2825563 A,2013-08-28,US 201213661971 A,2012-10-26,VIRTUAL REALITY DISPLAY SYSTEM,A method and apparatus for displaying a virtual environment. First eye position information for a first eye in a head of a person and second eye position information for a second eye in the head of the person is received. A first image of the virtual environment for the first eye is generated based on the first eye position information. A second image of the virtual environment for the second eye is generated based on the second eye position information for the second eye. The first image and the second image for display are sent to the person.,BOEING CO,COVINGTON CHRISTOPHER LEONARD,,https://lens.org/072-722-680-065-517,Patent Application,no,0,0,19,19,0,G06F3/013;;G06F3/012;;G02B27/017;;G02B2027/0134;;G02B27/0093;;G02B5/30;;G02B2027/0138;;G02B2027/014;;G02B2027/0187;;H04N13/344;;H04N13/144;;H04N13/366;;G06F3/011;;G02B27/01;;G02B30/00;;G16Z99/00;;G06T13/00;;G09G5/00;;G06F3/013;;G02B2027/0134;;G02B27/017;;G02B27/0093;;G02B2027/0138;;G02B2027/014;;G06F3/012;;G02B5/30;;G02B2027/0187;;H04N13/344;;H04N13/144;;H04N13/366;;G06F3/011,H04N13/04;;G02B27/01,,0,0,,,,ACTIVE
17,CA,C,CA 2825563 C,196-478-810-024-09X,2017-03-21,2017,CA 2825563 A,2013-08-28,US 201213661971 A,2012-10-26,VIRTUAL REALITY DISPLAY SYSTEM,A method and apparatus for displaying a virtual environment. First eye position information for a first eye in a head of a person and second eye position information for a second eye in the head of the person is received. A first image of the virtual environment for the first eye is generated based on the first eye position information. A second image of the virtual environment for the second eye is generated based on the second eye position information for the second eye. The first image and the second image for display are sent to the person.,BOEING CO,COVINGTON CHRISTOPHER LEONARD,,https://lens.org/196-478-810-024-09X,Granted Patent,no,0,0,19,19,0,G06F3/013;;G06F3/012;;G02B27/017;;G02B2027/0134;;G02B27/0093;;G02B5/30;;G02B2027/0138;;G02B2027/014;;G02B2027/0187;;H04N13/344;;H04N13/144;;H04N13/366;;G06F3/011;;G02B27/01;;G02B30/00;;G16Z99/00;;G06T13/00;;G09G5/00;;G06F3/013;;G02B2027/0134;;G02B27/017;;G02B27/0093;;G02B2027/0138;;G02B2027/014;;G06F3/012;;G02B5/30;;G02B2027/0187;;H04N13/344;;H04N13/144;;H04N13/366;;G06F3/011,H04N13/04;;G02B27/01,,0,0,,,,ACTIVE
18,US,B2,US 9058053 B2,164-253-040-717-878,2015-06-16,2015,US 201213661971 A,2012-10-26,US 201213661971 A,2012-10-26,Virtual reality display system,A method and apparatus for displaying a virtual environment. First eye position information for a first eye in a head of a person and second eye position information for a second eye in the head of the person is received. A first image of the virtual environment for the first eye is generated based on the first eye position information. A second image of the virtual environment for the second eye is generated based on the second eye position information for the second eye. The first image and the second image for display are sent to the person.,BOEING CO,COVINGTON CHRISTOPHER LEONARD,THE BOEING COMPANY (2012-10-26),https://lens.org/164-253-040-717-878,Granted Patent,yes,4,16,19,19,0,G06F3/013;;G06F3/012;;G02B27/017;;G02B2027/0134;;G02B27/0093;;G02B5/30;;G02B2027/0138;;G02B2027/014;;G02B2027/0187;;H04N13/344;;H04N13/144;;H04N13/366;;G06F3/011;;G02B27/01;;G02B30/00;;G16Z99/00;;G06T13/00;;G09G5/00;;G06F3/013;;G02B2027/0134;;G02B27/017;;G02B27/0093;;G02B2027/0138;;G02B2027/014;;G06F3/012;;G02B5/30;;G02B2027/0187;;H04N13/344;;H04N13/144;;H04N13/366;;G06F3/011,G06T15/00;;G06F3/01,,0,0,,,,ACTIVE
19,US,B2,US 10348885 B2,019-577-371-777-465,2019-07-09,2019,US 201715798266 A,2017-10-30,US 201715798266 A;;US 201662414776 P,2016-10-30,Method and apparatus for limiting portable device functionality,"The present disclosure relates generally to a system and method of reducing driver distractions from a portable device. More specifically, the present disclosure provides a driver communication safety system of limiting portable device functionality within a vehicle for safety purposes. According to the present disclosure, a proximity beacon may be placed within a vehicle and paired with a portable device, wherein the pairing may allow the driver communication safety system to control select applications and block access during predefined threshold activity, such as a threshold vehicle speed. In some embodiments, an administrator may control functionality of one or more portable devices used by a driver within a calibrated shielded zone of a vehicle.",COVINGTON JR JAMES MICHAEL;;COVINGTON CHRISTOPHER DILLON,COVINGTON JR JAMES MICHAEL;;COVINGTON CHRISTOPHER DILLON,,https://lens.org/019-577-371-777-465,Granted Patent,yes,9,0,2,2,0,H04L67/12;;H04W4/023;;H04L67/306;;H04M1/72463;;H04L67/52;;H04W4/023;;H04L67/306;;H04W76/14;;H04L67/12;;H04M1/72463;;H04L67/52,H04M3/00;;H04L29/08;;H04M1/72463;;H04W4/02;;H04W76/14,,0,0,,,,ACTIVE
20,US,A1,US 2018/0124234 A1,079-668-034-963-822,2018-05-03,2018,US 201715798266 A,2017-10-30,US 201715798266 A;;US 201662414776 P,2016-10-30,Method and Apparatus For Limiting Portable Device Functionality,"The present disclosure relates generally to a system and method of reducing driver distractions from a portable device. More specifically, the present disclosure provides a driver communication safety system of limiting portable device functionality within a vehicle for safety purposes. According to the present disclosure, a proximity beacon may be placed within a vehicle and paired with a portable device, wherein the pairing may allow the driver communication safety system to control select applications and block access during predefined threshold activity, such as a threshold vehicle speed. In some embodiments, an administrator may control functionality of one or more portable devices used by a driver within a calibrated shielded zone of a vehicle.",COVINGTON JR JAMES MICHAEL;;COVINGTON CHRISTOPHER DILLON,COVINGTON JR JAMES MICHAEL;;COVINGTON CHRISTOPHER DILLON,,https://lens.org/079-668-034-963-822,Patent Application,yes,0,6,2,2,0,H04L67/12;;H04W4/023;;H04L67/306;;H04M1/72463;;H04L67/52;;H04W4/023;;H04L67/306;;H04W76/14;;H04L67/12;;H04M1/72463;;H04L67/52,H04M1/72463,,0,0,,,,ACTIVE
21,PE,A1,PE 20070522 A1,161-445-888-871-538,2007-07-11,2007,PE 2006001112 A,2006-09-13,US 71756005 P;;US 74728006 P,2005-09-14,"2-[6-(3-AMINO-PIPERIDIN-1-IL)-3-METIL-2,4-DIOXO-3,4-DIHIDRO-2H-PIRIMIDIN-1-ILMETIL]-4-FLUORO-BENZONITRILO COMO INHIBIDOR DE DIPEPTIDIL PEPTIDASA Y COMPOSICIONES FARMACEUTICAS QUE LO CONTIENEN","REFERIDA AL COMPUESTO 2-[6-(3-AMINO-PIPERIDIN-1-IL)-3-METIL-2,4-DIOXO-3,4-DIHIDRO-2H-PIRIMIDIN-1-ILMETIL]-4-FLUORO-BENZONITRILO (COMPUESTO I) Y A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE AL COMPUESTO I, DONDE DICHA COMPOSICION PUEDE CONTENER OTROS COMPUESTOS ANTIDIABETICOS TALES COMO TIAZILIDINDIONAS, ENTRE ELLAS, 5-{[4-(3-(5-METIL-2-FENIL-4-OXAZOLIL)-1-OXO-PROPIL)-FENIL]-METIL}-TIAZOLIDIN-2,4-DIONA Y 5-[4-(1-FENIL-1-CILCOPROPANCARBONILAMIN)-BENCIL]-TIAZOLIDIN-2,4-DIONA; SULFONILUREAS, GLIBURIDA, TOLBUTAMIDA, TOLCICLAMIDA, ENTRE OTROS. EL COMPUESTO I ES UTIL EN EL TRATAMIENTO DE AFECCIONES MEDIADAS POR LA DIPEPTIDIL PEPTIDASA IV TAL COMO DIABETES, PARTICULARMENTE, DIABETES TIPO II, DISLIPIDEMIA DIABETICA, ACIDOSIS METABOLICA, OBESIDAD, ENTRE OTRAS",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD;;COVINGTON PAUL,,https://lens.org/161-445-888-871-538,Patent Application,no,0,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K31/44;;A61K31/513;;A61P3/10,,0,0,,,,DISCONTINUED
22,ES,T3,ES 2445180 T3,187-166-944-672-683,2014-02-28,2014,ES 06803523 T,2006-09-13,US 71755805 P;;US 74727306 P;;US 2006/0035708 W,2005-09-14,Administración de inhibidores de dipeptidil peptidasa,"Una composición farmacéutica formulada en una forma de dosis única en la que tal forma de dosis únicacomprende entre 5 mg y 250 mg del compuesto I, en la que el compuesto I tiene la fórmula con la excepción de las siguientes composiciones: (a) una composición farmacéutica formulada para administración por vía oral que comprende 10 a 100 mg delcompuesto I, 105 mg de ácido cítrico monohidratado, 18 mg de hidróxido sódico, un aroma y agua hasta 100 ml; y(b) una composición farmacéutica formulada para administración intravenosa que comprende 5 a 10 mg delcompuesto I, 1,05 mg de ácido cítrico monohidratado, 0,18 mg de hidróxido sódico, una cantidad suficiente dedextrosa monohidratada para hacer la formulación isotónica y agua hasta 1 ml.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD;;COVINGTON PAUL,,https://lens.org/187-166-944-672-683,Granted Patent,no,0,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;A61K31/131;;C07D209/12;;A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/44;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
23,AT,T1,AT E532518 T1,049-461-618-334-628,2011-11-15,2011,AT 06803649 T,2006-09-13,US 71756005 P;;US 74728006 P;;US 2006/0035958 W,2005-09-14,DIPEPTIDYL-PEPTIDASE-HEMMER ZUR BEHANDLUNG VON DIABETES,,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD;;COVINGTON PAUL,,https://lens.org/049-461-618-334-628,Granted Patent,no,0,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,,,0,0,,,,ACTIVE
24,CL,A1,CL 2007002649 A1,117-209-564-608-821,2008-04-11,2008,CL 2007002649 A,2007-09-12,US 2006/0035958 W;;US 89462807 P,2006-09-13,"COMPOSICION FARMACEUTICA QUE COMPRENDE 2-[6-(3-AMINO-PIPERIDIN-1-IL)-3-METIL-2,4-DIOXO-3,4-DIHIDRO-2H-PIRIMIDIN-1-ILMETIL]-4-FLUORO-BENZONITRILO; Y USO PARA EL TRATAMIENTO DE LA DIABETES.",,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J COVINGTON,,https://lens.org/117-209-564-608-821,Patent Application,no,0,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61K31/513;;A61P3/10,,0,0,,,,PENDING
25,ES,T3,ES 2376351 T3,075-104-670-397-754,2012-03-13,2012,ES 06803649 T,2006-09-13,US 71756005 P;;US 74728006 P;;US 2006/0035958 W,2005-09-14,INHIBIDORES DE LA DIPEPTIDIL-PEPTIDASA PARA EL TRATAMIENTO DE LA DIABETES.,"Composición farmacéutica formulada en una forma de dosificación unitaria en la que dicha forma de dosificación unitaria comprende entre 1 mg y 250 mg del compuesto I, en la que el compuesto I presenta la fórmula: **Fórmula**",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD;;COVINGTON PAUL,,https://lens.org/075-104-670-397-754,Granted Patent,no,0,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K31/513;;A61P3/10,,0,0,,,,ACTIVE
26,CN,A,CN 1783072 A,113-218-310-846-263,2006-06-07,2006,CN 200510088515 A,2005-07-29,US 95686604 A,2004-09-30,Easy-to-use data context filtering,,MICROSOFT CORP,BRYANT CHRISTOPHER W COVINGTON,MICROSOFT TECHNOLOGY LICENSING LLC (2015-05-04),https://lens.org/113-218-310-846-263,Patent Application,no,0,3,9,9,0,G06F16/2428;;G06F9/06;;G06F16/2428;;Y10S707/99933;;Y10S707/99934,G06F3/0482;;G06F17/30,,0,0,,,,INACTIVE
27,CN,B,CN 102908350 B,033-354-186-382-372,2014-07-23,2014,CN 201210398616 A,2006-09-13,US 71755805 P;;US 74727306 P,2005-09-14,Dipeptidyl peptidase inhibitors for treating diabetes,,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/033-354-186-382-372,Granted Patent,no,0,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;A61K31/335;;C07D209/12;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
28,NO,B1,NO 340910 B1,072-599-397-137-035,2017-07-10,2017,NO 20081592 A,2008-03-31,US 71756005 P;;US 74728006 P;;US 2006/0035958 W,2005-09-14,"Farmasøytiske sammensetninger, fremstilt artikkel og anvendelse av de farmasøytiske sammensetninger",,TAKEDA PHARMACEUTICALS CO,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/072-599-397-137-035,Granted Patent,no,2,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K31/513,,0,0,,,,ACTIVE
29,US,A1,US 2018/0140589 A1,103-365-966-175-156,2018-05-24,2018,US 201715721342 A,2017-09-29,US 201715721342 A;;US 201414280942 A;;US 201113080434 A;;US 53149506 A;;US 74727306 P;;US 71755805 P,2005-09-14,ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS,"Pharmaceutical compositions comprising 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and pharmaceutically acceptable salts thereof in combination with metformin and in combination with pioglitazone.",TAKEDA PHARMACEUTICALS CO,CHRISTOPHER RONALD J;;COVINGTON PAUL,TAKEDA SAN DIEGO INC (2006-11-02);;TAKEDA PHARMACEUTICAL COMPANY LIMITED (2006-11-09);;DEVELOPMENT PARTNERS LLC (2006-11-02),https://lens.org/103-365-966-175-156,Patent Application,yes,0,0,72,76,1,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/4439;;A61K31/131;;C07D209/12;;A61K31/155;;A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/44;;A61K31/513;;A61K31/535;;A61K31/5377;;A61K45/06;;A61P3/00;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,2,0,,,"Burkey WO2006/047248 with an international filing date of October 21, 2005 and priority data US provisional application no 60/621,891 filed on October 25, 2004;;Feng WO2005/095381 A1 with an international filing date December 15, 2004 and priority to 60/553,571 filed on March 15, 2004",DISCONTINUED
30,AU,C1,AU 2006/290908 C1,129-382-785-809-293,2014-04-03,2014,AU 2006/290908 A,2006-09-13,US 74727306 P;;US 71755805 P;;US 2006/0035708 W,2005-09-14,Dipeptidyl peptidase inhibitors for treating diabetes,"Pharmaceutical compositions comprising 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.",TAKEDA PHARMACEUTICALS CO,COVINGTON PAUL;;CHRISTOPHER RONALD J,,https://lens.org/129-382-785-809-293,Amended Patent,no,1,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;C07D209/12;;A61K31/131;;A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/44;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
31,DK,T4,DK 1942898 T4,146-160-557-361-784,2014-06-02,2014,DK 06803649 T,2006-09-13,US 71756005 P;;US 74728006 P;;US 2006/0035958 W,2005-09-14,Dipeptidylpeptidase-inhibitorer til behandling af diabetes,,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/146-160-557-361-784,Amended Patent,no,0,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K31/513;;A61P3/10,,0,0,,,,ACTIVE
32,UA,C2,UA 93689 C2,028-086-673-384-19X,2011-03-10,2011,UA A200804056 A,2006-09-13,US 71756005 P,2005-09-14,ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS,"Pharmaceutical compositions comprising 2-[6 (3-Amino-piperidin-l-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions. The compositions may be used for the treatment of diabetes.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/028-086-673-384-19X,Limited Patent,no,0,0,3,57,0,,A61K31/513;;A61K31/44;;A61P3/10,,0,0,,,,EXPIRED
33,CN,B,CN 101309689 B,061-163-122-103-702,2012-10-10,2012,CN 200680042417 A,2006-09-13,US 71755805 P;;US 2006/0035708 W;;US 74727306 P,2005-09-14,Dipeptidyl peptidase inhibitors for treating diabetes,"Pharmaceutical compositions comprising 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.",TAKAEDA CHEMICAL IND LTD,CHRISTOPHER RONALD J;;PAUL COVINGTON,,https://lens.org/061-163-122-103-702,Granted Patent,no,0,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;A61K31/131;;C07D209/12;;A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/44;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
34,SI,T2,SI 1942898 T2,169-860-886-818-898,2014-08-29,2014,SI 200631256 T,2006-09-13,US 71756005 P;;US 74728006 P;;US 2006/0035958 W;;EP 06803649 A,2005-09-14,DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETES,,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/169-860-886-818-898,Amended Patent,no,0,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K31/00;;A61P3/00,,0,0,,,,ACTIVE
35,CN,A,CN 102935081 A,196-710-006-642-747,2013-02-20,2013,CN 201210332271 A,2006-09-13,US 71755805 P;;US 74727306 P,2005-09-14,Dipeptidyl peptidase inhibitors for treating diabetis,"The invention relates to dipeptidyl peptidase inhibitors for treating diabetis. Pharmaceutical compositions comprising 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/196-710-006-642-747,Patent Application,no,0,2,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/335;;A61K31/513;;A61K31/34;;C07D209/12;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/535;;A61K31/5377;;A61K45/06;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
36,RS,B2,RS 52110 B2,032-833-617-809-991,2018-05-31,2018,RS P20120001 A,2006-09-13,US 71756005 P;;US 74728006 P;;US 2006/0035958 W;;EP 06803649 A,2005-09-14,DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETES,,TAKEDA PHARMACEUTICALS CO,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/032-833-617-809-991,Amended Patent,no,0,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K31/513;;A61P3/10,,0,0,,,,ACTIVE
37,US,A1,US 2007/0060528 A1,062-365-798-790-890,2007-03-15,2007,US 53149506 A,2006-09-13,US 53149506 A;;US 71755805 P;;US 74727306 P,2005-09-14,ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS,"Pharmaceutical compositions comprising 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.",CHRISTOPHER RONALD J;;COVINGTON PAUL,CHRISTOPHER RONALD J;;COVINGTON PAUL,TAKEDA SAN DIEGO INC (2006-11-01);;TAKEDA PHARMACEUTICAL COMPANY LIMITED (2006-11-09);;DEVELOPMENT PARTNERS LLC (2006-11-02),https://lens.org/062-365-798-790-890,Patent Application,yes,99,24,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K38/04;;A61K31/335;;C07D209/12;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/426;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,514/19;;514/369,0,0,,,,DISCONTINUED
38,HR,T4,HR P20140091 T4,104-801-481-768-484,2021-12-24,2021,HR P20140091 T,2006-09-13,US 71755805 P;;US 74727306 P;;EP 06803523 A;;US 2006/0035708 W,2005-09-14,ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS,,TAKEDA PHARMACEUTICALS CO,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/104-801-481-768-484,Amended Patent,no,0,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;A61K31/131;;C07D209/12;;A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/44;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
39,NO,L,NO 20081592 L,098-798-373-791-978,2008-05-23,2008,NO 20081592 A,2008-03-31,US 71756005 P;;US 74728006 P;;US 2006/0035958 W,2005-09-14,Dipeptidylpeptidaseinhibitorer for behandling av diabetes,"Farmasøytiske sammensetninger som innbefatter 2-[6-(3-amino-piperidin-1-yl)-3-metyl-2,4-diokso-3,4-dihydro-2H-pyrimidin-1-ylmetyl]-4-fluor-benzonitril og farmasøytisk akseptable salter derav er tilveiebrakt så vel som kits og fremstilte artikler som innbefatter de farmasøytiske sammensetningene så vel som fremgangsmåter for anvendelse av de farmasøytiske sammensetningene. Sammensetningene kan anvendes for behandling av diabetes.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/098-798-373-791-978,Abstract,no,0,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K31/513;;A61P3/10,,0,0,,,,ACTIVE
40,WO,A1,WO 2007/033265 A1,121-068-177-526-971,2007-03-22,2007,US 2006/0035707 W,2006-09-13,US 71755705 P;;US 74727806 P,2005-09-14,DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETIS,Pharmaceutical compositions comprising 2-[[2-[(3 R )-3-Amino-piperidinyl)-5-fluoro-6-oxo-6 H -pyrimidinyl]methyl]-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.,TAKEDA PHARMACEUTICAL;;CHRISTOPHER RONALD J;;COVINGTON PAUL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/121-068-177-526-971,Patent Application,yes,1,7,5,5,0,A61K31/44;;A61K31/44;;A61K31/426;;A61K31/426;;A61K31/513;;A61K31/513;;A61K38/26;;A61K38/26;;A61K45/06;;A61K45/06;;A61P3/10,A61K31/513;;A61K31/44;;A61P3/10,,0,0,,,,PENDING
41,CR,A,CR 9875 A,160-068-283-459-543,2008-08-01,2008,CR 9875 A,2008-04-09,US 71755805 P;;US 74727306 P,2005-09-14,INHIBIDORES DE DIPEPTIDILO PEPTIDASA PARA TRATAR DIABETES,"Se proveen composiciones farmaceuticas qeu comprenden 2-[[6-[(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1-(2H)-pirimidinil]metil]-benzonitrilo y sales farmaceuticamente aceptables del mismo, asi como estuches y articulos de fabricacion que comprenden las composiciones farmaceuticas asi como metodos para utilizar las composiciones farmaceuticas.",TAKEDA PHARMACEUTICAL,RONALD J CHRISTOPHER;;PAUL COVINGTON,,https://lens.org/160-068-283-459-543,Patent Application,no,0,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,C07D209/12;;A61K31/131;;A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/44;;A61K31/513;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,PENDING
42,CN,B,CN 102940638 B,025-112-161-083-067,2015-03-04,2015,CN 201210332314 A,2006-09-13,US 71755805 P;;US 74727306 P,2005-09-14,Dipeptidyl peptidase inhibitors for treating diabetic,,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/025-112-161-083-067,Granted Patent,no,0,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;A61K31/335;;C07D209/12;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/535;;A61K31/5377;;A61K45/00;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
43,AU,B2,AU 2006/290205 B2,107-086-321-601-06X,2012-12-13,2012,AU 2006/290205 A,2006-09-13,US 71756005 P;;US 74728006 P;;US 2006/0035958 W,2005-09-14,Dipeptidyl peptidase inhibitors for treating diabetes,"Pharmaceutical compositions comprising 2- [6- (3-Amino-piperidin-l-yl)-3-methyl-2, 4-dioxo-3, 4-dihydro-2H-pyrimidin-l-ylmethyl] -4-fluoro-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions. The compositions may be used for the treatment of diabetes.",TAKEDA PHARMACEUTICALS CO,COVINGTON PAUL;;CHRISTOPHER RONALD J,,https://lens.org/107-086-321-601-06X,Granted Patent,no,1,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K31/513;;A61K31/44;;A61P3/10,,0,0,,,,ACTIVE
44,CY,T1,CY 1112281 T1,199-736-276-562-08X,2015-12-09,2015,CY 121100057 T,2012-01-17,EP 06803649 A;;US 71756005 P;;US 74728006 P,2005-09-14,ΑΝΑΣΤΟΛΕΙΣ ΔΙΠΕΠΤΙΔΥΛ ΠΕΠΤΙΔΑΣΗΣ ΓΙΑ ΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΔΙΑΒΗΤΗ,"Παρέχονται φαρμακευτικές συνθέσεις που περιλαμβάνουν 2-[6-(3-Αμινο-πιπεριδιν-1-υλο)-3-μεθυλο-2,4-διοξο-3,4-διυδρο-2Η-πυριμιδιν-1-υλομεθυλο]-4-φθορο-βενζονιτρίλιο και φαρμακευτικά αποδεκτά άλατα αυτού, όπως και συσκευασίες (κιτ) και αντικείμενα κατασκευής που περιλαμβάνουν τις φαρμακευτικές συνθέσεις καθώς και μέθοδοι χρήσης των φαρμακευτικών συνθέσεων. Οι συνθέσεις μπορούν να χρησιμοποιηθούν για τη θεραπεία του διαβήτη.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/199-736-276-562-08X,Granted Patent,no,0,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K31/513;;A61P3/10,,0,0,,,,ACTIVE
45,US,A1,US 2014/0256757 A1,014-086-708-770-552,2014-09-11,2014,US 201414280942 A,2014-05-19,US 201414280942 A;;US 201113080434 A;;US 53149506 A;;US 74727306 P;;US 71755805 P,2005-09-14,ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS,"Pharmaceutical compositions comprising 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and pharmaceutically acceptable salts thereof in combination with metformin and in combination with pioglitazone.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/014-086-708-770-552,Patent Application,yes,2,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;A61K31/155;;C07D209/12;;A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/4439;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,514/274,0,0,,,,DISCONTINUED
46,NZ,A,NZ 566797 A,029-299-749-269-098,2011-04-29,2011,NZ 56679706 A,2006-09-13,US 71755805 P;;US 74727306 P;;US 2006/0035708 W,2005-09-14,Dipeptidyl peptidase inhibitors for treating diabetes,"Disclosed is a pharmaceutical composition formulated in a single dose form wherein such single dose form comprises between 5 mg and 250 mg of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1-(2H)-pyrimidinyl]methyl]-benzonitrile. Also disclosed is a kit comprising said composition and the use of said composition for the treatment of diabetes.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/029-299-749-269-098,Patent Application,no,0,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;A61K31/131;;C07D209/12;;A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/44;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,PENDING
47,WO,A2,WO 2007/033266 A2,036-339-593-740-935,2007-03-22,2007,US 2006/0035708 W,2006-09-13,US 71755805 P;;US 74727306 P,2005-09-14,ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS,"Pharmaceutical compositions comprising 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.",TAKEDA PHARMACEUTICAL;;CHRISTOPHER RONALD J;;COVINGTON PAUL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/036-339-593-740-935,Patent Application,yes,77,47,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/131;;A61K31/513;;A61K31/335;;C07D209/12;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/44;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,14,10,001-646-636-305-547;;055-060-170-111-046;;047-541-187-994-137;;038-616-238-846-386;;058-237-544-298-707;;020-283-715-912-897;;022-887-667-139-202;;080-476-458-432-186;;020-998-840-770-591;;078-826-117-240-27X,9753303;;10.2337/diabetes.47.10.1630;;10.1021/jm9810304;;9857085;;10085108;;10.1074/jbc.274.13.8694;;10425084;;10.1021/jm9902584;;9196039;;10.1006/bbrc.1997.6740;;10905484;;10.2337/diabetes.49.5.759;;8764338;;10.1210/jcem.85.3.6431;;10.1210/jc.85.3.1043;;10720037;;10.1007/s001250050471;;10.1007/bf00400683;;8778001;;3542646;;10.2337/diab.36.2.216,"MOL. CELL. ENDOCRINOL., vol. 135, no. 1, 1997, pages 67 - 77;;DIABETES, vol. 47, 1998, pages 1630 - 1636;;BIOORG MED. CHEM. LETT, vol. 2, 1992, pages 915 - 918;;J. MED. CHEM., vol. 41, 1998, pages 5150 - 5157;;J. BIOL CHEM., vol. 274, 1999, pages 8694 - 8697;;MOL. BIOL. DIABETES, vol. 2, 1994, pages 283 - 99;;J. MED. CHEM., vol. 42, 1999, pages 2741 - 2746;;VIDAL-PUIG ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 235, no. 1, 1997, pages 79 - 82;;DIABETES, vol. 49, no. 5, 2000, pages 759 - 767;;J. PHARMACOL. EXP. THER., vol. 278, 1996, pages 82 - 89;;J. CLIN. ENDOCRINOL. METAB., vol. 85, no. 3, 2000, pages 1043 - 1048;;DIABETES CARE, vol. 21, 1998, pages 897 - 893;;DIABETOLOGIA, vol. 39, 1996, pages 492 - 499;;DIABETES, vol. 36, 1987, pages 216 - 220",PENDING
48,CR,A,CR 9874 A,097-977-466-185-94X,2008-08-01,2008,CR 9874 A,2008-04-09,US 71756005 P;;US 74728006 P,2005-09-14,DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETES,,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/097-977-466-185-94X,Patent Application,no,0,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K31/44;;A61K31/513;;A61P3/10,,0,0,,,,PENDING
49,BR,A2,BR PI0616055 A2,101-067-467-110-704,2011-06-07,2011,BR PI0616055 A,2006-09-13,US 71756005 P;;US 74728006 P;;US 2006/0035958 W,2005-09-14,inibidores de dipeptidil peptidase para o tratamento do diabetes,"INIBIDORES DE DIPEPTIDIL PEPTIDASE PARA O TRATAMENTO DO DIABETES São providas composições farmacêuticas compreendendo 2- [6- (3-amino-piperidifl-1-il) -3-metil-2,4- benzonitrila e sais farmaceuticamente aceitáveis da mesma, bem como kits e artigos de fabricação compreendendo as composições farmacêuticas, bem como métodos de uso das composições farmacêuticas. As composições podem ser usadas para tratamento do diabetes.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/101-067-467-110-704,Patent Application,no,0,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K31/513;;A61K31/44;;A61P3/10,,0,0,,,,ACTIVE
50,CA,C,CA 2622472 C,097-136-569-323-237,2013-11-19,2013,CA 2622472 A,2006-09-13,US 71756005 P;;US 74728006 P;;US 2006/0035958 W,2005-09-14,DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETES,"Pharmaceutical compositions comprising 2- [6- (3-Amino-piperidin-l-yl)-3-methyl-2, 4-dioxo-3, 4-dihydro-2H-pyrimidin-l-ylmethyl] -4-fluoro-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions. The compositions may be used for the treatment of diabetes.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/097-136-569-323-237,Granted Patent,no,0,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K31/513;;A61K31/44;;A61P3/10,,0,0,,,,ACTIVE
51,CA,C,CA 2622608 C,117-769-311-937-307,2014-08-19,2014,CA 2622608 A,2006-09-13,US 71755805 P;;US 74727306 P;;US 2006/0035708 W,2005-09-14,DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETES,"Pharmaceutical compositions comprising 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/117-769-311-937-307,Granted Patent,no,0,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;C07D209/12;;A61K31/131;;A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/44;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
52,PL,T5,PL 1942898 T5,162-851-580-674-239,2014-10-31,2014,PL 06803649 T,2006-09-13,US 71756005 P;;US 74728006 P;;EP 06803649 A;;US 2006/0035958 W,2005-09-14,DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETES,,TAKEDA PHARMACEUTICALS CO,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/162-851-580-674-239,Unknown,no,0,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K31/513;;A61P3/10,,0,0,,,,PENDING
53,JP,A,JP 2013082725 A,180-002-771-291-982,2013-05-09,2013,JP 2012276223 A,2012-12-18,US 71755805 P;;US 74727306 P,2005-09-14,ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITOR,"PROBLEM TO BE SOLVED: To provide novel DPP-IV inhibitors for treating the condition of the I type or II type diabetes, and novel methods of administering such inhibitors for treating the disease.SOLUTION: Pharmaceutical compositions containing 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as a kit and an article of manufacture containing the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.",TAKEDA CHEMICAL INDUSTRIES LTD,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/180-002-771-291-982,Patent Application,no,1,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;A61K9/127;;C07D209/12;;A61K9/20;;A61K9/22;;A61K9/48;;A61K9/52;;A61K31/133;;A61K31/155;;A61K31/198;;A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/427;;A61K31/445;;A61K31/4453;;A61K31/535;;A61K31/5377;;A61K31/64;;A61K38/00;;A61K38/04;;A61K38/28;;A61K45/00;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;A61P43/00;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
54,PE,A1,PE 20070622 A1,055-031-606-056-429,2007-08-22,2007,PE 2006001111 A,2006-09-13,US 71755705 P;;US 74727806 P,2005-09-14,ADMINISTRACION DE INHIBIDORES DE DIPEPTIDIL PEPTIDASA,"SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE 2-[[6-[(3R)-3-AMINO-1-PIPERIDINIL]-3,4-DIHIDRO-3-METIL-2,4-DIOXO-1(2H)-PIRIMIDINIL]METIL]-BENZONITRILO EN COMBINACION CON UNO O MAS COMPUESTOS SELECCIONADOS ENTRE MODULADORES DE LA VIA DE SENALIZACION DE INSULINA, MEJORADORES DE LA SENSIBILIDAD DE INSULINA, ANTIDIABETICOS, AGONISTAS DE GLP-2, ENTRE OTROS. DICHA COMPOSICION ES ADMINISTRADA POR VIA ORAL´DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE DIABETES TIPO II",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/055-031-606-056-429,Patent Application,no,0,0,5,5,0,A61K31/44;;A61K31/44;;A61K31/426;;A61K31/426;;A61K31/513;;A61K31/513;;A61K38/26;;A61K38/26;;A61K45/06;;A61K45/06;;A61P3/10,A61K31/426;;A61K38/04,,0,0,,,,DISCONTINUED
55,SI,T1,SI 1942898 T1,051-222-022-478-501,2012-03-30,2012,SI 200631256 T,2006-09-13,US 71756005 P;;US 74728006 P;;US 2006/0035958 W;;EP 06803649 A,2005-09-14,DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETES,,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/051-222-022-478-501,Granted Patent,no,0,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K31/00;;A61P3/00,,0,0,,,,ACTIVE
56,TW,A,TW 200800212 A,082-830-433-819-511,2008-01-01,2008,TW 95134080 A,2006-09-14,US 71755705 P;;US 74727806 P,2005-09-14,Administration of dipeptidyl peptidase inhibitors,Pharmaceutical compositions comprising 2-[[2-[(3R)-3-Amino-piperidinyl)-5-fluoro-6-oxo-6H-pyrimidinyl]methyl]-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/082-830-433-819-511,Patent of Addition,no,0,0,5,5,0,A61K31/44;;A61K31/44;;A61K31/426;;A61K31/426;;A61K31/513;;A61K31/513;;A61K38/26;;A61K38/26;;A61K45/06;;A61K45/06;;A61P3/10,A61K31/513,,0,0,,,,PENDING
57,EP,A1,EP 1942898 A1,073-482-807-999-613,2008-07-16,2008,EP 06803649 A,2006-09-13,US 2006/0035958 W;;US 71756005 P;;US 74728006 P,2005-09-14,DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETES,,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/073-482-807-999-613,Patent Application,yes,0,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K31/513;;A61P3/10,,0,0,,,,ACTIVE
58,KR,A,KR 20080055875 A,073-423-878-755-237,2008-06-19,2008,KR 20087007907 A,2008-04-01,US 71756005 P;;US 74728006 P;;US 2006/0035958 W,2005-09-14,DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETES,"Pharmaceutical compositions comprising 2-[6-(3-Amino-piperidin-l-yl)-3-methyl-2, 4-dioxo-3, 4-dihydro-2H-pyrimidin-l-ylmethyl]-4-fluoro-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions. The compositions may be used for the treatment of diabetes.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/073-423-878-755-237,Patent Application,no,0,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K31/44;;A61P3/10,,0,0,,,,ACTIVE
59,US,A1,US 2011/0192748 A1,110-475-340-025-747,2011-08-11,2011,US 201113091460 A,2011-04-21,US 201113091460 A;;US 53167106 A;;US 71756005 P;;US 74728006 P,2005-09-14,Administration of Dipeptidyl Peptidase Inhibitors,"Pharmaceutical compositions comprising 2-[6-(3-Amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/110-475-340-025-747,Patent Application,yes,3,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,B65D85/00;;A61K31/513;;A61K38/22;;A61K38/28;;A61P3/10,206/438;;514/274;;514/6.5;;514/6.9,0,0,,,,DISCONTINUED
60,NO,B1,NO 342682 B1,124-636-159-088-48X,2018-07-02,2018,NO 20081569 A,2008-03-31,US 71755805 P;;US 74727306 P;;US 2006/0035708 W,2005-09-14,Faste farmasøytiske sammensetninger omfattende dipeptidyl peptidaseinhibitorer,"Farmasøytiske sammensetninger som innbefatter 2-[[6-[(3R)-3-amino-l-piperidinyI]-3,4-dihydro-3-metyl-2,4-diokso-1(2H)-pyrimidinyl]metyl]-benzonitril og farmasøytisk akseptable salter derav er tilveiebrakt så vel som kit og fremstilte artikler som innbefatter de farmasøytiske sammensetningene så vel som fremgangsmåter for anvendelse av de farmasøytiske sammensetningene.",TAKEDA PHARMACEUTICALS CO,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/124-636-159-088-48X,Granted Patent,no,2,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;A61K31/335;;C07D209/12;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
61,ZA,B,ZA 200802855 B,151-711-548-486-170,2009-11-25,2009,ZA 200802855 A,2006-09-13,US 71755805 P,2005-09-14,Dipeptidyl peptidase inhibitors for treating diabetes,,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;PAUL COVINGTON,,https://lens.org/151-711-548-486-170,Granted Patent,no,0,0,4,76,0,,A61K/;;A61P/,,0,0,,,,ACTIVE
62,US,A1,US 2019/0314352 A1,168-047-209-690-227,2019-10-17,2019,US 201916277537 A,2019-02-15,US 201916277537 A;;US 201715721342 A;;US 201414280942 A;;US 201113080434 A;;US 53149506 A;;US 74727306 P;;US 71755805 P,2005-09-14,ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS,"Pharmaceutical compositions comprising 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1 (2H)-pyrimidinyl]methyl]-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.",TAKEDA PHARMACEUTICALS CO,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/168-047-209-690-227,Patent Application,yes,4,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/4439;;A61K31/131;;C07D209/12;;A61K31/155;;A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/44;;A61K31/513;;A61K31/535;;A61K31/5377;;A61K45/06;;A61P3/00;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04;;C07K16/28;;C07K16/40,,0,0,,,,DISCONTINUED
63,KR,A,KR 20080055874 A,185-283-716-234-614,2008-06-19,2008,KR 20087007906 A,2006-09-13,US 71755805 P;;US 74727306 P;;US 2006/0035708 W,2005-09-14,DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETIS,"Pharmaceutical compositions comprising 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/185-283-716-234-614,Patent Application,no,0,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/131;;A61K31/335;;C07D209/12;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/44;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
64,AU,B2,AU 2006/290908 B2,197-416-183-148-159,2012-09-20,2012,AU 2006/290908 A,2006-09-13,US 74727306 P;;US 71755805 P;;US 2006/0035708 W,2005-09-14,Dipeptidyl peptidase inhibitors for treating diabetis,"Pharmaceutical compositions comprising 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.",TAKEDA PHARMACEUTICAL,COVINGTON PAUL;;CHRISTOPHER RONALD J,,https://lens.org/197-416-183-148-159,Granted Patent,no,1,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;C07D209/12;;A61K31/131;;A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/44;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
65,BR,A2,BR PI0616077 A2,064-195-793-888-462,2011-06-07,2011,BR PI0616077 A,2006-09-13,US 71755805 P;;US 74727306 P;;US 2006/0035708 W,2005-09-14,administração de inibidores de dipeptidil peptidase,"ADMINISTRAçãO DE INIBIDORES DE DIPEPTIDIL PEPTIDASE São providas composições farmacêuticas compreendendo 2- [[5-[(3R)-3-amino-1-piperidifinil]-3,4-diidro-3-metil-2,4-dioxo-1(2H)Pirí midinil]metíl] - benzonitrila e sais farmaceuticamente aceitáveis da mesma, bem como kits e artigos de manufatura compreendendo as composições farmacêuticas, bem como métodos de uso das composições farmacêuticas.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/064-195-793-888-462,Patent Application,no,0,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;A61K31/131;;C07D209/12;;A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/44;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
66,CN,B,CN 102935081 B,084-441-965-860-72X,2015-03-04,2015,CN 201210332271 A,2006-09-13,US 71755805 P;;US 74727306 P,2005-09-14,Dipeptidyl peptidase inhibitors for treating diabetis,,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/084-441-965-860-72X,Granted Patent,no,0,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;A61K31/335;;C07D209/12;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/535;;A61K31/5377;;A61K45/06;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
67,PL,T3,PL 1942898 T3,095-479-860-866-570,2012-04-30,2012,PL 06803649 T,2006-09-13,US 71756005 P;;US 74728006 P;;EP 06803649 A;;US 2006/0035958 W,2005-09-14,DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETES,,TAKEDA PHARMACEUTICALS CO,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/095-479-860-866-570,Patent Application,no,0,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K31/513;;A61P3/10,,0,0,,,,PENDING
68,ES,T5,ES 2445180 T5,081-243-787-783-277,2022-02-01,2022,ES 06803523 T,2006-09-13,US 71755805 P;;US 74727306 P;;US 2006/0035708 W,2005-09-14,Administración de inhibidores de dipeptidil peptidasa,,TAKEDA PHARMACEUTICALS CO,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/081-243-787-783-277,Amended Patent,no,0,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;A61K31/131;;C07D209/12;;A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/44;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
69,SI,T1,SI 1931350 T1,097-089-465-280-691,2014-03-31,2014,SI 200631737 T,2006-09-13,US 71755805 P;;US 74727306 P;;US 2006/0035708 W;;EP 06803523 A,2005-09-14,ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS,,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/097-089-465-280-691,Granted Patent,no,0,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/00;;A61K31/335;;C07D209/12;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P3/00;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
70,PT,E,PT 1942898 E,105-001-057-320-77X,2011-12-20,2011,PT 06803649 T,2006-09-13,US 71756005 P;;US 74728006 P,2005-09-14,DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETES,,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/105-001-057-320-77X,Granted Patent,no,0,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K31/513;;A61P3/10,,0,0,,,,ACTIVE
71,DK,T3,DK 1931350 T3,132-837-927-267-538,2014-02-10,2014,DK 06803523 T,2006-09-13,US 71755805 P;;US 74727306 P;;US 2006/0035708 W,2005-09-14,ADMINISTRATION AF INHIBITORER AF DIPEPTIDYLPEPTIDASE,,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/132-837-927-267-538,Granted Patent,no,0,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;A61K31/131;;C07D209/12;;A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/44;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
72,GE,B,GE P20135791 B,134-380-979-318-224,2013-03-25,2013,GE AP2006010608 A,2006-09-13,US 71755805 P;;US 74727306 P,2005-09-14,USE OF DIPEPTIDYL PEPTIDASE INHIBITORS,A pharmaceutical composition containing 5-250 mg compound of formula I and lactose monohydrate.,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/134-380-979-318-224,Granted Patent,no,0,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;A61K31/131;;C07D209/12;;A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/44;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
73,CN,A,CN 102940638 A,163-020-296-408-995,2013-02-27,2013,CN 201210332314 A,2006-09-13,US 71755805 P;;US 74727306 P,2005-09-14,Administration of dipeptidyl peptidase inhibitors,"Pharmaceutical compositions comprising 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/163-020-296-408-995,Patent Application,no,2,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;A61K31/335;;C07D209/12;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/535;;A61K31/5377;;A61K45/00;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,1,0,,,"王林: ""二肽基肽酶IV抑制剂P32/98"", 《国外医学药学分册》",ACTIVE
74,EA,B1,EA 015169 B1,010-143-739-551-259,2011-06-30,2011,EA 200800726 A,2006-09-13,US 71756005 P;;US 74728006 P;;US 2006/0035958 W,2005-09-14,USE OF DIPEPTIDYL PEPTIDASE INHIBITORS,"Pharmaceutical compositions comprising 2- [6- (3-Amino-piperidin-l-yl)-3-methyl-2, 4-dioxo-3, 4-dihydro-2H-pyrimidin-l-ylmethyl] -4-fluoro-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions. The compositions may be used for the treatment of diabetes.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/010-143-739-551-259,Granted Patent,no,2,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K31/513;;A61K31/44;;A61P3/10,,0,0,,,,ACTIVE
75,TW,B,TW I432200 B,031-583-058-956-067,2014-04-01,2014,TW 95134081 A,2006-09-14,US 71756005 P;;US 74728006 P,2005-09-14,Administration of dipeptidyl peptidase inhibitors,,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/031-583-058-956-067,Granted Patent,no,0,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,,,0,0,,,,ACTIVE
76,TW,B,TW I421075 B,078-652-799-756-275,2014-01-01,2014,TW 95134082 A,2006-09-14,US 71755805 P;;US 74727306 P,2005-09-14,Administration of dipeptidyl peptidase inhibitors,,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/078-652-799-756-275,Granted Patent,no,1,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,C07D209/12;;A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
77,SI,T2,SI 1931350 T2,074-671-942-774-053,2021-11-30,2021,SI 200631737 T,2006-09-13,US 71755805 P;;US 74727306 P;;US 2006/0035708 W;;EP 06803523 A,2005-09-14,ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS,,TAKEDA PHARMACEUTICALS CO,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/074-671-942-774-053,Amended Patent,no,0,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/00;;A61K31/335;;C07D209/12;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P3/00;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
78,HK,A1,HK 1118231 A1,101-166-486-315-178,2009-02-06,2009,HK 08112374 A,2008-11-12,US 2006/0035708 W;;US 71755805 P;;US 74727306 P,2005-09-14,ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS,,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/101-166-486-315-178,Patent Application,no,0,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K/;;A61K31/335;;C07D209/12;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/535;;A61K31/5377;;A61P/;;A61P3/00;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,PENDING
79,EP,B1,EP 1931350 B1,101-576-005-773-605,2013-11-20,2013,EP 06803523 A,2006-09-13,US 2006/0035708 W;;US 71755805 P;;US 74727306 P,2005-09-14,ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS,,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/101-576-005-773-605,Granted Patent,yes,1,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;A61K31/131;;C07D209/12;;A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/44;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
80,NZ,A,NZ 566799 A,130-340-577-810-994,2011-04-29,2011,NZ 56679906 A,2006-09-13,US 71756005 P;;US 74728006 P;;US 2006/0035958 W,2005-09-14,Dipeptidyl peptidase inhibitors for treating diabetes,"A pharmaceutical composition formulated in a single dose form wherein such single dose form comprises between 1 mg and 250 mg of 2-5[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile. Also disclosed is a kit comprising this composition and the use of the composition in the treatment of diabetes.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/130-340-577-810-994,Patent Application,no,0,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K31/513;;A61K31/44;;A61P3/10,,0,0,,,,PENDING
81,GE,B,GE P20135838 B,176-530-999-894-880,2013-06-10,2013,GE AP2006010609 A,2006-09-13,US 71756005 P;;US 74728006 P,2005-09-14,DIPEPTIDYL PEPTIDASE INHIBITORS USAGE AT DIABETES TREATMENT,,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/176-530-999-894-880,Granted Patent,no,0,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K31/513;;A61K31/44;;A61P3/10,,0,0,,,,ACTIVE
82,US,A1,US 2007/0060530 A1,020-976-530-207-448,2007-03-15,2007,US 53167106 A,2006-09-13,US 53167106 A;;US 71756005 P;;US 74728006 P,2005-09-14,ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS,"Pharmaceutical compositions comprising 2-[6-(3-Amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.",CHRISTOPHER RONALD J;;COVINGTON PAUL,CHRISTOPHER RONALD J;;COVINGTON PAUL,TAKEDA SAN DIEGO INC (2006-11-01);;TAKEDA PHARMACEUTICAL COMPANY LIMITED (2006-11-09);;DEVELOPMENT PARTNERS LLC (2006-11-02),https://lens.org/020-976-530-207-448,Patent Application,yes,99,73,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K38/04;;A61K31/426,514/19;;514/369,0,0,,,,DISCONTINUED
83,EP,B2,EP 1942898 B2,059-314-565-775-309,2014-05-14,2014,EP 06803649 A,2006-09-13,US 2006/0035958 W;;US 71756005 P;;US 74728006 P,2005-09-14,DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETES,,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/059-314-565-775-309,Granted Patent,yes,2,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K31/513;;A61P3/10,,0,0,,,,ACTIVE
84,CN,B,CN 101374523 B,068-043-336-726-874,2012-04-11,2012,CN 200680042380 A,2006-09-13,US 2006/0035958 W;;US 71756005 P;;US 74728006 P,2005-09-14,Dipeptidyl peptidase inhibitors for treating diabetes,"Pharmaceutical compositions comprising 2- [6- (3-Amino-piperidin-l-yl)-3-methyl-2, 4-dioxo-3, 4-dihydro-2H-pyrimidin-l-ylmethyl] -4-fluoro-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;PAUL COVINGTON,,https://lens.org/068-043-336-726-874,Granted Patent,no,0,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K31/513;;A61K31/44;;A61P3/10,,0,0,,,,ACTIVE
85,WO,A3,WO 2007/033266 A3,082-822-282-613-080,2007-05-10,2007,US 2006/0035708 W,2006-09-13,US 71755805 P;;US 74727306 P,2005-09-14,DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETIS,"Pharmaceutical compositions comprising 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.",TAKEDA PHARMACEUTICAL;;CHRISTOPHER RONALD J;;COVINGTON PAUL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/082-822-282-613-080,Search Report,yes,2,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;A61K31/131;;C07D209/12;;A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/44;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,PENDING
86,RS,B,RS 52110 B,141-969-998-477-226,2012-08-31,2012,RS P20120001 A,2006-09-13,US 71756005 P;;US 74728006 P;;US 2006/0035958 W;;EP 06803649 A,2005-09-14,DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETES,"Farmaceutska kompozicija formulisana u pojedinačnom doznom obliku, pri čemu takav pojedinačni dozni oblik sadrži između 1 mg i 250 mg jedinjenja I, pri čemu jedinjenje I ima formuluPrijava sadrži još 47 patentnih zahteva.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/141-969-998-477-226,Granted Patent,no,0,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K31/513;;A61P3/10,,0,0,,,,ACTIVE
87,PT,E,PT 1931350 E,142-296-467-544-939,2014-02-12,2014,PT 06803523 T,2006-09-13,US 71755805 P;;US 74727306 P,2005-09-14,ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS,,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/142-296-467-544-939,Granted Patent,no,0,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;A61K31/131;;C07D209/12;;A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/44;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
88,EP,B2,EP 1931350 B2,154-312-700-839-227,2021-08-04,2021,EP 06803523 A,2006-09-13,US 2006/0035708 W;;US 71755805 P;;US 74727306 P,2005-09-14,ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS,,TAKEDA PHARMACEUTICALS CO,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/154-312-700-839-227,Granted Patent,yes,4,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;A61K31/131;;C07D209/12;;A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/44;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,3,0,,,"'Safety and Efficacy Study of Alogliptin on Glycemic Control in Subjects with Type 2 Diabetes, March 2005;;WHO Drug Information, Vol. 20, No. 4, 2006, page 282 (post-published evidence regarding the structural formula of Alogliptin);;ZHANG ET AL, J. MEDI. CHEMI., vol. 54, 2011, pages 510 - 524",ACTIVE
89,AR,A1,AR 059027 A1,146-997-358-159-342,2008-03-12,2008,AR P060104030 A,2006-09-14,US 71755805 P;;US 74727306 P,2005-09-14,ADMINISTRACION DE INHIBIDORES DE DIPEPTIDIL PEPTIDASA,"Composiciones farmacéuticas que contienen 2-[[6-[(3R)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2H)-pirimidiniI]metiI]-benzonitriIo y sales aceptables pura uso farmacéutico del mismo, conjuntos de elementos y artículos elaborados que comprenden dichas composiciones farmacéuticas así como métodos de uso de las mismas.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/146-997-358-159-342,Patent Application,no,0,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,C07D209/12;;A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,DISCONTINUED
90,MA,B1,MA 29795 B1,162-057-233-311-291,2008-09-01,2008,MA 30769 A,2008-03-19,US 71756005 P;;US 74728006 P,2005-09-14,INHIBITEURS DE LA DIPEPTIDYL PEPTIDASE PERMETTTANT DE TRAITER LE DIABETE,"L'invention concerne des compositions pharmaceutiques comprenant un 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile et des sels de celles-ci pharmaceutiquement acceptables ainsi que des trousses et des articles de production comprenant lesdites compositions pharmaceutiques et des méthodes d'utilisation de ces compositions pharmaceutiques. On peut utiliser lesdites compositions pour traiter le diabète.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/162-057-233-311-291,Granted Patent,no,0,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,,,0,0,,,,ACTIVE
91,CN,A,CN 102908350 A,195-454-786-198-600,2013-02-06,2013,CN 201210398616 A,2006-09-13,US 71755805 P;;US 74727306 P,2005-09-14,Dipeptidyl peptidase inhibitors for treating diabetes,"The invention relates to dipeptidyl peptidase inhibitors for treating diabetes. Pharmaceutical compositions comprising 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/195-454-786-198-600,Patent Application,no,0,1,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;A61K31/335;;C07D209/12;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/535;;A61K31/5377;;A61K45/06;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
92,AU,A1,AU 2006/290908 A1,000-315-314-940-537,2007-03-22,2007,AU 2006/290908 A,2006-09-13,US 74727306 P;;US 71755805 P;;US 2006/0035708 W,2005-09-14,Dipeptidyl peptidase inhibitors for treating diabetis,,TAKEDA PHARMACEUTICAL,COVINGTON PAUL;;CHRISTOPHER RONALD J,,https://lens.org/000-315-314-940-537,Patent Application,no,0,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;C07D209/12;;A61K31/131;;A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/44;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
93,PE,A1,PE 20070458 A1,033-382-337-831-381,2007-07-05,2007,PE 2006001113 A,2006-09-13,US 71755805 P;;US 74727306 P,2005-09-14,"COMPOSICION FARMACEUTICA QUE COMPRENDE 2-[[6-(3R)-3-AMINO-1-PIPERIDINIL]-3,4-DIHIDRO-3-METIL-2,4-DIOXO-1(2H)-PIRIMIDINIL]METIL]-BENZONITRILO COMO INHIBIDOR DE DIPEPTIDIL PEPTIDASA","SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) 2-[[6-(3R)-3-AMINO-1-PIPERIDINIL]-3,4-DIHIDRO-3-METIL-2,4-DIOXO-1(2H)-PIRIMIDINIL]METIL]-BENZONITRILO QUE ES UN INHIBIDOR DE DIPEPTIDIL PEPTIDASA IV SIENDO UTIL EN EL TRATAMIENTO DE DIABETES TIPO II Y SE ENCUENTRA EN UNA CANTIDAD DE 5MG A 250MG EN LA COMPOSICION; Y B) UN ANTIDIABETICO TAL COMO METFORMINA, GLISOXEPIDA, REPAGLINIDA, ROSIGLITAZONA, ENTRE OTROS. DICHA COMPOSICION ES DE LIBERACION PROLONGADA Y ADMINISTRACION ORAL",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/033-382-337-831-381,Patent Application,no,0,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,C07D209/12;;A61K31/131;;A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/44;;A61K31/513;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
94,TW,A,TW 200744602 A,049-488-023-292-190,2007-12-16,2007,TW 95134081 A,2006-09-14,US 71756005 P;;US 74728006 P,2005-09-14,Administration of dipeptidyl peptidase inhibitors,"Pharmaceutical compositions comprising 2-[6-(3-Amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.",TAKEDA PHARMACEUTICALS CO,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/049-488-023-292-190,Patent of Addition,no,0,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K31/513,,0,0,,,,ACTIVE
95,EP,A2,EP 1931350 A2,082-899-214-284-356,2008-06-18,2008,EP 06803523 A,2006-09-13,US 2006/0035708 W;;US 71755805 P;;US 74727306 P,2005-09-14,ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS,,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/082-899-214-284-356,Patent Application,yes,0,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;A61K31/131;;C07D209/12;;A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/44;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
96,AR,A2,AR 108699 A2,191-548-835-430-114,2018-09-19,2018,AR P170101579 A,2017-06-08,US 71755805 P,2005-09-14,COMPOSICIONES FARMACÉUTICAS SÓLIDAS FORMULADAS COMO DOSIS UNITARIA QUE CONTIENEN UN INHIBIDOR DE LA DIPEPTIDIL PEPTIDASA,"Composiciones farmacéuticas sólidas formuladas como dosis unitaria que comprenden entre 5 mg y 250 mg del compuesto de fórmula (1), y un vehículo aceptable para uso farmacéutico.",TAKEDA PHARMACEUTICALS CO,COVINGTON PAUL;;CHRISTOPHER RONALD J,,https://lens.org/191-548-835-430-114,Amended Application,no,0,0,4,76,0,,A61K31/131;;A61K31/44;;A61K31/513;;A61P3/10,,0,0,,,,DISCONTINUED
97,US,A1,US 2007/0060529 A1,193-303-876-490-524,2007-03-15,2007,US 53166806 A,2006-09-13,US 53166806 A;;US 71755705 P;;US 74727806 P,2005-09-14,ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS,Pharmaceutical compositions comprising 2-[[2-[(3R)-3-Amino-piperidinyl)-5-fluoro-6-oxo-6H-pyrimidinyl]methyl]-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.,CHRISTOPHER RONALD J;;COVINGTON PAUL,CHRISTOPHER RONALD J;;COVINGTON PAUL,TAKEDA SAN DIEGO INC (2006-11-01);;TAKEDA PHARMACEUTICAL COMPANY LIMITED (2006-11-09);;DEVELOPMENT PARTNERS LLC (2006-11-02),https://lens.org/193-303-876-490-524,Patent Application,yes,94,5,5,5,0,A61K31/44;;A61K31/44;;A61K31/426;;A61K31/426;;A61K31/513;;A61K31/513;;A61K38/26;;A61K38/26;;A61K45/06;;A61K45/06;;A61P3/10,A61K38/04;;A61K31/426,514/19;;514/369,0,0,,,,DISCONTINUED
98,MY,A,MY 159522 A,024-804-863-015-449,2017-01-13,2017,MY PI20080653 A,2006-09-13,US 71755805 P;;US 74727306 P,2005-09-14,ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS,"PHARMACEUTICAL COMPOSITIONS COMPRISING 2-[[6-[(3R)-3-AMINO-1-PIPERIDINYL]-3.4-DIHYDRO-3-METHYL-2,4-DIOXO-1(2H)-PYRIMIDINYL]METHYL]-BENZONITRILE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF ARE PROVIDED AS WELL AS KITS AND ARTICLES OF MANUFACTURE COMPRISING THE PHARMACEUTICAL COMPOSITIONS AS WELL AS METHODS OF USING THE PHARMACEUTICAL COMPOSITIONS.",TAKEDA PHARMACEUTICALS CO,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/024-804-863-015-449,Granted Patent,no,0,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;A61K31/131;;C07D209/12;;A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/44;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
99,PL,T3,PL 1931350 T3,117-685-989-927-905,2014-05-30,2014,PL 06803523 T,2006-09-13,US 71755805 P;;US 74727306 P;;EP 06803523 A;;US 2006/0035708 W,2005-09-14,ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS,,TAKEDA PHARMACEUTICALS CO,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/117-685-989-927-905,Patent Application,no,0,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;A61K31/131;;C07D209/12;;A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/44;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,PENDING
100,AR,A1,AR 055435 A1,128-850-110-029-369,2007-08-22,2007,AR P060104031 A,2006-09-14,US 71756005 P;;US 74728006 P,2005-09-14,ADMINISTACION DE INHIBIDORES DE DIPEPTIDIL PEPTIDASA,"Composiciones farmacéuticas que contienen 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2H-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo y sales aceptables para uso farmacéutico del mismo, conjuntos de elementos y artículos elaborados que comprenden dichas composiciones farmacéuticas así como métodos de uso de las mismas.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/128-850-110-029-369,Patent Application,no,0,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,,,0,0,,,,DISCONTINUED
101,AR,A1,AR 058047 A1,053-623-005-297-733,2008-01-23,2008,AR P060104029 A,2006-09-14,US 74727806 P;;US 71755705 P,2005-09-14,ADMINISTRACION DE INHIBIDORES DE DIPEPTIDIL PEPTIDASA,"Composiciones farmacéuticas que contienen 2-[[2-(3R)-3-amino-piperidinil)-5-fluoro-6-oxo-6H-pirimidinil]metil]-benzonitrilo y sales aceptables para uso farmaccutico del mismo, conjuntos de elementos y artículos elaborados que comprenden dichas composiciones farmacéuticas así como métodos de uso de las mismas.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/053-623-005-297-733,Patent Application,no,0,0,5,5,0,A61K31/44;;A61K31/44;;A61K31/426;;A61K31/426;;A61K31/513;;A61K31/513;;A61K38/26;;A61K38/26;;A61K45/06;;A61K45/06;;A61P3/10,,,0,0,,,,PENDING
102,CN,B,CN 102908351 B,077-581-487-203-661,2014-07-23,2014,CN 201210399309 A,2006-09-13,US 71755805 P;;US 74727306 P,2005-09-14,Dipeptidyl peptidase inhibitors for treating diabetes,,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/077-581-487-203-661,Granted Patent,no,0,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;A61K31/335;;C07D209/12;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/535;;A61K31/5377;;A61K45/06;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
103,AU,A1,AU 2006/290205 A1,055-421-468-513-911,2007-03-22,2007,AU 2006/290205 A,2006-09-13,US 71756005 P;;US 74728006 P;;US 2006/0035958 W,2005-09-14,Dipeptidyl peptidase inhibitors for treating diabetes,,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/055-421-468-513-911,Patent Application,no,0,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K31/513;;A61K31/44;;A61P3/10,,0,0,,,,ACTIVE
104,JO,B1,JO 3721 B1,062-533-957-040-756,2021-01-31,2021,JO P20060308 A,2006-09-13,US 71755805 P,2005-09-14,Administration of Dipeptidyl Peptidase inhibitors,"<p>Pharmaceutical compositions comprising 2-((6-(3R)-3-Amino-1-piperidinyl)-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-Pyrimidinyl)methyl)-benzonitrile AND Pharmaceutical ACCEPTABLE SALTS THEREOF ARE PROVIDED AS WELL AS Kits and articles of manufacture comprising the Pharmaceutical compositions as well as methods of using the Pharmaceutical compositions.</p>",TAKEDA PHARMACEUTICALS CO,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/062-533-957-040-756,Granted Patent,no,0,0,4,76,0,,C07D263/46;;A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;C07D209/12;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32,,0,0,,,,ACTIVE
105,AR,A2,AR 109064 A2,063-644-526-536-651,2018-10-24,2018,AR P170101976 A,2017-07-14,US 71756005 P,2005-09-14,COMPOSICIÓN FARMACÉUTICA SÓLIDA FORMULADA BAJO UNA FORMA DE DOSIFICACIÓN UNITARIA QUE CONTIENE UN INHIBIDOR DE LA DIPEPTIDIL PEPTIDASA,"Composiciones farmacéuticas sólidas formuladas bajo una forma de dosificación unitaria, donde dicha forma de dosificación unitaria comprende entre 1 mg y 250 mg del compuesto de fórmula (1), y un vehículo farmacéuticamente aceptable. Reivindicación 12: La composición farmacéutica sólida acorde con cualquiera de las reivindicaciones 1 - 11, caracterizada porque dicha forma de dosificación unitaria comprende además un compuesto antidiabético distinto al compuesto de fórmula (1) que se selecciona del grupo que consiste en entre 125 mg y 2250 mg de metformina y entre 7,5 mg y 60 mg de pioglitazona. Reivindicación 18: La composición farmacéutica sólida acorde con cualquiera de las reivindicaciones 1 - 17, caracterizada porque se utiliza para tratar la diabetes Tipo I o Tipo II.",TAKEDA PHARMACEUTICALS CO,COVINGTON PAUL;;CHRISTOPHER RONALD J,,https://lens.org/063-644-526-536-651,Amended Application,no,0,0,3,57,0,,A61K31/513;;A61K31/155;;A61K31/4439;;A61P3/10,,0,0,,,,DISCONTINUED
106,HR,T1,HR P20120004 T1,061-772-967-337-416,2012-03-31,2012,HR P20120004 T,2012-01-02,US 71756005 P;;US 74728006 P;;US 2006/0035958 W,2005-09-14,DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETES,"Farmaceutska kompozicija formulirana u pojedinačnom doznom obliku, pri čemu takav pojedinačni dozni oblik sadrži između 1 mg i 250 mg spoja I, pri čemu spoj I ima formulu Patent sadrži još 47 patentnih zahtjeva.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/061-772-967-337-416,Granted Patent,no,0,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K31/513;;A61P3/10,,0,0,,,,ACTIVE
107,HR,T4,HR P20120004 T4,103-204-623-168-993,2014-06-06,2014,HR P20120004 T,2012-01-02,US 71756005 P;;US 74728006 P;;US 2006/0035958 W,2005-09-14,DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETES,,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/103-204-623-168-993,Amended Patent,no,0,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K31/513;;A61P3/10,,0,0,,,,ACTIVE
108,US,A1,US 2011/0212982 A1,138-983-118-776-264,2011-09-01,2011,US 201113080434 A,2011-04-05,US 201113080434 A;;US 53149506 A;;US 71755805 P;;US 74727306 P,2005-09-14,Administration of Dipeptidyl Peptidase Inhibitors,"Pharmaceutical compositions comprising 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/138-983-118-776-264,Patent Application,yes,7,16,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;A61K31/335;;C07D209/12;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,514/274,0,0,,,,DISCONTINUED
109,WO,A1,WO 2007/033350 A1,173-241-615-487-144,2007-03-22,2007,US 2006/0035958 W,2006-09-13,US 71756005 P;;US 74728006 P,2005-09-14,DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETES,"Pharmaceutical compositions comprising 2- [6- (3-Amino-piperidin-l-yl)-3-methyl-2, 4-dioxo-3, 4-dihydro-2H-pyrimidin-l-ylmethyl] -4-fluoro-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions. The compositions may be used for the treatment of diabetes.",TAKEDA PHARMACEUTICAL;;CHRISTOPHER RONALD J;;COVINGTON PAUL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/173-241-615-487-144,Patent Application,yes,2,66,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K31/513;;A61K31/44;;A61P3/10,,0,0,,,,PENDING
110,BR,B1,BR PI0616077 B1,027-545-099-637-159,2020-10-20,2020,BR PI0616077 A,2006-09-13,US 71755805 P;;US 74727306 P;;US 2006/0035708 W,2005-09-14,"composição farmacêutica formulada em uma dose única, kit, artigo de manufatura, uso da composição farmacêutica e uso de um ou mais compostos antidiabéticos","administração de inibidores de dipeptidil peptidase são providas composições farmacêuticas compreendendo 2- [[5-[(3r)-3-amino-1-piperidifinil]-3,4-diidro-3-metil-2,4-dioxo-1(2h)pirímidinil]metíl] - benzonitrila e sais farmaceuticamente aceitáveis da mesma, bem como kits e artigos de manufatura compreendendo as composições farmacêuticas, bem como métodos de uso das composições farmacêuticas.",TAKEDA PHARMACEUTICALS CO,PAUL COVINGTON;;RONALD J CHRISTOPHER,,https://lens.org/027-545-099-637-159,Granted Patent,no,0,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/44;;A61K31/131;;C07D209/12;;A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/513;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
111,DK,T3,DK 1942898 T3,048-738-818-371-426,2012-01-09,2012,DK 06803649 T,2006-09-13,US 71756005 P;;US 74728006 P;;US 2006/0035958 W,2005-09-14,Dipeptidylpeptidase-inhibitorer til behandling af diabetes,,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/048-738-818-371-426,Granted Patent,no,0,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K31/513;;A61P3/10,,0,0,,,,ACTIVE
112,UA,C2,UA 91717 C2,062-705-079-001-638,2010-08-25,2010,UA A200804053 A,2006-09-13,US 71755805 P;;US 2006/0035708 W,2005-09-14,"ADMINISTRATION OF 2-[[6-[(3R)-3-AMINO-L-PIPERIDINYL]-3,4-DIHYDRO-3-METHYL-2,4-DIOXO- L(2H)-PYRIMAIDINYL]METHYL]-BENZONITRILE FOR THE TREATMENT OF CONDITIONS MEDIATED WITH DIPEPTIDYL PEPTIDASE INHIBITORS","Pharmaceutical compositions comprising 2-[[6-[(3R)-3-amino-l-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo- l(2H)-pyrimaidinyl]methyl]-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/062-705-079-001-638,Limited Patent,no,0,0,4,76,0,,A61K31/513;;A61P3/10,,0,0,,,,EXPIRED
113,EA,B1,EA 015735 B1,119-341-861-997-203,2011-10-31,2011,EA 200800727 A,2006-09-13,US 71755805 P;;US 74727306 P;;US 2006/0035708 W,2005-09-14,"PHARMACEUTICAL COMPOSITIONS COMPRISING 2-[[6-[(3R)-3-AMINO-1-PIPERIDINYL]-3,4-DIHYDRO-3-METHYL-2,4-DIOXO-1(2H)-PYRIMIDINYL]METHYL]-BENZONITRILE","Pharmaceutical compositions comprising from 12.5 to 250 mg of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile (compound I) in a standard medical form as well as kits and articles comprising said pharmaceutical compositions.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/119-341-861-997-203,Granted Patent,no,2,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;A61K31/131;;C07D209/12;;A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/44;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
114,CA,A1,CA 2622472 A1,129-907-277-676-606,2007-03-22,2007,CA 2622472 A,2006-09-13,US 71756005 P;;US 74728006 P;;US 2006/0035958 W,2005-09-14,DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETES,,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/129-907-277-676-606,Patent Application,no,0,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K31/513;;A61K31/44;;A61P3/10,,0,0,,,,ACTIVE
115,JO,B1,JO 3254 B1,123-089-896-616-290,2018-09-16,2018,JO P20060309 A,2006-09-13,US 71756005 P,2005-09-14,Dipeptidyl Peptidase inhibitors for Treating diabetes,"Pharmaceutical compositions comprising 2-[6-(3-Amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1- ylmethyl]-4-fluoro benzonitrile and pharmaceutical acceptable salts thereof are provided as well as kits and articles of manufacture comprising the Pharmaceutical compositions as well as methods of using the Pharmaceutical compositions.",TAKEDA PHARMACEUTICALS CO,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/123-089-896-616-290,Granted Patent,no,0,0,3,57,0,,A61K31/44;;A61K31/513;;A61P3/10,,0,0,,,,ACTIVE
116,MY,A,MY 145447 A,151-726-482-686-381,2012-02-15,2012,MY PI20090970 A,2007-09-11,US 2006/0035958 W;;US 89462807 P,2006-09-13,"USE OF 2-6(3-AMINO-PIPERIDIN-1-YL)-3-METHYL-2, 4-DIOXO-3, 4-DIHYDRP-2H-PYRIMIDIN-1-YLMETHYL-4-FLUORO-BENZONITRILE","PHARMACEUTICAL COMPOSITIONS COMPRISING 2-[6-(3-AMINO-PIPERIDIN-1-YL)-3-METHYL-2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YLMETHYL]-4-FLUORO-BENZONITRILE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF ARE PROVIDED AS WELL AS KITS AND ARTICLES OF MANUFACTURE COMPRISING THE PHARMACEUTICAL COMPOSITIONS AS WELL AS METHODS OF USING THE PHARMACEUTICAL COMPOSITIONS.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;PAUL COVINGTON,,https://lens.org/151-726-482-686-381,Granted Patent,no,0,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61K31/513,,0,0,,,,ACTIVE
117,HK,A1,HK 1119086 A1,166-917-872-264-455,2009-02-27,2009,HK 08113164 A,2008-12-03,US 2006/0035958 W;;US 71756005 P;;US 74728006 P,2005-09-14,DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETES,,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/166-917-872-264-455,Patent Application,no,0,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K/;;A61P/,,0,0,,,,PENDING
118,ZA,B,ZA 200802857 B,168-123-800-883-642,2009-09-30,2009,ZA 200802857 A,2006-09-13,US 71756005 P;;US 74728006 P;;US 2006/0035958 W,2005-09-14,Dipeptidyl peptidase inhibitors for treating diabetes,,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;PAUL COVINGTON,,https://lens.org/168-123-800-883-642,Granted Patent,no,0,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K/;;A61P/,,0,0,,,,ACTIVE
119,DK,T4,DK 1931350 T4,001-604-396-500-451,2021-09-20,2021,DK 06803523 T,2006-09-13,US 71755805 P;;US 74727306 P;;US 2006/0035708 W,2005-09-14,ADMINISTRATION AF INHIBITORER AF DIPEPTIDYLPEPTIDASE,,TAKEDA PHARMACEUTICALS CO,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/001-604-396-500-451,Amended Patent,no,0,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;A61K31/131;;C07D209/12;;A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/44;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
120,BR,B8,BR PI0616077 B8,035-238-420-542-632,2021-05-25,2021,BR PI0616077 A,2006-09-13,US 71755805 P;;US 74727306 P;;US 2006/0035708 W,2005-09-14,"composição farmacêutica formulada em uma dose única, kit, artigo de manufatura, uso da composição farmacêutica e uso de um ou mais compostos antidiabéticos","administração de inibidores de dipeptidil peptidase. são providas composições farmacêuticas compreendendo 2- [[5-[(3r)-3-amino-1-piperidifinil]-3,4-diidro-3-metil-2,4-dioxo-1(2h)pirímidinil]metíl] - benzonitrila e sais farmaceuticamente aceitáveis da mesma, bem como kits e artigos de manufatura compreendendo as composições farmacêuticas, bem como métodos de uso das composições farmacêuticas.",TAKEDA PHARMACEUTICALS CO,PAUL COVINGTON;;RONALD J CHRISTOPHER,,https://lens.org/035-238-420-542-632,Amended Patent,no,0,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/44;;A61K31/131;;C07D209/12;;A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/513;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
121,ME,B,ME 02005 B,099-873-885-898-617,2012-08-31,2012,ME P15512 A,2006-09-13,US 71756005 P;;US 74728006 P;;EP 06803649 A;;US 2006/0035958 W,2005-09-14,DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETES,,TAKEDA PHARMACEUTICALS CO,COVINGTON PAUL;;CHRISTOPHER RONALD J,,https://lens.org/099-873-885-898-617,Granted Patent,no,0,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K31/513;;A61K31/44;;A61P3/10,,0,0,,,,ACTIVE
122,ES,T5,ES 2376351 T5,101-509-169-828-270,2014-07-15,2014,ES 06803649 T,2006-09-13,US 71756005 P;;US 74728006 P;;US 2006/0035958 W,2005-09-14,Inhibidores de la dipeptidil-peptidasa para el tratamiento de la diabetes,,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/101-509-169-828-270,Amended Patent,no,0,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K31/513;;A61P3/10,,0,0,,,,ACTIVE
123,CY,T1,CY 1114925 T1,122-102-978-244-766,2015-12-09,2015,CY 141100098 T,2014-02-06,EP 06803523 A;;US 71755805 P;;US 74727306 P,2005-09-14,ΧΟΡΗΓΗΣΗ ΑΝΑΣΤΟΛΕΩΝ ΔΙΠΕΠΤΙΔΥΛΟΠΕΠΤΙΔΑΣΗΣ,"Φαρμακευτικές συνθέσεις που περιλαμβάνουν 2-[[6-[(3R)-3-αμινο-1-πιπεριδινυλ] -3,4-διυδρο-3-μεθυλ-2,4-διοξο-1(2Η)-πυριμιδινυλ] μεθυλ] -βενζονιτρίλιο και φαρμακευτικώς αποδεκτά άλατα αυτού παρέχονται, καθώς και κιτ και εξαρτήματα της κατασκευής τα οποία περιλαμβάνουν τις φαρμακευτικές συνθέσεις, καθώς και μέθοδοι της χρήσης των φαρμακευτικών συνθέσεων.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/122-102-978-244-766,Granted Patent,no,0,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;A61K31/131;;C07D209/12;;A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/44;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
124,CN,A,CN 102908351 A,130-507-015-263-046,2013-02-06,2013,CN 201210399309 A,2006-09-13,US 71755805 P;;US 74727306 P,2005-09-14,Dipeptidyl peptidase inhibitors for treating diabetes,"The invention relates to dipeptidyl peptidase inhibitors for treating diabetes. Pharmaceutical compositions comprising 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/130-507-015-263-046,Patent Application,no,0,1,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;A61K31/335;;C07D209/12;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/535;;A61K31/5377;;A61K45/06;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
125,RS,B2,RS 53155 B2,141-393-014-861-083,2021-10-29,2021,RS P20140046 A,2006-09-13,US 71755805 P;;US 74727306 P;;US 2006/0035708 W;;EP 06803523 A,2005-09-14,ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS,,TAKEDA PHARMACEUTICALS CO,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/141-393-014-861-083,Amended Patent,no,0,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;A61K31/131;;C07D209/12;;A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/44;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
126,NO,L,NO 20081569 L,145-178-647-474-431,2008-06-10,2008,NO 20081569 A,2008-03-31,US 71755805 P;;US 74727306 P;;US 2006/0035708 W,2005-09-14,Administrasjon av dipeptidylpeptildaseinhibitorer,"Farmasøytiske sammensetninger som innbefatter 2-[[6-[(3R)-3-amino-l-piperidinyI]-3,4-dihydro-3-metyl-2,4-diokso-1(2H)-pyrimidinyl]metyl]-benzonitril og farmasøytisk akseptable salter derav er tilveiebrakt så vel som kit og fremstilte artikler som innbefatter de farmasøytiske sammensetningene så vel som fremgangsmåter for anvendelse av de farmasøytiske sammensetningene.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/145-178-647-474-431,Abstract,no,0,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;A61K31/335;;C07D209/12;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
127,PL,T5,PL 1931350 T5,175-527-045-813-361,2021-11-15,2021,PL 06803523 T,2006-09-13,US 71755805 P;;US 74727306 P;;EP 06803523 A;;US 2006/0035708 W,2005-09-14,ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS,,TAKEDA PHARMACEUTICALS CO,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/175-527-045-813-361,Unknown,no,0,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;A61K31/131;;C07D209/12;;A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/44;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,PENDING
128,HR,T1,HR P20140091 T1,194-311-957-788-839,2014-02-28,2014,HR P20140091 T,2006-09-13,US 71755805 P;;US 74727306 P;;EP 06803523 A;;US 2006/0035708 W,2005-09-14,ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS,,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/194-311-957-788-839,Granted Patent,no,0,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/131;;A61K31/513;;A61K31/335;;C07D209/12;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/44;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
129,RS,B,RS 53155 B,052-582-197-355-891,2014-06-30,2014,RS P20140046 A,2006-09-13,US 71755805 P;;US 74727306 P;;US 2006/0035708 W;;EP 06803523 A,2005-09-14,ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS,"Farmaceutska kompozicija formulisana kao pojedinačna dozna forma, naznačena time, što takva pojedinačna dozna forma sadrži između 5 mg i 250 mg Jedinjenja I, gde pomenuto Jedinjenje I ima formuluuz iznimku sledećih kompozicija:(a) farmaceutska kompozicija formulisana za oralnu administraciju koja sadrži 10 do 100 mg Jedinjenja I, 105 mg monohidrata limunske kiseline, 18 mg natrijum hidroksida, agensa za ukus i vode do 100 ml; i(b) farmaceutska kompozicija formulisana za intravenoznu administraciju koja sadrži 5 do 10 mg Jedinjenja I, 1.05 mg monohidrata limunske kiseline, 0.18 mg natrijum hidroksida, dovoljne količine monohidrata dekstroze da pomenuta formulacija bude izotonična, i vode do 1 ml.Prijava sadrži još 47 patentnih zahteva.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/052-582-197-355-891,Granted Patent,no,0,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;A61K31/131;;C07D209/12;;A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/44;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
130,MA,B1,MA 29799 B1,087-889-521-386-849,2008-09-01,2008,MA 30773 A,2008-03-19,US 71755805 P;;US 74727306 P,2005-09-14,ADMINISTRATION D'INHIBITEURS DE DIPEPTIDYL PEPTIDASE,"La présente invention porte sur des compositions pharmaceutiques renfermant du 2-[[6-[(3R)-3-amino-1-pipéridinyl]-3,4-dihydro-3-méthyl-2,4-dioxo-1(2H)-pyrimidinyl]méthyl]-benzonitrile et des sels pharmaceutiquement acceptables de ce composé, sur des trousses et des articles manufacturés comprenant ces compositions pharmaceutiques, ainsi que sur des procédés d'utilisation de ces compositions pharmaceutiques.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/087-889-521-386-849,Granted Patent,no,0,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;C07D209/12;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
131,MY,A,MY 147393 A,088-921-714-596-977,2012-11-30,2012,MY PI20080654 A,2006-09-13,US 71756005 P;;US 74728006 P,2005-09-14,ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS,"ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS PHARMACEUTICALCOMPOSITIONS COMPRISING 2- [6- (3-AMINO- PIPERIDIN-1-YL)-3-METHYL-2, 4-DIOXO-3, 4-DIHYDRO-2H- 5 PYRIMIDIN-1-YLMETHYL]-4-FLUORO-BENZONITRILE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF ARE PROVIDED AS WELL AS KITS AND ARTICLES OF MANUFACTURE COMPRISING THE PHARMACEUTICAL COMPOSITIONS AS WELL AS METHODS OF USING THE PHARMACEUTICAL COMPOSITIONS. THE 10 COMPOSITIONS MAY BE USED FOR THE TREATMENT OF DIABETES.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;PAUL COVINGTON,,https://lens.org/088-921-714-596-977,Granted Patent,no,0,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K31/513,,0,0,,,,ACTIVE
132,EP,B1,EP 1942898 B1,104-703-818-479-268,2011-11-09,2011,EP 06803649 A,2006-09-13,US 2006/0035958 W;;US 71756005 P;;US 74728006 P,2005-09-14,DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETES,,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/104-703-818-479-268,Granted Patent,yes,2,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K31/513;;A61P3/10,,0,0,,,,ACTIVE
133,TW,A,TW 200803861 A,162-196-535-659-832,2008-01-16,2008,TW 95134082 A,2006-09-14,US 71755805 P;;US 74727306 P,2005-09-14,Administration of dipeptidyl peptidase inhibitors,"Pharmaceutical compositions comprising 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/162-196-535-659-832,Patent of Addition,no,0,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;A61K31/131;;C07D209/12;;A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/44;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
134,CA,A1,CA 2622608 A1,162-782-526-384-015,2007-03-22,2007,CA 2622608 A,2006-09-13,US 71755805 P;;US 74727306 P;;US 2006/0035708 W,2005-09-14,DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETIS,,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/162-782-526-384-015,Patent Application,no,0,0,72,76,0,A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07K2317/76;;C07C257/06;;C07C317/40;;C07D209/26;;C07C2602/08;;A61K31/155;;A61K31/4439;;A61K31/513;;A61P1/02;;A61P1/04;;A61P1/14;;A61P11/08;;A61P13/12;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P37/08;;A61P43/00;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/131;;A61K31/513;;C07K2317/76;;A61K31/131;;A61K31/44;;A61K45/06;;A61K2039/505;;C07K16/2896;;C07K16/40;;C07C257/06;;C07C2602/08;;C07D209/26;;C07C317/40;;A61K31/513;;A61K31/155;;A61K31/4439,A61K31/513;;A61K31/131;;C07D209/12;;A61K31/335;;A61K31/34;;A61K31/341;;A61K31/343;;A61K31/395;;A61K31/403;;A61K31/4035;;A61K31/404;;A61K31/405;;A61K31/415;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/44;;A61K31/535;;A61K31/5377;;A61P3/00;;A61P3/10;;A61P11/08;;A61P25/04;;A61P29/00;;A61P37/08;;C07C257/06;;C07C259/04;;C07C317/40;;C07D207/337;;C07D209/26;;C07D209/46;;C07D209/82;;C07D231/12;;C07D263/32;;C07D263/46;;C07D277/00;;C07D279/00;;C07D307/72;;C07D307/92;;C07D313/12;;C07D487/04;;C07D491/044;;C07D491/052;;C07D495/04,,0,0,,,,ACTIVE
135,WO,A1,WO 2020/028476 A1,182-424-921-202-82X,2020-02-06,2020,US 2019/0044310 W,2019-07-31,US 201816052045 A,2018-08-01,"SYSTEMS, APPARATUS AND METHODS FOR COLLECTING AND SEPARATING FLOATING DEBRIS AND WATER FROM A BODY OF WATER","Systems, apparatus and methods useful for collecting and separating floating debris and water from a body of water on a vessel, the vessel including at least one inflow regulator (IFR) chamber at least partially separated from a main collection compartment and at least one fluid discharge pump.",OCEAN CLEANER LLC,COVINGTON RUSSELL;;FOLSE KIM;;GUNTER CHRISTOPHER,,https://lens.org/182-424-921-202-82X,Patent Application,yes,5,0,18,34,0,E02B15/046;;B63B35/32;;C02F1/40;;C02F2101/32;;C02F2103/007;;C02F2201/008;;E02B15/048;;Y02A20/204;;E02B15/046;;E02B15/048;;B63B35/32;;E02B15/046;;B63B35/32;;C02F1/40;;C02F2103/007;;C02F2201/008;;E02B15/046;;E02B15/048;;E02B15/0864;;E02B15/10;;E02B15/106,E02B15/10,,0,0,,,,PENDING
136,SG,A,SG 11202100505V A,178-981-977-687-018,2021-02-25,2021,SG 11202100505V A,2019-07-31,US 201816052045 A;;US 2019/0044310 W,2018-08-01,"SYSTEMS, APPARATUS AND METHODS FOR COLLECTING AND SEPARATING FLOATING DEBRIS AND WATER FROM A BODY OF WATER",,OCEAN CLEANER LLC,COVINGTON RUSSELL;;FOLSE KIM;;GUNTER CHRISTOPHER,,https://lens.org/178-981-977-687-018,Unknown,no,0,0,18,34,0,E02B15/046;;B63B35/32;;C02F1/40;;C02F2101/32;;C02F2103/007;;C02F2201/008;;E02B15/048;;Y02A20/204;;E02B15/046;;E02B15/048;;B63B35/32;;E02B15/046;;B63B35/32;;C02F1/40;;C02F2103/007;;C02F2201/008;;E02B15/046;;E02B15/048;;E02B15/0864;;E02B15/10;;E02B15/106,E02B15/10,,0,0,,,,PENDING
137,EC,A,EC SP099250 A,098-095-324-379-628,2009-06-30,2009,EC SP099250 A,2009-04-09,US 89462807 P;;US 2006/0035958 W,2006-09-13,"USO DE 2-6-(3-amino-piperidin-1-Il)-3-metil-2,4-dioxo-3,4-dihIdro-2H-pIrimidin-1-IlmetIL-4-fluoro-benzonitrilo","RESUMEN DE LA INVENCIÓNSe proporcionan composiciones farmacéuticas que comprenden 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2H-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo y sales farmacéuticamente aceptables del mismo, así como también kits y artículos de fabricación que comprenden las composiciones farmacéuticas, así como también los métodos para utilizar las composiciones farmacéuticas.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD;;OGAWA ATSUSHI;;COVINGTON PAUL,,https://lens.org/098-095-324-379-628,Patent Application,no,0,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61K31/513;;A61P31/18,,0,0,,,,PENDING
138,AU,A1,AU 2007/296556 A1,009-170-936-354-121,2008-03-20,2008,AU 2007/296556 A,2007-09-11,US 89462807 P;;US 2006/0035958 W;;US 2007/0078177 W,2006-09-13,"Use of 2-6- (3-Amino-piperidin-l-yl) -3-methyl-2, 4-dioxo-3, 4-dihydr0-2H-pyrimidin-1-ylmet hyl-4-fluoro-benzonitrile",,TAKEDA PHARMACEUTICAL,COVINGTON PAUL;;CHRISTOPHER RONALD J;;OGAWA ATSUSHI,,https://lens.org/009-170-936-354-121,Patent Application,no,0,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61K31/4439;;A61K31/513;;A61K45/06;;A61P3/10;;A61P5/00;;A61P5/50;;A61P31/18;;A61P35/00,,0,0,,,,ACTIVE
139,CY,T1,CY 1112292 T1,013-393-990-463-241,2015-12-09,2015,CY 111101129 T,2011-11-22,EP 07842260 A;;US 89462807 P,2007-03-13,"ΧΡΗΣΗ ΤΟΥ 2-6-(3-ΑΜΙΝΟ-ΠΙΠΕΡΙΔΙΝ-1-ΥΛ)-3-ΜΕΘΥΛ-2,4-ΔΙΟΞΟ-3,4-ΔΙΥΔΡΟ-2Η-ΠΥΡΙΔΙΝ-1-ΥΛΜΕΘΥΛ-4-ΦΘΟΡΟ-ΒΕΝΖΟΝΙΤΡΙΛΙΟΥ ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΤΟΥ ΔΙΑΒΗΤΗ, ΤΟΥ ΚΑΡΚΙΝΟΥ, ΑΥΤΟΑΝΟΣΩΝ ΔΙΑΤΑΡΑΧΩΝ ΚΑΙ ΤΗΣ ΜΟΛΥΝΣΕΩΣ HIV","Παρέχονται φαρμακευτικές συνθέσεις περιλαμβάνουσες 2-[6-(3-αμινο-πιπεριδιν-1-υλ)-3-μεθυλ-2,4-διοξο-3,4-διυδρο-2Η-πυριμιδιν-1-υλμεθυλ]-4-φθορο-βενζονιτρίλιο και φαρμακευτικά αποδεκτά άλατα αυτού καθώς επίσης και συσκευασίες και κατασκευαστικά προϊόντα που περιλαμβάνουν τις φαρμακευτικές συνθέσεις καθώς επίσης και μέθοδοι χρήσεως των φαρμακευτικών συνθέσεων.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;OGAWA ATSUSHI;;COVINGTON PAUL,,https://lens.org/013-393-990-463-241,Granted Patent,no,0,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61K31/513;;A61P3/10;;A61P5/50;;A61P31/18;;A61P35/00,,0,0,,,,ACTIVE
140,HK,A1,HK 1131057 A1,064-979-224-470-301,2010-01-15,2010,HK 09110733 A,2009-11-17,US 2007/0078177 W;;US 2006/0035958 W;;US 89462807 P,2006-09-13,"USE OF 2-6-(3-AMINO-PIPERIDIN-1-YL)-3-METHYL-2,4-DIOXO-3,4-DIHYDRO-2H- PYRIMIDIN-1-YLMETHYL-4-FLUORO-BENZONITRILE FOR TREATING DIABETES, CANCER, AUTOIMMUNE DISORDERS AND HIV INFECTION",,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;OGAWA ATSUSHI;;COVINGTON PAUL,,https://lens.org/064-979-224-470-301,Patent Application,no,0,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61K/;;A61P/,,0,0,,,,PENDING
141,ES,T3,ES 2370873 T3,118-857-114-941-397,2011-12-23,2011,ES 07842260 T,2007-09-11,US 89462807 P,2007-03-13,"UTILIZACION DEL 2-6-(3-AMINO-PIPERIDIN-1-IL)-3-METIL-2,4-DIOXO-3,4-DIHIDRO-2H-PIRIMIDIN-1-ILMETIL-4-FLUORO-BENZONITRILO PARA EL TRATAMIENTO DE LA DIABETES, EL CANCER, LOS TRASTORNOS AUTOINMUNITARIOS Y LA INFECCION POR EL VIH.","2-[6-(3-Amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2H-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo (Compuesto I) para su utilización como un medicamento cuando se administra a una dosis semanal de entre 50 mg y 250 mg, en el que la dosis semanal se administra una vez a la semana.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;OGAWA ATSUSHI;;COVINGTON PAUL,,https://lens.org/118-857-114-941-397,Granted Patent,no,0,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61K31/513;;A61P3/10;;A61P5/50;;A61P31/18;;A61P35/00,,0,0,,,,ACTIVE
142,PT,E,PT 2073810 E,149-871-879-963-489,2011-09-30,2011,PT 07842260 T,2007-09-11,US 89462807 P;;US 2006/0035958 W,2006-09-13,"USE OF 2-6-(3-AMINO-PIPERIDIN-1-YL)-3-METHYL-2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YLMETHYL-4-FLUORO-BENZONITRILE FOR TREATING DIABETES, CANCER, AUTOIMMUNE DISORDERS AND HIV INFECTION",,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;OGAWA ATSUSHI;;COVINGTON PAUL,,https://lens.org/149-871-879-963-489,Granted Patent,no,0,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61K31/513;;A61P3/10;;A61P5/50;;A61P31/18;;A61P35/00,,0,0,,,,ACTIVE
143,SI,T1,SI 2073810 T1,017-442-095-815-830,2011-12-30,2011,SI 200730772 T,2007-09-11,US 2006/0035958 W;;US 89462807 P;;US 2007/0078177 W;;EP 07842260 A,2006-09-13,"USE OF 2-6-(3-AMINO-PIPERIDIN-1-YL)-3-METHYL-2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YLMETHYL-4-FLUORO-BENZONITRILE FOR TREATING DIABETES, CANCER, AUTOIMMUNE DISORDERS AND HIV INFECTION",,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;OGAWA ATSUSHI;;COVINGTON PAUL,,https://lens.org/017-442-095-815-830,Granted Patent,no,0,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61K31/513;;A61P3/00;;A61P5/00;;A61P31/00;;A61P35/00,,0,0,,,,ACTIVE
144,CR,A,CR 10711 A,020-018-349-709-671,2009-06-05,2009,CR 10711 A,2009-04-13,US 89462806 P,2006-09-13,"USO DE 2-6-(3-AMINO-PIPERIDIN-1-IL)-3-METIL-2,4-DIOXO-3,4-DIHIDRO-2H-PIRIMIDIN-1-ILMETIL-4-FLUORO-BENZONITRILO",,TAKEDA PHARMACEUTICAL,RONALD J CHRISTOPHER;;ATSUSHI OGAWA;;PAUL COVINGTON,,https://lens.org/020-018-349-709-671,Patent Application,no,0,0,1,1,0,,A61K31/513;;A61P3/10;;A61P5/50;;A61P31/18;;A61P35/00,,0,0,,,,PENDING
145,US,A1,US 2011/0077402 A1,021-514-197-883-425,2011-03-31,2011,US 96544810 A,2010-12-10,US 96544810 A;;US 4699708 A;;US 89462807 P,2007-03-13,ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS,"Pharmaceutical compositions comprising 2-[6-(3-Amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL;;OGAWA ATSUSHI,,https://lens.org/021-514-197-883-425,Patent Application,yes,0,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61K31/506;;C07D401/04;;A61P3/10;;A61P31/18;;A61P35/00;;A61P37/00,544/310;;514/274,0,0,,,,DISCONTINUED
146,EP,A2,EP 2073810 A2,120-527-633-767-562,2009-07-01,2009,EP 07842260 A,2007-09-11,US 2007/0078177 W;;US 2006/0035958 W;;US 89462807 P,2006-09-13,"USE OF 2-6-(3-AMINO-PIPERIDIN-1-YL)-3-METHYL-2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YLMETHYL-4-FLUORO-BENZONITRILE FOR TREATING DIABETES, CANCER, AUTOIMMUNE DISORDERS AND HIV INFECTION",,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;OGAWA ATSUSHI;;COVINGTON PAUL,,https://lens.org/120-527-633-767-562,Patent Application,yes,0,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61K31/513;;A61P3/10;;A61P5/50;;A61P31/18;;A61P35/00,,0,0,,,,ACTIVE
147,NO,B1,NO 342004 B1,063-626-515-084-38X,2018-03-12,2018,NO 20091133 A,2009-03-17,US 89462807 P;;US 2006/0035958 W;;US 2007/0078177 W,2006-09-13,"2-[6-(3-amino-piperidin-1-yl)-3-metyl-2,4-diokso-3,4-dihydro-2H-pyrimidin-1-ylmetyl]-4-fluor-benzonitril for anvendelse som et medikament for behandling av diabetes, cancer, en autoimmun sykdom eller HIV infeksjon","Farmasøytiske sammensetninger som innbefatter 2-[6-(3-amino-piperidin-l-yl)-3-metyl-2,4-diokso-3,4-dihydro-2H-pyrimidin-1-ylmetyl]-4-fluor-benzonitril og farmasøytisk akseptable salter derav er tilveiebrakt så vel som kit og fremstilte artikler som innbefatter de farmasøytiske sammensetningene så vel som fremgangsmåter for anvendelse av de farmasøytiske sammensetningene.",TAKEDA PHARMACEUTICALS CO,CHRISTOPHER RONALD J;;COVINGTON PAUL;;OGAWA ATSUSHI,,https://lens.org/063-626-515-084-38X,Granted Patent,no,1,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61K31/506,,0,0,,,,ACTIVE
148,TW,A,TW 200827344 A,096-494-425-700-367,2008-07-01,2008,TW 96134051 A,2007-09-12,US 2006/0035958 W;;US 89462807 P,2006-09-13,Administration of dipeptidyl peptidase inhibitors,"Pharmaceutical compositions comprising 2-[6-(3-Amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;OGAWA ATSUSHI;;COVINGTON PAUL,,https://lens.org/096-494-425-700-367,Patent of Addition,no,0,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,C07D401/04;;A61K31/444;;A61K31/506;;A61P3/10;;A61P31/18;;A61P35/00;;A61P37/00,,0,0,,,,ACTIVE
149,AT,T1,AT E522216 T1,145-625-178-552-629,2011-09-15,2011,AT 07842260 T,2007-09-11,US 2006/0035958 W;;US 89462807 P;;US 2007/0078177 W,2006-09-13,"VERWENDUNG VON 2-6-(3-AMIN-PIPERIDIN-1-YL)-3- METHYL-2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1- YLMETHYL-4-FLUOR-BENZONITRIL ZUR BEHANDLUNG VON DIABETES, KREBS, AUTOIMMUNERKRANKUNGEN UND HIV- INFEKTIONEN",,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;OGAWA ATSUSHI;;COVINGTON PAUL,,https://lens.org/145-625-178-552-629,Granted Patent,no,0,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,,,0,0,,,,ACTIVE
150,UA,C2,UA 99112 C2,144-173-745-424-615,2012-07-25,2012,UA A200903416 A,2007-09-11,US 2006/0035958 W,2006-09-13,"USE OF 2-[6-(3-AMINO-PIPERIDIN-1-YL)-3-METHYL-2,4-DIOXO-3,4-DIHYDR0-2H-PYRIMIDIN-1-YLMETHYL]-4-FLUOROBENZONITRILE","Pharmaceutical compositions comprising 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl]-4-fluorobenzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;OGAWA ATSUSHI;;COVINGTON PAUL,,https://lens.org/144-173-745-424-615,Limited Patent,no,0,0,1,1,0,,A61K31/513;;A61P3/10;;A61P5/50;;A61P31/18;;A61P35/00;;A61P37/00,,0,0,,,,EXPIRED
151,PE,A1,PE 20081150 A1,186-481-816-424-830,2008-10-03,2008,PE 2007001217 A,2007-09-11,US 2006/0035958 W;;US 89462807 P,2006-09-13,INHIBIDORES DE DIPETIDILPEPTIDASA,"REFERIDA AL COMPUESTO 2-[6-(3-AMINO-PIPERIDIN-1-IL)-3-METIL-2,4-DIOXO-3,4-DIHIDRO-2H-PIRIMIDIN-1-ILMETIL]-4-FLUORO-BENZONITRILO (COMPUESTO I) O UNA SAL DEL MISMO, EL CUAL SE ADMINISTRA EN UNA DOSIS SEMANAL DE ENTRE 50 MG Y 250 MG. LA SAL PREFERIDA DEL COMPUESTO I ES EL SUCCINATO. DICHO COMPUESTO TIENE ACTIVIDAD INHIBITORIA DE LA DIPEPTIDILPEPTIDASA IV Y ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES TALES COMO DIABETES TIPO I O II, ENFERMEDAD INFLAMATORIA INTESTINAL, MUCOSITIS ORAL, ENTRE OTRAS",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL;;OGAWA ATSUSHI,,https://lens.org/186-481-816-424-830,Patent Application,no,0,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61K31/513;;C07D211/00,,0,0,,,,DISCONTINUED
152,ZA,B,ZA 200901814 B,188-754-765-812-959,2010-06-30,2010,ZA 200901814 A,2007-09-11,US 2006/0035958 W;;US 71756005 P;;US 74728006 P,2005-09-14,"Use of 2-6- (3-amino-piperidin-1-yl) -3-methyl-2, 4-dioxo-3, 4-dihydro-2H-pyrimidin-1-yl methyl-4-fluoro-benzonitrile",,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;OGAWA ATSUSHI;;COVINGTON PAUL,,https://lens.org/188-754-765-812-959,Granted Patent,no,0,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K/;;A61P/,,0,0,,,,ACTIVE
153,CN,A,CN 101616673 A,196-338-741-681-293,2009-12-30,2009,CN 200780039574 A,2007-09-11,US 2006/0035958 W;;US 89462807 P,2006-09-13,"Use of 2-6- (3-amino-piperidin-l-yl) -3-methyl-2, 4-dioxo-3, 4-dihydr0-2h-pyrimidin-1-ylmet hyl-4-fluoro-benzonitrile","Pharmaceutical compositions comprising 2-[6-(3-Amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;ATSUSHI OGAWA;;PAUL COVINGTON,,https://lens.org/196-338-741-681-293,Patent Application,no,0,3,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61K31/513,,0,0,,,,DISCONTINUED
154,CA,A1,CA 2663279 A1,096-280-701-848-605,2008-03-20,2008,CA 2663279 A,2007-09-11,US 2006/0035958 W;;US 89462807 P;;US 2007/0078177 W,2006-09-13,ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS,"Pharmaceutical compositions comprising 2-[6-(3-Amino-piperidin-1-yl)-3-me thyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile an d pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.",TAKEDA PHARMACEUTICALS CO,COVINGTON PAUL;;OGAWA ATSUSHI;;CHRISTOPHER RONALD J,,https://lens.org/096-280-701-848-605,Patent Application,no,0,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61K31/513;;A61P3/10;;A61P5/50;;A61P31/18;;A61P35/00,,0,0,,,,ACTIVE
155,JP,A,JP 2015129143 A,148-960-020-577-831,2015-07-16,2015,JP 2015020882 A,2015-02-05,US 2006/0035958 W;;US 89462807 P,2006-09-13,"USE OF 2-6-(3-AMINO-PIPERIDIN-1-YL)-3-METHYL-2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDINE-1-YLMETHYL-4-FLUORO-BENZONITRILE","PROBLEM TO BE SOLVED: To provide an administration method of compounds used for inhibiting dipeptidyl peptidase IV, and to provide a therapeutic method based on the administration concerned.SOLUTION: The invention provides a pharmaceutical composition containing 2-[6-(3-amino-piperidine-1-yl)-3-methyl-2,4-dioxo 3,4-dihydro-2H-pyrimidine 1-ylmethyl]-4-fluoro-benzonitrile represented by the following formula and a pharmaceutically acceptable salt thereof, and a kit and product comprising the pharmaceutical composition concerned, and a method for using the pharmaceutical composition concerned. Specifically, a method comprising administering the compound concerned to a patient at a dose of 1-250 mg/week wherein the weekly dose is administered once per week.",TAKEDA CHEMICAL INDUSTRIES LTD,RONALD J CHRISTOPHER;;OGAWA ATSUSHI;;COVINGTON PAUL,,https://lens.org/148-960-020-577-831,Patent Application,no,4,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61K9/20;;A61K31/506;;A61P3/10;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04,,0,0,,,,PENDING
156,ME,B,ME 01960 B,003-935-669-862-319,2015-05-20,2015,ME P47211 A,2007-09-11,US 2006/0035958 W;;US 89462807 P;;EP 07842260 A;;US 2007/0078177 W;;US 71756005 P;;US 74728006 P,2005-09-14,"USE OF 2-6- (3-AMINO-PIPERIDIN-L-YL) -3-METHYL-2, 4-DIOXO-3, 4-DIHYDR0-2H-PYRIMIDIN-1-YLMET HYL-4-FLUORO-BENZONITRILE",,TAKEDA PHARMACEUTICALS CO,CHRISTOPHER RONALD J;;OGAWA ATSUSHI;;COVINGTON PAUL,,https://lens.org/003-935-669-862-319,Granted Patent,no,0,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K31/513;;A61P3/10;;A61P5/50;;A61P31/18;;A61P35/00,,0,0,,,,ACTIVE
157,AR,A1,AR 062760 A1,026-053-920-729-420,2008-12-03,2008,AR P070104030 A,2007-09-11,US 89462807 P;;US 2006/0035958 W,2006-09-13,ADMINISTRACION DE INHIBIDORES DE DIPEPTIDILPETIDASA,"Composiciones farmacéuticas que contienen 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2H-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo (compuesto 1) y sales aceptables para su uso farmacéutico, conjuntos de elementos y artículos elaborados que comprenden dichas composiciones farmacéuticas, así como sus métodos de uso. Reivindicacion 1: Un método caracterizado porque comprende la administracion de una dosis semanal de entre 1 mg y 250 mg del compuesto (1), a un paciente, donde la dosis semanal se administra una vez por semana.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;OGAWA ATSUSHI;;COVINGTON PAUL,,https://lens.org/026-053-920-729-420,Patent Application,no,0,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,,,0,0,,,,DISCONTINUED
158,TW,B,TW I434838 B,067-653-182-188-007,2014-04-21,2014,TW 96134051 A,2007-09-12,US 2006/0035958 W;;US 89462807 P,2006-09-13,"Use of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-l-yl-methyl]-4-fluoro-benzonitrile",,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;OGAWA ATSUSHI;;COVINGTON PAUL,,https://lens.org/067-653-182-188-007,Granted Patent,no,0,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,,,0,0,,,,ACTIVE
159,EA,B1,EA 017799 B1,160-184-517-639-706,2013-03-29,2013,EA 200970273 A,2007-09-11,US 2006/0035958 W;;US 89462807 P;;US 2007/0078177 W,2006-09-13,"USE OF 2-[6-(3-AMINOPIPERIDIN-1-YL)-3-METHYL-2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YLMETHYL]-4-FLUOROBENZONITRILE","Use of 2-[6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl]-4-fluorobenzonitrile and pharmaceutically acceptable salt thereof is proposed to inhibit dipeptidyl peptidase IV, in particular for the treatment of conditions mediated by DPP-IV such as diabetes, cancer, autoimmune disorders, HIV-infection.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;OGAWA ATSUSHI;;COVINGTON PAUL,,https://lens.org/160-184-517-639-706,Granted Patent,no,4,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61K31/513;;A61P3/10;;A61P5/50;;A61P31/18;;A61P35/00,,0,0,,,,ACTIVE
160,WO,A3,WO 2008/033851 A3,027-242-529-452-499,2008-08-28,2008,US 2007/0078177 W,2007-09-11,US 2006/0035958 W;;US 89462807 P,2006-09-13,"USE OF 2-6- (3-AMINO-PIPERIDIN-L-YL) -3-METHYL-2, 4-DIOXO-3, 4-DIHYDR0-2H-PYRIMIDIN-1-YLMET HYL-4-FLUORO-BENZONITRILE","Pharmaceutical compositions comprising 2-[6-(3-Amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.",TAKEDA PHARMACEUTICAL;;CHRISTOPHER RONALD J;;OGAWA ATSUSHI;;COVINGTON PAUL,CHRISTOPHER RONALD J;;OGAWA ATSUSHI;;COVINGTON PAUL,,https://lens.org/027-242-529-452-499,Search Report,yes,4,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61K31/513;;A61P3/10;;A61P5/50;;A61P31/18;;A61P35/00,,0,0,,,,PENDING
161,KR,A,KR 20150032590 A,138-720-514-912-761,2015-03-26,2015,KR 20157004543 A,2007-09-11,US 2006/0035958 W;;US 89462807 P;;US 2007/0078177 W,2006-09-13,"USE OF 2-[6-(3-AMINO-PIPERIDIN-1-YL)-3-METHYL-2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YLMETHYL]-4-FLUORO-BENZONITRILE",,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;OGAWA ATSUSHI;;COVINGTON PAUL,,https://lens.org/138-720-514-912-761,Patent Application,no,0,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61K31/4439;;A61K31/506;;A61K31/513,,0,0,,,,DISCONTINUED
162,MA,B1,MA 30725 B1,138-733-034-324-779,2009-09-01,2009,MA 31740 A,2009-03-30,US 2006/0035958 W;;US 89462807 P;;US 2007/0078177 W,2006-09-13,ADMINISTRATION D'INHIBITEURS DE LA DIPEPTIDYL PEPTIDASE,"L'INVENTION CONCERNE DES COMPOSITIONS PHARMACEUTIQUES COMPRENANT DU 2-[6-(3-AMINO-PIPÉRIDIN-1-YL) -3-MÉTHYL-2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YLMÉTHYL]-4-FLUORO-BENZONITRILE ET DES SELS PHARMACEUTIQUEMENT ACCEPTABLES DE CE COMPOSÉ, AINSI QUE DES TROUSSES ET DES ARTICLES DE FABRICATION COMPRENANT CES COMPOSITIONS PHARMACEUTIQUES ET DES MÉTHODES D'UTILISATION DESDITES COMPOSITIONS PHARMACEUTIQUES.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;OGAWA ATSUSHI;;COVINGTON PAUL,,https://lens.org/138-733-034-324-779,Granted Patent,no,0,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,,,0,0,,,,ACTIVE
163,CA,C,CA 2663279 C,175-612-278-883-826,2016-05-17,2016,CA 2663279 A,2007-09-11,US 2006/0035958 W;;US 89462807 P;;US 2007/0078177 W,2006-09-13,"USE OF 2-6-(3-AMINO-PIPERIDIN-1-YL)-3-METHYL-2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YLMETHYL-4-FLUORO-BENZONITRILE FOR TREATING DIABETES, CANCER, AUTOIMMUNE DISORDERS AND HIV INFECTION","Pharmaceutical compositions comprising 2-[6-(3-Amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.",TAKEDA PHARMACEUTICALS CO,CHRISTOPHER RONALD J;;OGAWA ATSUSHI;;COVINGTON PAUL,,https://lens.org/175-612-278-883-826,Granted Patent,no,0,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61K31/513;;A61P3/10;;A61P5/50;;A61P31/18;;A61P35/00,,0,0,,,,ACTIVE
164,NZ,A,NZ 575521 A,174-901-141-196-886,2012-03-30,2012,NZ 57552107 A,2007-09-11,US 2006/0035958 W;;US 89462807 P;;US 2007/0078177 W,2006-09-13,"USE OF 2-6-(3-AMINO-PIPERIDIN-L-YL)-3-METHYL-2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YLMETHYL-4-FLUORO-BENZONITRILE","Disclosed is the use of 2-[6-(3-Amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2Hpyrimidin-1-ylmethyl]-4-fluoro-benzonitrile (as pictured) in the production of a medicament for the treatment of diabetes, wherein the medicament is adapted to be administered at a weekly dose of between 1 mg and 250 mg once per week.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;OGAWA ATSUSHI;;COVINGTON PAUL,,https://lens.org/174-901-141-196-886,Patent Application,no,0,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61P35/00;;A61K31/513;;A61P3/10;;A61P5/50;;A61P31/18,,0,0,,,,PENDING
165,AU,B2,AU 2007/296556 B2,043-474-608-112-401,2013-09-19,2013,AU 2007/296556 A,2007-09-11,US 89462807 P;;US 2006/0035958 W;;US 2007/0078177 W,2006-09-13,"2-6- (3-Amino-piperidin-1-yl) -3-methyl-2, 4-dioxo-3, 4-dihydro-2H-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile","Pharmaceutical compositions comprising 2-[6-(3-Amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.",TAKEDA PHARMACEUTICALS CO,OGAWA ATSUSHI;;COVINGTON PAUL;;CHRISTOPHER RONALD J,,https://lens.org/043-474-608-112-401,Granted Patent,no,4,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61K31/4439;;A61K31/513;;A61K45/06;;A61P3/10;;A61P5/00;;A61P5/50;;A61P31/18;;A61P35/00,,0,0,,,,ACTIVE
166,MX,A,MX 2009002772 A,040-473-672-513-492,2009-05-28,2009,MX 2009002772 A,2007-09-11,US 2006/0035958 W;;US 89462807 P;;US 2007/0078177 W,2006-09-13,ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS.,"Pharmaceutical compositions comprising 2-[6-(3-Amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H -pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.",TAKEDA PHARMACEUTICAL,OGAWA ATSUSHI;;CHRISTOPHER RONALD J;;COVINGTON PAUL,,https://lens.org/040-473-672-513-492,Patent Application,no,0,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61K31/4439;;A61K31/44;;A61K31/513;;A61K45/06;;A61P3/10;;A61P5/00;;A61P31/18;;A61P35/00,,0,0,,,,ACTIVE
167,KR,A,KR 20170127074 A,129-738-213-857-243,2017-11-20,2017,KR 20177032684 A,2007-09-11,US 2006/0035958 W;;US 89462807 P;;US 2007/0078177 W,2006-09-13,2-6-3---1--3--24--34--2--1--4-- USE OF 2-[6-3-AMINO-PIPERIDIN-1-YL-3-METHYL-24-DIOXO-34-DIHYDRO-2H-PYRIMIDIN-1-YLMETHYL]-4-FLUORO-BENZONITRILE,"본 발명은, 2-[6-(3-아미노-피페리딘-1-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2H-피리미디딘-1-일메틸]-4-플루오로-벤조니트릴과 이것의 약학적으로 허용 가능한 염을 함유하는 약학적 조성물, 상기 약학적 조성물을 포함하는 키트 및 제조물과, 상기 약학 조성물의 사용 방법을 제공한다.",TAKEDA PHARMACEUTICALS CO,CHRISTOPHER RONALD J;;OGAWA ATSUSHI;;COVINGTON PAUL,,https://lens.org/129-738-213-857-243,Patent Application,no,2,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61K31/513;;A61K31/4439;;A61K31/506,,0,0,,,,DISCONTINUED
168,HR,T1,HR P20110800 T1,009-618-869-939-420,2011-12-31,2011,HR P20110800 T,2011-11-02,US 2006/0035958 W;;US 2007/0078177 W;;US 89462807 P,2006-09-13,"USE OF 2-6-(3-AMINO-PIPERIDIN-1-YL)-3-METHYL-2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YLMETHYL-4-FLUORO-BENZONITRILE FOR TREATING DIABETES, CANCER, AUTOIMMUNE DISORDERS AND HIV INFECTION","2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-diokso-3,4-dihidro-2H-pirimidin-1-ilmetil]-4-fluoro-benzonitril (Spoj I), naznačen time, što se koristi kao lijek kada se primijeni u tjednoj dozi koja iznosi između 50 mg i 250 mg, pri čemu se tjedna doza primjenjuje jednom tjedno. Patent sadrži još 7 patentnih zahtjeva.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;OGAWA ATSUSHI;;COVINGTON PAUL,,https://lens.org/009-618-869-939-420,Granted Patent,no,0,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61K31/513;;A61P3/10;;A61P5/50;;A61P31/18;;A61P35/00,,0,0,,,,ACTIVE
169,JO,B1,JO 2755 B1,193-435-539-317-944,2014-03-15,2014,JO P20070385 A,2007-09-12,US 89462807 P;;US 2006/0035958 W,2006-09-13,"USE OF 2-6 (3- AMINO-PIPERIDIN-1-YL)-3-METHYL-2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YLMETHYL-4-FLUORO-BENZONITRILFOR TREATING DIABETES,CANCER , AUTOIMMUNE DISORDERS AND HIV INFECTION","pharmaceutical compositionscomprising 2-[6-(3-Amino-piperidin-I-yl)-3-methyl-2,4-dioxo-3.4-dihydro-2H-pyrimidine-1- ylmethyl]-4-flouro-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the Pharmaceutical compositions as well as methods of using the Pharmaceutical compositions.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;OGAWA ATSUSHI;;COVINGTON PAUL,,https://lens.org/193-435-539-317-944,Granted Patent,no,0,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,,,0,0,,,,ACTIVE
170,US,A1,US 2013/0172377 A1,016-245-595-646-587,2013-07-04,2013,US 201313773282 A,2013-02-21,US 201313773282 A;;US 201113091460 A;;US 53167106 A;;US 74728006 P;;US 71756005 P,2005-09-14,ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS,"Pharmaceutical compositions and methods comprising 2-[6-(3-Amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile or a pharmaceutically acceptable salt thereof administered once weekly.",TAKEDA PHARMACEUTICAL;;TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL;;OGAWA ATSUSHI,,https://lens.org/016-245-595-646-587,Patent Application,yes,1,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K31/513,514/274,0,0,,,,ACTIVE
171,PL,T3,PL 2073810 T3,057-844-407-087-653,2012-01-31,2012,PL 07842260 T,2007-09-11,US 2006/0035958 W;;US 89462807 P;;EP 07842260 A;;US 2007/0078177 W,2006-09-13,"USE OF 2-6-(3-AMINO-PIPERIDIN-1-YL)-3-METHYL-2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YLMETHYL-4-FLUORO-BENZONITRILE FOR TREATING DIABETES, CANCER, AUTOIMMUNE DISORDERS AND HIV INFECTION",,TAKEDA PHARMACEUTICALS CO,CHRISTOPHER RONALD J;;OGAWA ATSUSHI;;COVINGTON PAUL,,https://lens.org/057-844-407-087-653,Patent Application,no,0,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61P3/10;;A61K31/513;;A61P5/50;;A61P31/18;;A61P35/00,,0,0,,,,PENDING
172,DK,T3,DK 2073810 T3,095-597-744-641-320,2011-10-31,2011,DK 07842260 T,2007-09-11,US 2006/0035958 W;;US 89462807 P;;US 2007/0078177 W,2006-09-13,"Anvendelse af 2-6-(3-aminio-piperidin-l-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-l-ylmethyl-4-fluor-benzonitril til behandling af diabetes, cancer, autoimmune sygdomme og HIV infektion",,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;OGAWA ATSUSHI;;COVINGTON PAUL,,https://lens.org/095-597-744-641-320,Granted Patent,no,0,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61K31/513;;A61P3/10;;A61P5/50;;A61P31/18;;A61P35/00,,0,0,,,,ACTIVE
173,CO,A2,CO 6160321 A2,082-776-293-237-813,2010-05-20,2010,CO 09032924 A,2009-03-31,US 2006/0035958 W;;US 89462807 P,2006-09-13,"USO DE 2-6-(3-AMINO-PIPERIDIN-1-IL)-3-METIL-2,4-DIOXO-3,4-DIHIDRO-2H-PIRIMIDIN-1-ILMETIL-4-FLUORO-BENZONITRILO","1.- Un método caracterizado porque comprende: administrar una dosificación semanal entre 1 mg y 250 mg del compuesto I a un paciente donde la dosis semanal se administra una vez a la semana. 2.- El método de conformidad con la reivindicación 1, caracterizado porque la dosificación semanal del compuesto 1 administrada al paciente está entre 50 mg y 250 mg. 3.- El método de conformidad con la reivindicación 1, caracterizado porque la dosificación semanal del compuesto 1 administrada al paciente está entre 100 mg y 250 mg. 4.- El método de conformidad con la reivindicación 1, caracterizado porque la dosificación semanal del compuesto I administrada al paciente es de 50 mg. 5.- El método de conformidad con la reivindicación 1, caracterizado porque la dosificación semanal del compuesto 1 administrada al paciente es de 75 mg. 6.- El método de conformidad con la reivindicación 1, caracterizado porque la dosificación semanal del compuesto I administrada al paciente es de 100 mg. 7.- El método de conformidad con la reivindicación 1, caracterizado porque la dosificación semanal del compuesto I administrada al paciente es de 125 mg. 8.- El método de conformidad con la reivindicación 1, caracterizado porque la dosificación semanal del compuesto I administrada al paciente es de 150 mg. 9.- El método de conformidad con la reivindicación 1, caracterizado porque la dosificación semanal del compuesto I administrada al paciente es de 175 mg. 10.- El método de conformidad con la reivindicación 1, caracterizado porque la dosificación semanal del compuesto I administrada al paciente es de 200 mg. 11.- El método de conformidad con cualquiera de las reivindicaciones 1-10, caracterizado porque el compuesto I se administra como una base libre. 12.- El método de conformidad con cualquiera de las reivindicaciones 1-10, caracterizado porque el compuesto I se administra como una sal farmacéuticamente aceptable. 13.- El método de conformidad con cualquiera de las reivindicaciones 1-10, caracterizado porque el compuesto I se administra como una sal de succinato.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;OGAWA ATSUSHI;;COVINGTON PAUL,,https://lens.org/082-776-293-237-813,Patent Application,no,0,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61K31/513,,0,0,,,,PENDING
174,CN,A,CN 103211819 A,123-246-047-591-734,2013-07-24,2013,CN 201310142194 A,2007-09-11,US 2006/0035958 W;;US 89462807 P,2006-09-13,Administration of dipeptidyl peptidase inhibitors,"Pharmaceutical compositions comprising 2-[6-(3-Amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;OGAWA ATSUSHI;;COVINGTON PAUL,,https://lens.org/123-246-047-591-734,Patent Application,no,1,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61K31/506;;A61P3/10,,0,0,,,,DISCONTINUED
175,US,B2,US 8906901 B2,002-580-885-600-544,2014-12-09,2014,US 201313773282 A,2013-02-21,US 201313773282 A;;US 201113091460 A;;US 53167106 A;;US 74728006 P;;US 71756005 P,2005-09-14,Administration of dipeptidyl peptidase inhibitors,"Pharmaceutical compositions and methods comprising 2-[6-(3-Amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile or a pharmaceutically acceptable salt thereof administered once weekly.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL;;OGAWA ATSUSHI,,https://lens.org/002-580-885-600-544,Granted Patent,yes,100,0,54,57,0,A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513;;A61P3/00;;A61P31/18;;A61P35/00;;A61P43/00;;A61P5/50;;A61P3/10;;A61K31/513;;A61K31/44;;A61K31/513;;A61K31/426;;A61K31/44;;A61K38/26;;A61K45/06;;A61K9/2018;;A61K31/513,A61K31/00;;A61K31/426;;A61K31/44;;A61K31/513;;A61K38/26;;A61K45/06,514/210.2;;514/866,99,77,016-254-725-817-570;;060-881-802-482-478;;151-702-902-980-944;;065-835-793-759-598;;056-084-407-231-998;;025-092-381-169-940;;044-836-514-312-80X;;153-058-463-015-074;;092-506-320-218-945;;009-124-714-168-182;;029-419-987-087-71X;;142-231-691-018-696;;030-597-907-038-182;;092-092-401-768-095;;150-152-929-142-561;;104-949-654-022-72X;;004-513-874-372-374;;013-609-310-533-235;;032-875-073-112-461;;110-056-504-353-16X;;118-810-099-497-09X;;078-197-927-298-503;;071-515-277-690-250;;196-161-283-060-885;;058-388-210-176-126;;044-846-100-148-877;;053-237-550-409-715;;056-275-822-763-694;;046-678-331-045-552;;027-078-358-193-24X;;085-654-520-046-077;;040-984-657-300-792;;141-527-988-581-46X;;063-552-437-482-809;;118-982-379-617-739;;105-531-079-310-255;;010-560-859-402-01X;;120-214-639-645-390;;053-458-170-682-882;;044-409-289-561-52X;;052-898-343-286-646;;080-050-592-171-046;;029-742-513-220-275;;032-396-311-341-254;;001-545-732-843-596;;061-027-478-133-092;;064-061-728-757-841;;037-355-492-172-605;;037-850-361-411-205;;143-077-482-928-638;;052-187-696-800-160;;041-960-659-407-470;;016-177-359-235-67X;;066-316-254-402-241;;021-374-994-278-584;;044-997-350-981-106;;052-594-221-411-215;;078-137-597-055-650;;080-828-826-401-68X;;116-504-427-971-62X;;110-998-775-267-633;;034-499-243-336-537;;036-899-076-589-398;;106-967-721-452-343;;126-521-362-341-498;;183-595-670-141-016;;010-859-921-749-855;;052-338-434-942-674;;025-448-715-974-689;;020-332-360-015-334;;002-689-909-402-534;;130-926-644-077-277;;041-750-520-495-191;;077-494-958-444-459;;097-689-191-524-060;;022-692-845-390-409;;040-611-685-068-415,1503595;;10.1021/jm970759u;;9685237;;12061252;;10.1248/bpb.25.1432;;12419954;;8504825;;10.1111/j.1432-1033.1993.tb17886.x;;10.1111/j.1476-5381.1986.tb11146.x;;3542106;;pmc1917167;;10.1248/cpb.39.2126;;1797434;;10.1002/jhet.5570040107;;477949;;10.1016/s0040-4020(01)87190-8;;7651891;;10.1016/0196-9781(94)00213-p;;10.1007/bf02790141;;7779574;;10.1021/ar9600650;;10.1016/0167-0115(92)90152-k;;10.1016/0040-4020(96)00467-x;;10.1007/3-540-69178-2_5;;7009415;;6749673;;10.1021/jm000522p;;11356106;;10.1016/s0960-894x(00)00286-9;;10915049;;10.2337/diab.44.9.1126;;7657039;;10.2337/diabetes.44.9.1126;;10.1210/jc.80.3.952;;7883856;;10.1210/jcem.80.3.7883856;;12054731;;10.1016/s0006-291x(02)00359-5;;10.1016/0167-0115(96)87780-9;;10.2337/diabetes.47.5.764;;9588448;;12163006;;10.1016/s0006-291x(02)00753-2;;10093513;;10.1016/s0040-4020(97)00872-7;;10.1021/jo00255a002;;10.1016/0040-4039(94)88205-3;;12690074;;10.1073/pnas.0230620100;;pmc154298;;8496914;;10.1021/jm00062a020;;10.1039/jr9510002682;;10.1039/c39870000568;;10.1002/chin.198934229;;8879541;;10.1016/0968-0896(96)00107-1;;10.1517/14728214.11.3.525;;16939389;;10.1016/s1095-6433(99)00014-8;;10356762;;5663640;;10.1021/jm00308a057;;5796959;;10.1038/223524a0;;3288821;;10.1002/med.2610080204;;11883961;;10.1006/bbrc.2002.6607;;10.2337/diacare.25.8.1490-b;;12145269;;8381211;;10.1038/361362a0;;pmc2916679;;10.1002/chin.200301150;;10.1039/p19870002585;;4085064;;10.1248/cpb.33.3160;;10.1016/s0040-4039(02)01140-1;;10.1128/aem.56.2.381-388.1990;;pmc183349;;16348113;;10.1210/endo.136.8.7628397;;7628397;;10.1210/en.136.8.3585;;7932565;;10.1021/jm00046a022;;pmc3471218;;8799497;;10.1248/bpb.19.897;;10.1016/s0040-4020(01)92914-x;;11389867;;10.1016/s0003-9969(00)00065-0;;9057855;;10.1021/jm960594+;;10.1021/jo970761t;;11671839;;12892317;;10.1080/713609354;;7742327;;10.1021/bi00018a026;;10.1081/scc-120002124;;10.1002/cber.19080410139;;10.1021/jo00230a035;;10.2337/diacare.24.3.489;;11289473;;12566708;;10.1159/000067917;;8100523;;10.1111/j.1432-1033.1993.tb17986.x;;493181;;10.1039/dt9870001127;;10.1055/s-1992-26096;;120313;;4429603;;10.1016/0006-2952(74)90283-4;;10.1007/bf02591576;;788428;;7251022;;4733674;;10.1016/0006-2952(73)90122-6;;4200097;;10.1016/0006-2952(73)90333-x;;10.3987/com-97-s(n)103;;10.1016/0168-8227(94)01012-o;;7781494;;10.1016/s0040-4020(03)00593-3;;10.1093/oxfordjournals.jbchem.a124647;;7896751,"Abdel-Fallah et al. ""Synthesis and reactions of 2-[2- (2,4,6-trimethylbenzyol)vinyl]-4H-3,1- benzoxazin-4-one and antimicrobial activity"" Indian journal of heterocyclic chemistry 1999, National Academy of Chemistry, 8(3), 177-182 (Abstract).;;Abdel-Rahman, R M. ""Synthesis of some new fluorine bearing trisubstituted 3-thioxo-1,2,4-triazin-5-ones as potential anticancer agents"" II Farmaco Mar. 1992, 47(3), 319-326; Elsevier Masson.;;Akahoshi et al. ""Synthesis and Pharmacological Activity of Triazolo[1,5-a)triazine Derivatives Inhibiting Eosinophilia"" Journal of Medicinal Chemistry 1998, 41(16), 2985-2993, XP002390903.;;Alagarsamy et al. ""Synthesis and pharmacological investigation of some novel 2-phenyl-3(substituted methyl amino) quinazolin-4(3H)-ones as H1-receptor blockers"" Pharmazie 2002, 57(5) 306-307, XP008084498.;;Alagarsamy et al. ""Synthesis, analgesic, anti-inflammatory and antibacterial activities of some novel 2-phenyl-3-substituted quinazolin-4(3H) ones,"" Biological and Pharmaceutical Bulletin 2002, 25(11) 1432-1435 XP0080845131SSN.;;Argaud et al. ""Metaformin decreases gluconeogenesis by enhancing the pyruvate kinase flux in isolated rat hepatocytes"" European J. Biochem. 1999, 213, 1341-1348.;;Ashcroft et al. ""Structure-activity relationships of alloxan-like compounds derived from uric acid"" Br. J. Pharmacol. 1986, 89, 469-472.;;Bahaji et al. ""Studies on Immunostimulating Derivatives Synthesis of Some Pyrrolo-1 2-C-Pyrimidines"" Chemical and Pharmaceutical Bulletin (Tokyo)1991, XP002392081 abstract Database Biosis [Online] Biosciences Information Service, Philadelphia, PA, US.;;Baker et al. ""Irreversible Enzyme Inhibitors. LXXXV. On the Mode of Pyrimidine Binding of 5-alkyl and 5-Arylpyrimidines to Dihydrofolic Reductase (1,2)"" Journal of Heterocyclic Chemistry Mar. 1967, 4 39-48.;;Bal, Gunther ""Dipeptidyl Peptidase IV and Prolyl Oligopeptidase: Design, Synthesis and Evaluation of Substrates and Inhibitors"" 2002 Universiteit Antwerpen (238 pages).;;Barakat, S.E.S. ""Synthesis and Hypoglycemic Activity of Some New 4(3H)-Quinazolinone Analogues"" Saudi Pharmaceutical Journal 2000, 8(4), 198-204.;;Barakat, S.E.S. ""Synthesis and hypoglycemic activity of some new 3-[4- [[[(cyclohexylamino) carbonyl) amino)sulfony)phenyll-4(3H).quinazolinones"" Az. J. Pharm. Sci. 2000, vol. 25, 48-57.;;Barnela et al. ""Studies in isoxazolo[3,2-b]quiazolone from 2-hydroxy-3-methyl-4-quinazole"" Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1986), 25B(7), 709-11 (Abstract 2 pages).;;Barnickel et al. STN Printout, Abstract of WO01/23364 (one page).;;Belgodere et al., ""Synthesis of substituted pyrimidines. I. Study of the structure and of the tautomeric equilibria"" Chem. Abstracts 1976, Columbus, OH, 85(9).;;Bezugl et al. Synthesis of arylsulfonyl hydrazide of 3-R-quinazolone-4-carbonyl-2-acid, Pharmaceutical Journal 1979, 70-71.;;Bhaduri et al. ""Urinary Metabolite of 2-Piperazino-3 (H)-4-Quinazolone (Centpiperalone), A Potent Blood Sugar Lowering Agent"" Indian J. Biochem. Biophys. 1975, 12, 413-414.;;Borrell et al. ""Synthesis, structure and cytotoxicity evaluation of paliadium(II) complexes of 4-amino-3-hydrazino-1,2,4-triazin-5(4H)-ones and 4-amino-3-(N-methylhydrazino)-1,2,4-triazin-5(4H)-ones"" Anales de Quimica 1995, 91, 243-252, XP008000323.;;Botta et al. ""Researches on Antiviral Agents. 31. Synthesis and Transformations of Racemic and Chiral 6-Oxiranyl Pyrimidinones."" Tetrahedron 1993, 49(27), 6053-6070, XP002329846.;;Bouras et al. ""Metabolism of Enterostatin in Rat Intestine, Brain, Membranes and Serum: Differential Involvement of Proline-Specific Peptidases"" Peptides 1995, 16(3), 399-405.;;Brun et al. ""Effects of Oral Zinc Gluconate on Glucose Effectiveness and Insulin Sensitivity in Humans"" Biological Trace Element Research 1995, 47, 385-391.;;Buchwald et al. ""Rational Development of Practical Catalysts for Aromatic Carbon-Nitrogen Bond Formation"" 1998, Accounts of Chemical Research, 31, 808-818.;;Buckley et al. ""Analysis of the Degradation of Insulinotropin [GLP-1(7-37)] in Human Plasma And Production of Degradation Resistant Analogs"" (abstract) Regul Pept 1992 40, 117A.;;Buysens et al. ""Synthesis of New pyrrolo[3,4-b]- and [3,4-c]pyridin(on)es and Related 1,7-Naphthyridinones and 2,7-Naphthyridines via Intramolecular Diels-Alder Reactions of 2(1H)-Pyrazinones"" Tetrahedron 1996, 52(27), 9161-9178, XP004104003.;;Caira Mino R. ""Crystalline Polymorphism of Organic Compounds"" Topics in Current Chemistry 1998, 198, 163-208, XP001156954.;;Chatterjee et al. ""Effect of Centpiperalone in Insulin Deficient Diabetes"" Indian Journal of Experimental Biology 1980, 18, 1005-1008.;;Chatterjee et al. ""Effect of Centpiperalone, a New Hypoglycemic Agent on Insulin Biosynthesis & Release from Isolated Pancreatic Islets of Rat"" Indian Journal of Experimental Biology Mar. 1982, 20, 270-272.;;Chenard et al. ""Quinazolin-4-one alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Antagonists: Structure-Activity Relationship of the C-2 Side Chain Tether"" J. Med. Chem 2001, 44, 1710-1717.;;Coppola et al. ""1-Aminomethylisoquinoline-4-carboxylates as Novel Dipeptidylpeptidase IV Inhibitors"" Bioorganic & Medicinal Chemistry Letters 2000, 10, 1555-1558.;;Deacon et al. ""Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects"" Diabetes 1996, (44), 1125-1131.;;Deacon et al. ""Degradation of Glucagon-Like Peptide 1 by Human Plasma in Vitro Yields an N-Terminally Truncated Peptide That Is a Major Endogenous Metabolite in Vivo"" Journal of Clinical Endocrinology and Metabolism 1995, 80(3), 952-957.;;Deacon et al. ""Dipeptidyl peptidase IV Inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective"" Biochemical and Biophysical Research Communications 2000, 294, 1-4.;;Deacon et al. ""Dipeptidyl peptidase IV inhibition influences GLP-1 metabolism in vivo"" Regulatory Peptides Jul. 1996, 64(1-3), 30.;;Deacon et al. ""Dipeptidyl Peptidase IV Inhibition Potentiates the Insulinotropic Effect of Glucagon-Like Peptide 1 in the Anesthetized Pig"" Diabetes May 1998, 47, 764-769.;;Demuth et al. ""Rebuttal to Deacon and Holst: Metaformin effects on depeptidyl peptidase IV degradation of glucagons-like peptide-1"" versus ""Dipeptidyl peptidase inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective"" Biochemical and Biophysical Research Communications 2002, 296, 229-232.;;Desai et al ""Synthesis and anti-HIV activity of some non-nucleoside 2,3-disubstituted quinazoline derivatives (Part-V)"" Indian Journal of Experimental Biology Dec. 1998, 36(12), 1280-1283, XP008084509 ISSN: 0019-5889.;;Dey et al. ""Regioselective [4+2) Cycloaddition versus Nucleophilic Reactions of N-Arylamino Substituted 1 ,3-Diaza-1,3-Butadienes with Ketenes : Synthesis of Pyrimidinone and Fused Pyrimidinone Derivatives. Part II"" Tetrahedron 1997, 53(40), 13829-13840.;;Dumas, Donald J. ""Total Synthesis of Peramine"" Journal of Organic Chemistry 1988, 53, 4650-4653, XP002087391.;;Edstrom et al. ""Cyclodehydration of 4[(carboxymethyamino}pyridin-2-ones. A new, efficient synthesis of pyrrolo [3,2-c] pyridin-4-ones and pyrido [3,4-b] pyrrolizidin-1-ones"" HCAPLUS 1995:104821 (source, Tetrahedron Letters 1994, 35(38), 6985-6988).;;Engel et al. ""The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism"" Proc. Nat. Acad. Sci. Early Edition 2003, 1-6.;;Fraisse et al. ""Long-Chained Substituted Uric Acid and 5,6-Diaminouracil Derivatives as Novel Agents against Free Radical Processes: Synthesis and in Vitro Activity"" Journal of Medicinal Chemistry 1993, 36, 1456-1473, XP002329847.;;Fraser et al. ""The Reaction of ""Paludrine"" (Proguanil) with Ethyl Acetoacetate"" The Reaction of Fraser and Kermak 1951, 2682-2686.;;Garratt et al. ""A Novel Synthesis of Dihydropyrimidines"" J. Chem. Soc., Chem. Commun. 1987, 568-569.;;Garratt et al. ""One-Carbon Compounds as Synthetic Intermediates. The Syntheis of Hydropyrimidines and Hydroquinazolines by Sequential Nucleophilic Addition to Diphenyl Cyanocarbonimidate with Concomitant Cyclization"" J. Org. Chem. 1988, 54, 1062-1069.;;Gazit et al. ""Tyrphostins IV-Highly Potent Inhibitors of EGF Receptor Kinase. Structure-Activity Relationship Study of 4-Anilidoquinazolines"" Bioorganic & Medicinal Chemistry 1996, 4(8), 1203-1207.;;Green et al ""Inhibition of dipeptidyl peptidase IV activity as a therapy of Type 2 diabetes"" Expert Opinion Emerging Drugs 2006, 11(3); 525-539.;;Guerrieri et al. ""Vanadium inhibition of serine and systeine proteases"" Comparative Biochemistry and Physiology Part A 1987, 122, 331-336.;;Gupta et al. ""A Novel Class of Hypoglycaemic Agents : Syntheses & SAR in 2-Substituted 4(3H)-Quinazolones, 2-Substituted 4-Hydroxypolymethylene [5,6]pyrimidines & 3-Substituted 4-Oxo-pyrido [I,2-alpha]pyrimidines"" Indian Journal of Chemistry 1971, 9, 201-206.;;Gupta et al. ""Drugs Acting on the Central Nervous System. Syntheses of Substituted Quinazolones and Quinazolines and Triazepino- and Triazocinoquinazolones"" Division of Medicinal Chemistry, Central Drug Research Institute 1967, 392-395.;;Gupta et al. ""Fluorine containing Biologically Active Agents: Synthesis of some New Pyrimidine Derivatives"" J. Indian Chem. Soc. Oct. 1994, 71, 635-636, XP000889664.;;Gupta et al. ""New Potent Blood Sugar Lowering Compound"" Nature Aug. 2, 1969, 223, 524.;;Hamid et al. ""Substituted Quinazolines, 1. Synthesis and Antitumor Activity of Certain Substituted 2-Mercapto-4(dH)-quinazolinone Analogs"" Scientia Pharmaceutica (2001), 69(4), 351-355.;;Hermecz et al. ""Pyrido[1,2-alpha]Pyrimidines; New Chemical Entities in Medicinal Chemistry"" Medicinal Research Reviews 1988, 8(2), 203-230.;;Hinke et al. ""Metaformin Effects on Dipeptidylpeptidase IV Degradation of Glucagon-like Peptide-1"" Biochemical and Biophysical Research Communications 2002, 291, 1302-1308.;;Hinke et al. ""On Combination Therapy of Diabetes With Metaformin and Dipeptidyl Peptidase IV Inhibitors"" Diabetes Care 2002, 25(8), 1490-1492.;;Holz et al. ""Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37)"" Nature 1993, 361, 362-365.;;Jakubkiene et al. ""(6-Methyl-2-methylsulfanyl-4-oxo-3,4-dihydro-3-pyrimidinyl)acetic acid and related compounds exhibiting anti-inflammatory activity"" Pharmazie 2002, 57(9), 610-613.;;Jatzen et al. ""Sustained and Controlled Release Drug Delivery System"" Modern Pharmaceutics 3rd Edition, Marcel Dekker Inc. 1996, pp. 451 and 596 New York.;;Jones et al. ""Azafluorenes Containing Two Bridgehead Nitrogen Atoms"" Journal of the Chemical Society, Perkin Transactions 1 1987, 12, 2585-2592.;;Kamata et al. ""Studies of antitumor-active 5-fluorouracil derivatives. I. Synthesis of N-phthalidyl 5-fluorouracil derivatives"" CAPLUS Abstract 105: 191027 (source, Chemical & Pharmaceutical Bulletin (1985), 33(8), 3160-75.;;Kesarwani et al. ""Solid-phase synthesis of quinazolin-(3H)-ones with three-point diversity"" Tetrahedron Letters 2002, 43, 5579-5581.;;Khalid et al. ""Purification and Partial Characterization of a Prolyl-Dipeptidyl Aminopeptidase From Lactobacillus helveticus CNRZ 32"" Applied and Environmental Microbiology 1990, 56(2), 381-388.;;Kieffer et al. ""Degradation of Glucose-Dependant Insulinotropic Polypeptide and Truncated Glucagon-Like Peptide 1 in Vitro and in Vivo by Dipeptidyl Peptidase IV"" Endocrinology 1995, 136(8), 3585-3596.;;Kim et al. ""Structure-Activity Relationships of 1,3-Dialkylxanthine Derivatives at Rat A3 Adenosine Receptors"" Journal of Medicinal Chemistry 1994, 37, 3373-3382, XP002329848.;;Kimura et al. ""Oral Administration of Insulin as Poly(Vinyl Alcohol)-Gel Spheres in Diabetic Rats"" Biological & Pharmaceutical Bulletin 1996, 19(6), 897-900.;;Kobe et al. ""The Synthesis of s-Triazolo[4.3-alpha] 1,3,5-Triazines"" Tetrahedron 1970, 26, 3357-3368, XP002390908.;;Koreeda et al. ""Isolation and characterization of dipeptidyl peptidase IV from Prevotella loescheii ATCC 15930"" Archives of Oral Biology 2001, 46, 759-766.;;Kotani et al. ""Highly Selective Aldose Reductase Inhibitors. 3. Structural Diversity of 3-(Arylmethyl)-2,4,5-trioxoimidazolidine-1-acetic Acids"" Journal of Medicinal Chem. 1997, 40(5) 684-694 XPOO0652330.;;Kotra et al. ""4-Azido-2-pyrimidone Nucleosides and Related Chemistry"" Journal of Organic Chemistry 1997, 62, 7267-7271, XP002390905.;;Kozhevnikov et al. ""4-Quinazolinones. II. 2-(Aminomethyl)-3-aryl-4-quinazolinones"" CAPLUS document No. 78:16128 (source, Tr. Perm. Sel.-Khoz. Inst. (1971), No. 79, 66-72.;;Ku{hacek over (s)}ar et al. ""Diethyl N,N-Dimethylaminomethyleemalonate in the Sysnthsis of Fused Heterocyclic Systems"" Heterocyclic Chem. 1996, 33, 1041-1046.;;Lakhan et al. ""Studies of 4(3H)-quinazolinone derivatives as antimalarials"" HCAPLUS document No. 107:228515 (source, Journal of Indian Chemical Society (1987), 64(5), 316-18) Abstract.;;Lambeir et al. ""Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IV"" Critical Reviews in Clinical Laboratories Sciences 2003, 40(3), 209-294.;;Li et al. ""Permolybdate and Pertungstate-Potent Stimulators of Insulin Effects in Rat Adipocytes: Mechanism of Action"" Biochemistry 1995, 34, 6218-6225.;;Lin, Jian ""Total Synthesis and Biological Evaluation of Fluoroolefin-containing Dipeptidyl Isosteres as Inhibitors of Dipeptidyl Peptidase IV (CD26)"" Dissertation presented to State University of New York at Albany, Department of Chemistry (1998).;;Liu, Gang: ""Fungal endophyte-Epichloe and its secondary metabolites"" XP002392084 Database CA [online] Chemical Abstract service, Columbus, Ohio, US; Reg No. 102482-94-0. Database Accession No. 2004:340837 abstract.;;Loeser et al. ""Selective N-Alkylation of Primary Amines with Chloroacetamides Under pH-Controlled Aqueous Conditions"" Synthetic Communications 2002, 32(3), 403-409.;;Majima R., ""Ober die Kondensation der Alkylguanidine mit Acetessigester usw"" Berichet der Deutschen Chemischen Gesellschaft 1908 41(1) 176-186.;;Mall et al. ""Reactivity Difference of Cis-Trans Pairs: Different Behavior of Stilbene Oxides and Activated Stilbene Imines"" Journal of Organic Chemistry 1987, 52(21) 4812-4814.;;Mannucci et al. ""Effect of Metaformin on Glucagon-Like Peptide 1 (GLP-1) and Leptin Levels in Obese Nondiabetic Subjects"" Diabetes Care 2001, 24(3), 489-494.;;Marcus et al. ""HIV: epidemiology and strategies for therapy and vaccination"" Intervirology 2002, 45(4-6), 260-266 (Abstract).;;Mentlein et al. ""Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum"" Eur. J. Biochem. 1993, 214, 829-835.;;Misra et al. ""Synthesis of N-aryl-N'-[2-phenyl-3-quinazoline(3H)-4-one] acylthiourea derivatives as anticonvulsants"" Polish journal of pharmacology and pharmacy Mar. 1979, 31(2) 161-167, Institute of Pharmacology Polish Academy of Sciences XP008084507.;;Miyamura et al. ""Reactions of Copper(II) Complexes of Optically Active N-Substituted Diamines with Alk-3-en-2-ones or 4-Hydroxyalkan-2-ones: Formation of Optically Active Macrocycles"" Journal of the Chemical Society, Dalton Transactions 1987, 1127-1132, XP008082357.;;Molina et al. ""Iminophosphorane-Mediated Annulation of 1,3,5-Triazine to Benzimidazole: Synthesis of 1 ,3,5-Triazino[1,2-alpha]benzimidazoles"" Synthesis Mar. 1992, 297-302, XP002390907.;;Mukerjee et al. ""Chronic Toxicity Studies of a Hypoglycemic Compound : Centpiperalone in Rats & Rhesus Monkeys"" Indian Journal of Experimental Biology Dec. 1979, 17, 1346-1349.;;Mukerjee et al. ""Effect of 2-piperazino-4(3H)-quinazolinone monoacetate on the tissue respiration, glucose uptake and lactic acid production by rat hemidiaphragm"" Biochemical Pharmacology 1974, 23, 3066-3067.;;Mukerjee et al. ""Studies on the Mechanism of Centpiperalone-Induced Hypoglycemia"" Acta Diabet. 1976, 13(8), 8-25.;;Mukerjee et al. ""Tissue Distribution of [3H]Centpiperalone after Oral Administration"" Indian J. Biochem. Biophys. 1980, 17, 399-401.;;Mukherjee et al. ""Effect of 2-piperazino-4(3H)-quinazolinone monoacetate on some aspects of carbohydrate metabolism of albino rats"" Biochemical Pharmacology 1973, 22, 2205-2206.;;Mukherjee et al. ""Studies on the Metabolic Changes Induced by a Synthetic Insulinogenic Agent"" Indian J. Physiol. & Allied Sci. 1976, 30(3), 105-116.;;Mukherjee et al., Influence of Timing Oral Dosing of a Novel Hypoglycaemic Agent A-4166 in Relation to Food, Diabetologia vol. 38 A194 Supplement 1 (1995).;;Mukherjee, Surath K., ""A novel hypoglycemic compound"" Biochemical Pharmacology 1972, vol. 22 1529-1531.;;Mukkerjee, Sucharita ""[2+2] versus [4+2] cycloaddition reactions of 1 ,3-diaza-1 ,3-butadienes with various mono and disubstituted ketenes and supporting mechanistic considerations""HeterOcycles, vol. 47, No. 2, 1998 XPOO 1539476.;;Murthy et al. New Hypoglycemic Agents: Part V-Synthesis & Hypoglycemic Activity of Some New 1-[[p-(4-0XO-2-MethyI/Phenyl-3 (4H)-Quinazolinyl) Phenyl]] 3-Aryl-2-Ureas, Indian Drugs 1987, 25(1), 19-22.;;Murthy et al. ""New Hypoglycemic Agents: Synthesis and Hypoglycemic Activity of Some New 1-[{p-(4-OXO-2-Substituted-3(4H)-Quinazolinyl)-Phenyl } Sulphonyl]-3-Aryl/Cyclohexyl-2-Thioureas"" Current Science Dec. 20, 1987, 56(24), 1263-1265.;;Nakamura et al. ""Effect of chronic vanadate administration in partially depancreatized rats"" Diabetes Research and Clinical Practice 1995, 27, 51-59. (Abstract Only).;;Noguchi et al. ""Generation of NH-azomethine imine intermediates through the 1,2-hydrogen shift of hydrazones and their intermolecular cycloaddition reaction with olefinic dipolarophiles"" Tetrahedron 2003, 59, 4123-4133.;;Ohkubo et al. ""Dipeptidyl Peptidase IV From Porcine Seminal Plasma: Purification, Characterization, and N-Terminal Amino Acid Sequence"" J. Biochem. 1994, 116(5), 1182-11826.",ACTIVE
176,EP,B1,EP 2073810 B1,127-315-316-062-788,2011-08-31,2011,EP 07842260 A,2007-09-11,US 2007/0078177 W;;US 2006/0035958 W;;US 89462807 P,2006-09-13,"USE OF 2-6-(3-AMINO-PIPERIDIN-1-YL)-3-METHYL-2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YLMETHYL-4-FLUORO-BENZONITRILE FOR TREATING DIABETES, CANCER, AUTOIMMUNE DISORDERS AND HIV INFECTION",,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;OGAWA ATSUSHI;;COVINGTON PAUL,,https://lens.org/127-315-316-062-788,Granted Patent,yes,4,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61K31/513;;A61P3/10;;A61P5/50;;A61P31/18;;A61P35/00,,0,0,,,,ACTIVE
177,BR,A2,BR PI0716971 A2,185-053-473-156-944,2013-10-15,2013,BR PI0716971 A,2007-09-11,US 2006/0035958 W;;US 89462807 P;;US 2007/0078177 W,2006-09-13,"USO DE 2-6(3-AMINO-PIPERINI-L-IL)-3-METIL-2,4-DIOXO-3,4-DIHIDRO-2 H-PIRIMIDIN-1ILMETIL-4-FLUORO-BENXONITRILA",,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;OGAWA ATSUSHI;;COVINGTON PAUL,,https://lens.org/185-053-473-156-944,Patent Application,no,0,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61K31/513;;A61P3/10;;A61P5/50;;A61P31/18;;A61P35/00,,0,0,,,,DISCONTINUED
178,US,A1,US 2008/0287476 A1,007-781-246-628-893,2008-11-20,2008,US 4699708 A,2008-03-12,US 4699708 A;;US 89462807 P,2007-03-13,ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS,"Pharmaceutical compositions comprising 2-[6-(3-Amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL;;OGAWA ATSUSHI,TAKEDA SAN DIEGO INC (2008-07-29);;TAKEDA PHARMACEUTICAL COMPANY LIMITED (2008-07-21);;DEVELOPMENT PARTNERS LLC (2008-07-22);;TAKEDA GLOBAL RESEARCH & DEVELOPMENT CENTER INC (2008-07-22),https://lens.org/007-781-246-628-893,Patent Application,yes,153,7,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61K31/513;;A61P3/10;;A61P35/00;;C07D239/545,514/274;;544/312,0,0,,,,DISCONTINUED
179,RS,B,RS 51965 B,031-244-903-867-437,2012-02-29,2012,RS P20110472 A,2007-09-11,US 2006/0035958 W;;US 89462807 P,2006-09-13,"USE OF 2-6-(3-AMINO-PIPERIDIN-1-YL)-3-METHYL-2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YLMETHYL-4-FLUORO-BENZONITRILE FOR TREATING DIABETES, CANCER, AUTOIMMUNE DISORDERS AND HIV INFECTION","2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-diokso-3,4-dihidro-2H-pirimidin-l-ilmetil]-4-fluoro-benzonitril (Jedinjenje I), naznačeno time, što se koristi kao lek kada se primeni u nedeljnoj dozi koja iznosi između 50 mg i 250 mg, pri čemu se nedeljna doza primenjuje jednom nedeljno.Prijava sadrži još 7 patentnih zahteva.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;OGAWA ATSUSHI;;COVINGTON PAUL,,https://lens.org/031-244-903-867-437,Granted Patent,no,0,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61K31/513;;A61P3/10;;A61P5/50;;A61P31/18;;A61P35/00,,0,0,,,,ACTIVE
180,KR,A,KR 20090088854 A,148-049-978-961-291,2009-08-20,2009,KR 20097007057 A,2007-09-11,US 89462807 P;;US 2006/0035958 W,2006-09-13,ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS,"Pharmaceutical compositions comprising 2-[6-(3-Amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3, 4-dihydro-2H-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions. ® KIPO & WIPO 2009",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;OGAWA ATSUSHI;;COVINGTON PAUL,,https://lens.org/148-049-978-961-291,Patent Application,no,0,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61K31/4439;;A61P31/18;;A61P35/00,,0,0,,,,DISCONTINUED
181,NO,L,NO 20091133 L,094-368-851-514-217,2009-05-14,2009,NO 20091133 A,2009-03-17,US 89462807 P;;US 2006/0035958 W;;US 2007/0078177 W,2006-09-13,"Anvendelse av 2-6-(3-amino-piperidin-L-yl)-3-metyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmetyl-4-fluor-benzonitril","Farmasøytiske sammensetninger som innbefatter 2-[6-(3-amino-piperidin-l-yl)-3-metyl-2,4-diokso-3,4-dihydro-2H-pyrimidin-1-ylmetyl]-4-fluor-benzonitril og farmasøytisk akseptable salter derav er tilveiebrakt så vel som kit og fremstilte artikler som innbefatter de farmasøytiske sammensetningene så vel som fremgangsmåter for anvendelse av de farmasøytiske sammensetningene.",TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;COVINGTON PAUL;;OGAWA ATSUSHI,,https://lens.org/094-368-851-514-217,Abstract,no,0,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61K31/506;;A61P3/10;;A61P31/18;;A61P35/00;;A61P37/00,,0,0,,,,ACTIVE
182,WO,A2,WO 2008/033851 A2,074-614-710-579-178,2008-03-20,2008,US 2007/0078177 W,2007-09-11,US 2006/0035958 W;;US 89462807 P,2006-09-13,ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS,"Pharmaceutical compositions comprising 2-[6-(3-Amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.",TAKEDA PHARMACEUTICAL;;CHRISTOPHER RONALD J;;OGAWA ATSUSHI;;COVINGTON PAUL,CHRISTOPHER RONALD J;;OGAWA ATSUSHI;;COVINGTON PAUL,,https://lens.org/074-614-710-579-178,Patent Application,yes,0,29,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61K31/4439;;A61K31/513;;A61K45/06;;A61P5/00;;A61P31/18;;A61P35/00,,0,0,,,,PENDING
183,GE,B,GE P20125701 B,179-238-449-811-447,2012-12-10,2012,GE AP2007011217 A,2007-09-11,US 2006/0035958 W;;US 89462807 P,2006-09-13,"APPLICATION OF 2-[6-(3-AMINO-PIPERIDIN-1-YL)-3-METHYL-2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YLMETHYL]-4-FLUORO-BENZONITRILE","There are represented 2-[6-(3-Amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimid-in-1-ylmethyl]-4-fluoro-benzonitrile and pharmaceutically acceptable salts thereof, pharmaceutical compositions on a basis thereof and application thereat the treatment. Table: 1",TAKEDA PHARMACEUTICALS CO,COVINGTON PAUL;;OGAWA ATSUSHI;;CHRISTOPHER RONALD J,,https://lens.org/179-238-449-811-447,Granted Patent,no,0,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61P5/50;;A61K31/513;;A61P3/10;;A61P31/18;;A61P35/00,,0,0,,,,ACTIVE
184,AR,A2,AR 110010 A2,033-216-332-039-260,2019-02-13,2019,AR P170103019 A,2017-10-31,US 2006/0035958 W;;US 89462807 P,2006-09-13,"COMPOSICIÓN FARMACÉUTICA FORMULADA EN UNA FORMA DE DOSIS ÚNICA DE 2-[6-(3-AMINO-PIPERIDIN-1-IL)-3-METIL-2,4-DIOXO-3,4-DIHIDRO-2H-PIRIMIDIN-1-ILMETIL]-4-FLUORO-BENZONITRILO","Composiciones farmacéuticas que contienen 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2H-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo y sales aceptables para su uso farmacéutico, conjuntos de elementos y artículos elaborados que comprenden dichas composiciones farmacéuticas, así como sus métodos de uso. Reivindicación 1: Una composición farmacéutica formulada en una forma de dosis única caracterizada porque la composición farmacéutica es una forma de dosis unitaria para una vez por semana, oral, sólida que comprende 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg o 250 mg de 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2H-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo (Compuesto I); y un portador farmacéuticamente aceptable.",TAKEDA PHARMACEUTICALS CO,OGAWA ATSUSHI;;COVINGTON PAUL;;CHRISTOPHER RONALD J,,https://lens.org/033-216-332-039-260,Amended Application,no,0,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61K31/513;;A61K35/00;;A61K45/06;;A61P3/10;;A61P31/18,,0,0,,,,PENDING
185,DO,A,DO P2009000044 A,064-549-944-902-467,2010-03-31,2010,DO 2009000044 A,2009-03-12,DO 2009000044 A,2009-03-12,"USO DE 2-6- (3-AMINO-PIPERIDIN-1-IL)-3-METIL-2,4-DIOXO-3,4-DIHIDRO-2H-PIRIDIN-1-ILMETIL-4-FLUORO-BENZONITRILO",,TAKEDA PHARMACEUTICAL,CHRISTOPHER RONALD J;;OGAWA ATSUSHI;;COVINGTON PAUL,,https://lens.org/064-549-944-902-467,Patent Application,no,0,0,1,1,0,,,,0,0,,,,PENDING
186,KR,A,KR 20190054186 A,124-428-657-408-013,2019-05-21,2019,KR 20197013794 A,2007-09-11,US 2006/0035958 W;;US 89462807 P;;US 2007/0078177 W,2006-09-13,2-6-3---1--3--24--34--2--1--4-- USE OF 2-[6-3-AMINO-PIPERIDIN-1-YL-3-METHYL-24-DIOXO-34-DIHYDRO-2H-PYRIMIDIN-1-YLMETHYL]-4-FLUORO-BENZONITRILE,"본 발명은, 2-[6-(3-아미노-피페리딘-1-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2H-피리미디딘-1-일메틸]-4-플루오로-벤조니트릴과 이것의 약학적으로 허용 가능한 염을 함유하는 약학적 조성물, 상기 약학적 조성물을 포함하는 키트 및 제조물과, 상기 약학 조성물의 사용 방법을 제공한다.",TAKEDA PHARMACEUTICALS CO,CHRISTOPHER RONALD J;;OGAWA ATSUSHI;;COVINGTON PAUL,,https://lens.org/124-428-657-408-013,Patent Application,no,1,0,52,52,0,A61K31/4439;;A61K31/513;;A61K45/06;;C07D401/04;;A61P3/00;;A61P31/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61P5/00;;A61P5/50;;A61P3/10;;A61P31/18;;A61P3/10;;A61P35/00;;A61K9/2018;;A61K31/4439;;A61K31/506;;A61K31/513;;A61K31/506;;C07D401/04;;A61K31/513;;A61K31/4439;;A61K45/06,A61K31/513;;A61K31/4439;;A61K31/506,,0,0,,,,ACTIVE
187,GB,A,GB 2591350 A,100-318-732-271-355,2021-07-28,2021,GB 202102161 A,2019-07-31,US 2019/0044310 W;;US 201816052045 A,2018-08-01,"Systems, apparatus and methods for collecting and separating floating debris and water from a body of water","Systems, apparatus and methods useful for collecting and separating floating debris and water from a body of water on a vessel, the vessel including at least one inflow regulator (IFR) chamber at least partially separated from a main collection compartment and at least one fluid discharge pump.",OCEAN CLEANER LLC,RUSSELL COVINGTON;;KIM MICHAEL FOLSE;;CHRISTOPHER HOWELL GUNTER,,https://lens.org/100-318-732-271-355,Patent Application,no,5,0,18,34,0,E02B15/046;;B63B35/32;;C02F1/40;;C02F2101/32;;C02F2103/007;;C02F2201/008;;E02B15/048;;Y02A20/204;;E02B15/046;;E02B15/048;;B63B35/32;;E02B15/046;;B63B35/32;;C02F1/40;;C02F2103/007;;C02F2201/008;;E02B15/046;;E02B15/048;;E02B15/0864;;E02B15/10;;E02B15/106,E02B15/10,,0,0,,,,ACTIVE
188,US,A1,US 2019/0338481 A1,083-750-066-203-42X,2019-11-07,2019,US 201816052045 A,2018-08-01,US 201816052045 A;;US 201715492724 A;;US 201514881394 A;;US 201462064776 P,2014-10-16,"SYSTEMS, APPARATUS AND METHODS FOR COLLECTING AND SEPARATING FLOATING DEBRIS AND WATER FROM A BODY OF WATER","Systems, apparatus and methods useful for collecting and separating floating debris and water from a body of water on a vessel, the vessel including at least one inflow regulator (IFR) chamber at least partially separated from a main collection compartment and at least one fluid discharge pump.",OCEAN CLEANER LLC,COVINGTON RUSSELL S;;FOLSE KIM MICHAEL;;GUNTER CHRISTOPHER HOWELL,OCEAN CLEANER LLC (2019-02-20),https://lens.org/083-750-066-203-42X,Patent Application,yes,0,6,18,34,0,E02B15/046;;B63B35/32;;C02F1/40;;C02F2101/32;;C02F2103/007;;C02F2201/008;;E02B15/048;;Y02A20/204;;E02B15/046;;E02B15/048;;B63B35/32;;E02B15/046;;B63B35/32;;C02F1/40;;C02F2103/007;;C02F2201/008;;E02B15/046;;E02B15/048;;E02B15/0864;;E02B15/10;;E02B15/106,E02B15/08;;B63B35/32;;C02F1/40;;E02B15/10,,0,0,,,,ACTIVE
189,GB,B,GB 2612185 B,018-364-529-965-963,2023-07-19,2023,GB 202212818 A,2019-07-31,US 201816052045 A;;GB 202102161 A,2018-08-01,"Systems, apparatus and methods for collecting debris from a body of water",,OCEAN CLEANER LLC,RUSSELL S COVINGTON;;KIM MICHAEL FOLSE;;CHRISTOPHER HOWELL GUNTER,,https://lens.org/018-364-529-965-963,Granted Patent,no,3,0,18,34,0,E02B15/046;;B63B35/32;;C02F1/40;;C02F2101/32;;C02F2103/007;;C02F2201/008;;E02B15/048;;Y02A20/204;;E02B15/046;;E02B15/048;;B63B35/32;;E02B15/046;;B63B35/32;;C02F1/40;;C02F2103/007;;C02F2201/008;;E02B15/046;;E02B15/048;;E02B15/0864;;E02B15/10;;E02B15/106,E02B15/04;;B63B35/32,,0,0,,,,ACTIVE
190,AU,B2,AU 2019/315447 B2,096-431-762-206-804,2022-04-14,2022,AU 2019/315447 A,2019-07-31,US 201816052045 A;;US 2019/0044310 W,2018-08-01,"Systems, apparatus and methods for collecting and separating floating debris and water from a body of water","Systems, apparatus and methods useful for collecting and separating floating debris and water from a body of water on a vessel, the vessel including at least one inflow regulator (IFR) chamber at least partially separated from a main collection compartment and at least one fluid discharge pump.",OCEAN CLEANER LLC,COVINGTON RUSSELL S;;FOLSE KIM MICHAEL;;GUNTER CHRISTOPHER HOWELL,,https://lens.org/096-431-762-206-804,Granted Patent,no,3,0,18,34,0,E02B15/046;;B63B35/32;;C02F1/40;;C02F2101/32;;C02F2103/007;;C02F2201/008;;E02B15/048;;Y02A20/204;;E02B15/046;;E02B15/048;;B63B35/32;;E02B15/046;;B63B35/32;;C02F1/40;;C02F2103/007;;C02F2201/008;;E02B15/046;;E02B15/048;;E02B15/0864;;E02B15/10;;E02B15/106,E02B15/10,,0,0,,,,ACTIVE
191,GB,A,GB 2612185 A,140-744-526-426-638,2023-04-26,2023,GB 202212818 A,2019-07-31,US 201816052045 A;;GB 202102161 A,2018-08-01,"Systems, apparatus and methods for collecting and separating floating debris and water from a body of water","A debris removal system comprising a vessel 10 having a main cargo compartment 60, an intake opening (e.g. chamber 310) coupling the main compartment to a body of water 30 during debris collection, an air discharge vent 356 coupled to the main compartment for venting gases from the main compartment and allowing it to be filled with water/debris, a fluid discharge pump (184, Fig. 45) coupled to the main compartment for drawing water and debris through the intake opening in the main compartment, a debris pump (380, Fig. 45), a debris pump inlet (382, Fig. 45) coupling a debris pump, distinct from the fluid pump, to the main compartment for removing debris that has been allowed to rise within the main compartment. Also claimed is a method. The intake opening may include partially floating inflow regulators (IFRs) (140, Fig. 45) or wave dampeners to minimise mixing of debris and water. The vessel is designed to efficiently separate water from debris, pumping debris, such as oil, to storage e.g. barges, and pumping separated water back into the body of water, allowing continual debris clean up.",OCEAN CLEANER LLC,RUSSELL S COVINGTON;;KIM MICHAEL FOLSE;;CHRISTOPHER HOWELL GUNTER,,https://lens.org/140-744-526-426-638,Patent Application,no,3,0,18,34,0,E02B15/046;;B63B35/32;;C02F1/40;;C02F2101/32;;C02F2103/007;;C02F2201/008;;E02B15/048;;Y02A20/204;;E02B15/046;;E02B15/048;;B63B35/32;;E02B15/046;;B63B35/32;;C02F1/40;;C02F2103/007;;C02F2201/008;;E02B15/046;;E02B15/048;;E02B15/0864;;E02B15/10;;E02B15/106,E02B15/04;;B63B35/32,,0,0,,,,ACTIVE
192,CA,A1,CA 3106974 A1,092-640-508-539-385,2020-02-06,2020,CA 3106974 A,2019-07-31,US 201816052045 A;;US 2019/0044310 W,2018-08-01,"SYSTEMS, APPARATUS AND METHODS FOR COLLECTING AND SEPARATING FLOATING DEBRIS AND WATER FROM A BODY OF WATER","Systems, apparatus and methods useful for collecting and separating floating debris and water from a body of water on a vessel, the vessel including at least one inflow regulator (IFR) chamber at least partially separated from a main collection compartment and at least one fluid discharge pump.",OCEAN CLEANER LLC,COVINGTON RUSSELL S;;FOLSE KIM MICHAEL;;GUNTER CHRISTOPHER HOWELL,,https://lens.org/092-640-508-539-385,Patent Application,no,0,0,18,34,0,E02B15/046;;B63B35/32;;C02F1/40;;C02F2101/32;;C02F2103/007;;C02F2201/008;;E02B15/048;;Y02A20/204;;E02B15/046;;E02B15/048;;B63B35/32;;E02B15/046;;B63B35/32;;C02F1/40;;C02F2103/007;;C02F2201/008;;E02B15/046;;E02B15/048;;E02B15/0864;;E02B15/10;;E02B15/106,E02B15/10,,0,0,,,,PENDING
193,AU,A1,AU 2022/204920 A1,162-903-105-746-426,2022-07-28,2022,AU 2022/204920 A,2022-07-08,AU 2022/204920 A;;AU 2019/315447 A;;US 201816052045 A;;US 2019/0044310 W,2018-08-01,"Systems, apparatus and methods for collecting and separating floating debris and water from a body of water","Systems, apparatus and methods useful for collecting and separating floating debris and water from a body of water on a vessel, the vessel including at least one inflow regulator (IFR) chamber at least partially separated from a main collection compartment and at least one fluid discharge pump.",OCEAN CLEANER LLC,COVINGTON RUSSELL S;;FOLSE KIM MICHAEL;;GUNTER CHRISTOPHER HOWELL,,https://lens.org/162-903-105-746-426,Patent Application,no,0,0,18,34,0,E02B15/046;;B63B35/32;;C02F1/40;;C02F2101/32;;C02F2103/007;;C02F2201/008;;E02B15/048;;Y02A20/204;;E02B15/046;;E02B15/048;;B63B35/32;;E02B15/046;;B63B35/32;;C02F1/40;;C02F2103/007;;C02F2201/008;;E02B15/046;;E02B15/048;;E02B15/0864;;E02B15/10;;E02B15/106,E02B15/10,,0,0,,,,PENDING
194,GB,B,GB 2611913 B,101-547-673-672-241,2023-08-09,2023,GB 202219853 A,2019-07-31,US 201816052045 A;;GB 202212818 A,2018-08-01,"Apparatus, systems and methods for collecting debris from a body of water",,OCEAN CLEANER LLC,RUSSELL S COVINGTON;;KIM MICHAEL FOLSE;;CHRISTOPHER HOWELL GUNTER,,https://lens.org/101-547-673-672-241,Granted Patent,no,6,0,18,34,0,E02B15/046;;B63B35/32;;C02F1/40;;C02F2101/32;;C02F2103/007;;C02F2201/008;;E02B15/048;;Y02A20/204;;E02B15/046;;E02B15/048;;B63B35/32;;E02B15/046;;B63B35/32;;C02F1/40;;C02F2103/007;;C02F2201/008;;E02B15/046;;E02B15/048;;E02B15/0864;;E02B15/10;;E02B15/106,E02B15/04;;B63B35/32,,0,0,,,,ACTIVE
195,GB,A,GB 2611913 A,155-924-989-517-328,2023-04-19,2023,GB 202219853 A,2019-07-31,US 201816052045 A;;GB 202212818 A,2018-08-01,"Systems, apparatus and methods for collecting and separating floating debris and water from a body of water","A debris removal system comprising a vessel 10 having a main cargo compartment 60, an intake opening (e.g. chamber 310) coupling the main compartment to a body of water 30 during debris collection, an air discharge vent 356 coupled to the main compartment for venting gases from the main compartment and allowing it to be filled with water/debris, a fluid discharge pump (184, Fig. 45) coupled to the main compartment for drawing water and debris through the intake opening in the main compartment, a debris pump (380, Fig. 45), a debris pump inlet (382, Fig. 45) coupling a debris pump, distinct from the fluid pump, to the main compartment for removing debris that has been allowed to rise within the main compartment. Also claimed is a method, a system & method including sensors for selectively controlling the pump, and a system and method wherein the main compartment includes internal walls, dividers or baffles around which fluid flows. The vessel is designed to efficiently separate water from debris, pumping debris, such as oil, to storage e.g. barges, and pumping separated water back into the body of water, allowing continual debris clean up.",OCEAN CLEANER LLC,RUSSELL S COVINGTON;;KIM MICHAEL FOLSE;;CHRISTOPHER HOWELL GUNTER,,https://lens.org/155-924-989-517-328,Patent Application,no,5,0,18,34,0,E02B15/046;;B63B35/32;;C02F1/40;;C02F2101/32;;C02F2103/007;;C02F2201/008;;E02B15/048;;Y02A20/204;;E02B15/046;;E02B15/048;;B63B35/32;;E02B15/046;;B63B35/32;;C02F1/40;;C02F2103/007;;C02F2201/008;;E02B15/046;;E02B15/048;;E02B15/0864;;E02B15/10;;E02B15/106,E02B15/04;;B63B35/32,,0,0,,,,ACTIVE
196,GB,B,GB 2591350 B,176-473-275-744-774,2022-10-19,2022,GB 202102161 A,2019-07-31,US 2019/0044310 W;;US 201816052045 A,2018-08-01,"Systems, apparatus and methods for collecting and separating floating debris and water from a body of water",,OCEAN CLEANER LLC,RUSSELL S COVINGTON;;KIM MICHAEL FOLSE;;CHRISTOPHER HOWELL GUNTER,,https://lens.org/176-473-275-744-774,Granted Patent,no,5,0,18,34,0,E02B15/046;;B63B35/32;;C02F1/40;;C02F2101/32;;C02F2103/007;;C02F2201/008;;E02B15/048;;Y02A20/204;;E02B15/046;;E02B15/048;;B63B35/32;;E02B15/046;;B63B35/32;;C02F1/40;;C02F2103/007;;C02F2201/008;;E02B15/046;;E02B15/048;;E02B15/0864;;E02B15/10;;E02B15/106,E02B15/10,,0,0,,,,ACTIVE
197,US,B2,US 10683627 B2,043-003-997-057-053,2020-06-16,2020,US 201816052045 A,2018-08-01,US 201816052045 A;;US 201715492724 A;;US 201514881394 A;;US 201462064776 P,2014-10-16,"Systems, apparatus and methods for collecting and separating floating debris and water from a body of water","Systems, apparatus and methods useful for collecting and separating floating debris and water from a body of water on a vessel, the vessel including at least one inflow regulator (IFR) chamber at least partially separated from a main collection compartment and at least one fluid discharge pump.",OCEAN CLEANER LLC,COVINGTON RUSSELL S;;FOLSE KIM MICHAEL;;GUNTER CHRISTOPHER HOWELL,OCEAN CLEANER LLC (2019-02-20),https://lens.org/043-003-997-057-053,Granted Patent,yes,48,1,18,34,0,E02B15/046;;B63B35/32;;C02F1/40;;C02F2101/32;;C02F2103/007;;C02F2201/008;;E02B15/048;;Y02A20/204;;E02B15/046;;E02B15/048;;B63B35/32;;E02B15/046;;B63B35/32;;C02F1/40;;C02F2103/007;;C02F2201/008;;E02B15/046;;E02B15/048;;E02B15/0864;;E02B15/10;;E02B15/106,E02B15/04;;B63B35/32;;C02F1/40;;C02F103/00;;E02B15/08;;E02B15/10,,5,0,,,"Ecooceane Products, http://ecooceane.com/products/, 7 pp.;;Oil Spill Recover Europe Ltd., YouTube video demonstration page and company information, 7 pp.;;Patzek, Tad W., “Energy and Environment Subcommittee of the Energy and Commerce Committee Jun. 9, 2010 Briefing”, Jun. 8, 2010, 16 pp.;;“Oil Skimmer ‘The Big Gulp’”, 2 pages, News Item Reported by Fox News 8, John Snell, Anchor, http://ladcompanies.com/index.php/home/news/101-oil-skimmer-qthe-big-gulpq.html, 2 pp.;;“Oil Whale How it Works”, Copyright 2016 by Oilwhale Oy, http://www.oilwhale.fi/how-it-works/, 5 pp.",ACTIVE
198,NO,A1,NO 20210204 A1,057-410-572-310-849,2021-02-17,2021,NO 20210204 A,2021-02-17,US 2019/0044310 W;;US 201816052045 A,2018-08-01,"SYSTEMS, APPARATUS AND METHODS FOR COLLECTING AND SEPARATING FLOATING DEBRIS AND WATER FROM A BODY OF WATER",,OCEAN CLEANER LLC,COVINGTON RUSSEL S;;FOLSE KIM MICHAEL;;GUNTER CHRISTOPHER HOWELL,"OCEAN CLEANER LLC, US (2021-07-19)",https://lens.org/057-410-572-310-849,Patent Application,no,0,0,18,34,0,E02B15/046;;B63B35/32;;C02F1/40;;C02F2101/32;;C02F2103/007;;C02F2201/008;;E02B15/048;;Y02A20/204;;E02B15/046;;E02B15/048;;B63B35/32;;E02B15/046;;B63B35/32;;C02F1/40;;C02F2103/007;;C02F2201/008;;E02B15/046;;E02B15/048;;E02B15/0864;;E02B15/10;;E02B15/106,E02B15/04,,0,0,,,,PENDING
199,AU,A1,AU 2019/315447 A1,116-525-479-878-737,2021-02-18,2021,AU 2019/315447 A,2019-07-31,US 201816052045 A;;US 2019/0044310 W,2018-08-01,"Systems, apparatus and methods for collecting and separating floating debris and water from a body of water","Systems, apparatus and methods useful for collecting and separating floating debris and water from a body of water on a vessel, the vessel including at least one inflow regulator (IFR) chamber at least partially separated from a main collection compartment and at least one fluid discharge pump.",OCEAN CLEANER LLC,COVINGTON RUSSELL S;;FOLSE KIM MICHAEL;;GUNTER CHRISTOPHER HOWELL,,https://lens.org/116-525-479-878-737,Patent Application,no,0,0,18,34,0,E02B15/046;;B63B35/32;;C02F1/40;;C02F2101/32;;C02F2103/007;;C02F2201/008;;E02B15/048;;Y02A20/204;;E02B15/046;;E02B15/048;;B63B35/32;;E02B15/046;;B63B35/32;;C02F1/40;;C02F2103/007;;C02F2201/008;;E02B15/046;;E02B15/048;;E02B15/0864;;E02B15/10;;E02B15/106,E02B15/10,,0,0,,,,ACTIVE
200,US,A1,US 2006/0074879 A1,146-667-308-733-973,2006-04-06,2006,US 95686604 A,2004-09-30,US 95686604 A,2004-09-30,Easy-to-use data context filtering,"A method and system for the graphical formulation of filter queries is disclosed which enables data queries to be easily via selection from a menu. A signal is received to filter, or query, a data table. Next, the context of the signaled key field is analyzed, and a menu of filters based on that context is formulated and displayed. A filter selection is received, and the corresponding filter is executed. The results of the filter are displayed on the screen.",MICROSOFT CORP,COVINGTON CLINTON D;;BERGMAN PHILIP E;;BEYENE TIGINESH M;;DICKINSON RICHARD;;BRYANT CHRISTOPHER W,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2004-09-30),https://lens.org/146-667-308-733-973,Patent Application,yes,9,30,9,9,0,G06F16/2428;;G06F9/06;;G06F16/2428;;Y10S707/99933;;Y10S707/99934,G06F3/0482;;G06F17/30,707/3,0,0,,,,DISCONTINUED
201,EP,A2,EP 1643386 A2,189-020-071-894-383,2006-04-05,2006,EP 05105142 A,2005-06-13,US 95686604 A,2004-09-30,Easy-to-use data context filtering,"A method and system for the graphical formulation of filter queries is disclosed which enables data queries to be easily via selection from a menu. A signal is received to filter, or query, a data table. Next, the context of the signaled key field is analyzed, and a menu of filters based on that context is formulated and displayed. A filter selection is received, and the corresponding filter is executed. The results of the filter are displayed on the screen.
",MICROSOFT CORP,BRYANT CHRISTOPHER W;;COVINGTON CLINTON D;;BERGMAN PHILIP E;;DICKINSON RICHARD;;BEYENE TIGINESH M,,https://lens.org/189-020-071-894-383,Patent Application,yes,4,3,9,9,0,G06F16/2428;;G06F9/06;;G06F16/2428;;Y10S707/99933;;Y10S707/99934,G06F3/0482;;G06F17/30,,0,0,,,,DISCONTINUED
202,JP,A,JP 2006107431 A,094-278-876-342-184,2006-04-20,2006,JP 2005175171 A,2005-06-15,US 95686604 A,2004-09-30,EASY-TO-USE DATA CONTEXT FILTERING,"<P>PROBLEM TO BE SOLVED: To provide easy-to-use data context filtering. <P>SOLUTION: A method and system for the graphical formulation of filter queries is disclosed which enables data queries to be easily chosen via selection from a menu. A signal is received to filter, or query, a data table. Next, the context of the signaled key field is analyzed, and a menu of filters based on that context is formulated and displayed. A filter selection is received, and the corresponding filter is executed. The results of the filter displayed on the screen. <P>COPYRIGHT: (C)2006,JPO&NCIPI",MICROSOFT CORP,BRYANT CHRISTOPHER W;;COVINGTON CLINTON D;;BERGMAN PHILIP E;;DICKINSON RICHARD;;BEYENE TIGINESH M,,https://lens.org/094-278-876-342-184,Patent Application,no,5,1,9,9,0,G06F16/2428;;G06F9/06;;G06F16/2428;;Y10S707/99933;;Y10S707/99934,G06F3/0482,,0,0,,,,PENDING
203,KR,A,KR 20060048768 A,064-086-092-686-97X,2006-05-18,2006,KR 20050057767 A,2005-06-30,US 95686604 A,2004-09-30,EASY-TO-USE DATA CONTEXT FILTERING,,MICROSOFT CORP,BRYANT CHRISTOPHER W;;COVINGTON CLINTON D;;BERGMAN PHILIP E;;DICKINSON RICHARD;;BEYENE TIGINESH M,,https://lens.org/064-086-092-686-97X,Patent Application,no,0,1,9,9,0,G06F16/2428;;G06F9/06;;G06F16/2428;;Y10S707/99933;;Y10S707/99934,G06F3/0482;;G06F9/06,,0,0,,,,DISCONTINUED
204,EP,A3,EP 1643386 A3,091-342-812-940-112,2007-01-03,2007,EP 05105142 A,2005-06-13,US 95686604 A,2004-09-30,Easy-to-use data context filtering,"A method and system for the graphical formulation of filter queries is disclosed which enables data queries to be easily via selection from a menu. A signal is received to filter, or query, a data table. Next, the context of the signaled key field is analyzed, and a menu of filters based on that context is formulated and displayed. A filter selection is received, and the corresponding filter is executed. The results of the filter are displayed on the screen.
",MICROSOFT CORP,BRYANT CHRISTOPHER W;;COVINGTON CLINTON D;;BERGMAN PHILIP E;;DICKINSON RICHARD;;BEYENE TIGINESH M,,https://lens.org/091-342-812-940-112,Search Report,yes,5,0,9,9,0,G06F16/2428;;G06F9/06;;G06F16/2428;;Y10S707/99933;;Y10S707/99934,G06F3/0482;;G06F17/30,,0,0,,,,DISCONTINUED
205,US,B2,US 9395864 B2,099-930-282-635-509,2016-07-19,2016,US 201113293968 A,2011-11-10,US 201113293968 A;;US 201113222914 A,2011-08-31,Animation for expanding/collapsing content and for sorting content in an electronic document,Animation for the expansion and collapse of content in a user interface may be provided. The user interface may be displayed by a computer and may contain a content surface for editing content. The content may include a top data row and data items in rows below the top data row on the content surface. The computer may then receive an input to expand/collapse the data items into the top data row. The computer may then animate a display of the data items expanding/collapsing into the top data row. Animation for the sorting of content in a user interface may also be provided. The user interface may be displayed by a computer and may contain a content surface for editing a plurality of rows containing content. The computer may then receive a request to sort the content. The computer may then animate a sort of the content.,LEONG JOSH;;EDWARDS CHRISTOPHER D;;CHENG KAREN XIAOXU;;ROTHSCHILLER CHAD B;;COVINGTON CLINTON DEE;;BENDIG KRISTA ANNE;;MICROSOFT TECHNOLOGY LICENSING LLC,LEONG JOSH;;EDWARDS CHRISTOPHER D;;CHENG KAREN XIAOXU;;ROTHSCHILLER CHAD B;;COVINGTON CLINTON DEE;;BENDIG KRISTA ANNE,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14),https://lens.org/099-930-282-635-509,Granted Patent,yes,26,1,3,3,0,G06F3/0482;;G06F16/9038;;G06F40/18;;G06F3/0482;;G06F16/9038;;G06F40/18;;G06F3/048,G06F3/048,,12,0,,,"Morrison, Scott, ""Sorting Data in the Silverlight DataGrid,"" Published Jun. 10, 2008, Retrieved Jun. 7, 2011, http://blogs.msdn.com/b/scmorris/archive/2008/06/10/sorting-data-in-the-silverlight-datagrid.aspx, 4 pages.;;ShowSim, ""Official Release of ShowSim 4.0,"" Apr. 8, 2010, Retrieved Jun. 7, 2011, http://www.showsim.com/NewsDetails.aspx?NewsID=2, 2 pages.;;U.S. Office Action mailed Jan. 31, 2013 in U.S. Appl. No. 13/222,914, 15 pages.;;U.S. Office Action mailed Jun. 12, 2013 in U.S. Appl. No. 13/222,914, 15 pages.;;Expand animation, Collapse animation-r.a.d.panelbar, published Sep. 12, 2009 by Telerik. Internet Wayback archive. 1 pg. (cited in Jul. 16, 2014 OA).;;Telerik; Tree View / Expand Animation by Telerik, Feb. 2011. Internet Wayback archive downloaded at http://web.archive.org/web/20110227141012/http://demos.telerik.com/aspnetajax/treeview/examples/functionality/expandanimation/defaultcs.aspx. 3 pages (cited in Jul. 1, 2015 OA).;;Telerik; Tree View for ASP.NET AJAX, by Telerik, Feb. 2011, 7 pages. Internet Wayback archive downloaded at http://web.archive.org/web/20110220002544/http://www.telerik.com/products/aspnet-ajax/treeview.aspx. (cited in Jul. 1, 2015 OA).;;U.S. Office Action mailed Feb. 14, 2014 in U.S. Appl. No. 13/222,914, 14 pages.;;U.S. Office Action mailed Jul. 16, 2014 in U.S. Appl. No. 13/222,914, 12 pages.;;U.S. Office Action mailed Jul. 1, 2015 in U.S. Appl. No. 13/222,914, 12 pages.;;U.S. Office Action mailed Dec. 3, 2015 in U.S. Appl. No. 13/222,914, 23 pgs.;;Animated Collapsible Div Version 2.4 by Dynamic Drive. Internet wayback archive, Aug. 8, 2010, 7 pgs.",ACTIVE
206,US,A1,US 2013/0055167 A1,171-948-951-827-394,2013-02-28,2013,US 201113222914 A,2011-08-31,US 201113222914 A,2011-08-31,Animation for Expanding/Collapsing Content and for Sorting Content in an Electronic Document,Animation for the expansion and collapse of content in a user interface may be provided. The user interface may be displayed by a computer and may contain a content surface for editing content. The content may include a top data row and data items in rows below the top data row on the content surface. The computer may then receive an input to expand/collapse the data items into the top data row. The computer may then animate a display of the data items expanding/collapsing into the top data row. Animation for the sorting of content in a user interface may also be provided. The user interface may be displayed by a computer and may contain a content surface for editing a plurality of rows containing content. The computer may then receive a request to sort the content. The computer may then animate a sort of the content.,LEONG JOSH;;EDWARDS CHRISTOPHER D;;CHENG KAREN XIAOXU;;ROTHSCHILLER CHAD B;;COVINGTON CLINTON DEE;;BENDIG KRISTA ANNE;;MICROSOFT CORP,LEONG JOSH;;EDWARDS CHRISTOPHER D;;CHENG KAREN XIAOXU;;ROTHSCHILLER CHAD B;;COVINGTON CLINTON DEE;;BENDIG KRISTA ANNE,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2011-08-28),https://lens.org/171-948-951-827-394,Patent Application,yes,7,20,3,3,0,G06F3/0482;;G06F16/9038;;G06F40/18;;G06F3/0482;;G06F16/9038;;G06F40/18;;G06F3/048,G06F3/048,715/854,4,0,,,"Expand animation, Collapse animation-r.a.d.panelbar, published 9/12/2009 by Telerik. Internet Wayback archive. 1 pg.;;TreeView / Expand Animation by Telerik, Feb 2011. Internet Wayback archive downloaded at http://web.archive.org/web/20110227141012/http://demos.telerik.com/aspnet-ajax/treeview/examples/functionality/expandanimation/defaultcs.aspx. 3 pages.;;Tree View for ASP.NEt AJAX , by Telerik, February 2011, 7 pages. Internet Wayback archive downloaded at http://web.archive.org/web/20110220002544/http://www.telerik.com/products/aspnet-ajax/treeview.aspx;;Animated Collapsible Div Version 2.4 by Dynamic Drive. Internet wayback archive, August 8th, 2010 . 7 pages.",DISCONTINUED
207,US,A1,US 2007/0005630 A1,081-948-156-897-534,2007-01-04,2007,US 16985605 A,2005-06-29,US 16985605 A,2005-06-29,Modifying table definitions within a database application,"Methods, systems, and computer program products modify a table definition of a database table within a database application. A method involves providing a user interface for creating a new field in the database table, receiving data that creates the new field while displaying the database table, and modifying schema of the database table to include the new field and the data. The method also involves interpreting a data type of the data as the data is received. A data type interpreted for a column in the database table that contains the new field is the data type of the data received in the new field. Still further, the method involves handling objects dependent on the database table in a manner unbeknownst to a user of the database table. Thus, the schema is modified while the objects dependent on the database table remain visible or open to the user.",MICROSOFT CORP,SELCA VITORE;;BRYANT CHRISTOPHER W;;GROFF SHANE L;;NARAMORE THERESA A;;BEYENE TIGINESH M;;COVINGTON CLINTON D,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2005-06-28),https://lens.org/081-948-156-897-534,Patent Application,yes,43,23,2,9,0,G06F16/217;;G06F16/217;;Y10S707/99943,G06F7/00,707/102,0,0,,,,INACTIVE
208,US,A1,US 2013/0055123 A1,130-684-432-616-540,2013-02-28,2013,US 201113293968 A,2011-11-10,US 201113293968 A;;US 201113222914 A,2011-08-31,Animation for Expanding/Collapsing Content and for Sorting Content in an Electronic Document,Animation for the expansion and collapse of content in a user interface may be provided. The user interface may be displayed by a computer and may contain a content surface for editing content. The content may include a top data row and data items in rows below the top data row on the content surface. The computer may then receive an input to expand/collapse the data items into the top data row. The computer may then animate a display of the data items expanding/collapsing into the top data row. Animation for the sorting of content in a user interface may also be provided. The user interface may be displayed by a computer and may contain a content surface for editing a plurality of rows containing content. The computer may then receive a request to sort the content. The computer may then animate a sort of the content.,LEONG JOSH;;EDWARDS CHRISTOPHER D;;CHENG KAREN XIAOXU;;ROTHSCHILLER CHAD B;;COVINGTON CLINTON DEE;;BENDIG KRISTA ANNE;;MICROSOFT CORP,LEONG JOSH;;EDWARDS CHRISTOPHER D;;CHENG KAREN XIAOXU;;ROTHSCHILLER CHAD B;;COVINGTON CLINTON DEE;;BENDIG KRISTA ANNE,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14),https://lens.org/130-684-432-616-540,Patent Application,yes,10,1,3,3,0,G06F3/0482;;G06F16/9038;;G06F40/18;;G06F3/0482;;G06F16/9038;;G06F40/18;;G06F3/048,G06F3/048,715/765,0,0,,,,ACTIVE
209,US,B2,US 7716168 B2,024-126-117-741-879,2010-05-11,2010,US 16985605 A,2005-06-29,US 16985605 A,2005-06-29,Modifying table definitions within a database application,"Methods, systems, and computer program products modify a table definition of a database table within a database application. A method involves providing a user interface for creating a new field in the database table, receiving data that creates the new field while displaying the database table, and modifying schema of the database table to include the new field and the data. The method also involves interpreting a data type of the data as the data is received. A data type interpreted for a column in the database table that contains the new field is the data type of the data received in the new field. Still further, the method involves handling objects dependent on the database table in a manner unbeknownst to a user of the database table. Thus, the schema is modified while the objects dependent on the database table remain visible or open to the user.",MICROSOFT CORP,SELCA VITORE;;BRYANT CHRISTOPHER W;;GROFF SHANE L;;NARAMORE THERESA A;;BEYENE TIGINESH M;;COVINGTON CLINTON D,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2005-06-28),https://lens.org/024-126-117-741-879,Granted Patent,yes,106,17,2,9,0,G06F16/217;;G06F16/217;;Y10S707/99943,G06F17/30,707/102;;707/3;;707/101;;707/205,34,2,015-718-706-880-87X;;040-393-580-637-973,10.1109/dsn.2004.1311926;;10.1016/j.diin.2005.07.003,"Anonymous, ""Method and Apparatus for Automatic Character Line Fill of Decimal Fields."" IBM Technical Disclosure Bulletin vol. 36, No. 10, pp. 155-156, Oct. 1993.;;Miastkowski, S. ""Excel 5.0-a Quick-start Guide to Using Excel's Powerful New Features."" Macworld vol. 11, No. 10, pp. 146-151, Oct. 1994.;;Microsoft Corp. Help File on 'Series' 'Repeated Entries', and 'Auto Fill' (screen shot) of Microsoft Excel 97 (1996), taken Mar. 2001, 6 pp.;;Crew, Ed, ed. ""Lesson in Excel 97: Lesson One . . . "", Web page tutorial on Excel 97 downloaded from pathways.uwe.ac.uk/Edict/Excel-01.asp on Mar. 29, 2002, 6 pp.;;Sonic.net. ""Microsoft Excel 5.0 (Tips on Using MS Excel 5.0 Repeat Entries)"" downloaded from www.sonic.net/.about.sbaumann/excel.html on Apr. 2, 2002, 5 pp.;;Microsoft Office 2000/Visual Basic Programmer's Guide, ""Creating Dynamic Reports with Query Tables in Excel"", http://msdn.microsoft.com/library/en-us/odeopg/html/deconcreatingdynamicreportswithq..., downloaded May 16, 2006, 2 pp.;;Khor, ""Microsoft Office Excel 2003 Preview"", Jun. 2003, http://msdn.microsoft.com/library/en-us/odc-x12003-ta/html/odc-xlov.asp?frame=true, downloaded May 16, 2006, 19 pp.;;U.S. Appl. No. 10/667,543, filed Sep. 22, 2003 entitled ""Extension of Formulas and Formatting in an Electronic Spreadsheet"".;;U.S. Appl. No. 10/782,074, filed Feb. 19, 2004 entitled ""Data Source Write back and Offline Data Editing and Storage in a Spreadsheet"".;;U.S. Appl. No. 11/317,648, filed Dec. 22, 2005 entitled ""Data Source Task Pane"".;;U.S. Appl. No. 11/300,728, filed Dec. 15, 2005 entitled ""Offline Multi-Table Data Editing and Storage System"".;;U.S. Appl. No. 11/231,260, filed Sep. 20, 2005 entitled ""Templates in a Schema Editor"".;;Official Action in U.S. Appl. No. 10/667,543 mailed Feb. 15, 2006.;;Official Action in U.S. Appl. No. 10/667,543 mailed Aug. 2, 2006.;;U.S. Appl. No. 10/782,074, filed Feb. 19, 2004, entitled ""Data Source Write Back and Offline Data Editing and Storage in a Spreadsheet"".;;Davidson, Louis, ""Professional SQL Server 2000 Database Design,"" Wrox Press Ltd., 2001, 464 pp.;;U.S. Official Action in U.S. Appl. No. 11/231,260, Selca et al., mailed Jul. 18, 2008.;;U.S. Official Action in U.S. Appl. No. 11/343,957 mailed Jan. 15, 2008.;;U.S. Official Action in U.S. Appl. No. 11/317,648 mailed Apr. 17, 2008.;;U.S. Official Action mailed Oct. 16, 2007 in U.S. Appl. No. 11/231,260.;;U.S. Official Action mailed Jan. 9, 2008 in U.S. Appl. No. 11/300,728.;;PCT International Search Report in PCT/US2007/002662 mailed Jul. 5, 2007.;;Davidson, ""Professional SQL Server 2000 Database Design"", Wrox Press Ltd., 2001, 464 pp.;;""Mapping Windows XP Professional to Your Business Needs"", Microsoft: Windows XP Resource Kits, http://www.microsoft.com/resources/documentation/Windows/XP/all/reskit/en-us/Default.asp?url=/resources/documentation/Windows/XP/all/reskit/en-us/prba-dwp-tnvo.asp, printed Dec. 15, 2005, 8 pp.;;Strong, Craeg, ""Release Information"", http://www.zope.org/Members/arielpartners/CVSFile/readme/document-view, Apr. 2003, 6 pp.;;Onion, Fritz, ""Understanding Paths in ASP.NET"", Informit.com, http://www.informit.com/articles/article.asp?p=101145&redir=1, Sep. 2003, 4 pp.;;U.S. Official Action mailed Jan. 12, 2009 in U.S. Appl. No. 11/231,260.;;EP Search Report in 07763001.0-2201/198439 mailed May 29, 2009.;;U.S. Official Action mailed Jul. 31, 2009 in U.S. Appl. No. 11/231,260, pp. 1-23.;;EP Examination Report in 07763001.0-2201/1984839 mailed Aug. 7, 2009, pp. 1-4.;;U.S. Official Action mailed Sep. 25, 2009 in U.S. Appl. No. 11/231,260 (14917.0202USI), pp. 1-23.;;Ganapathi, et al., ""Why PCs Are Fragile and What We Can Do About It: A Study of Windows Registry Problems"", Proceedings of the 2004 International Conference on Dependable Systems and Networks, 2004, 6 pp.;;Carvey, ""The Windows Registry as a Forensic Resource"", Digital Investigation, 2005, pp. 201-205.;;EP Summons to Attend Oral Hearing in 07763001.0-2201/1984839 mailed Oct. 29, 2009, pp. 1-9.",INACTIVE
210,ZA,B,ZA 734414 B,049-405-075-514-49X,1975-02-26,1975,ZA 734414 A,1973-06-28,US 26989972 A,1972-07-07,IMPROVED PROGRAMMABLE CALCULATOR,,HEWLETT PACKARD CO,WATSON R;;WENNINGER F;;SIMOCE K;;SPANGLER R;;BURMEISTER E;;CHRISTOPHER C;;JUDD M;;CADA F;;COVINGTON W,,https://lens.org/049-405-075-514-49X,Granted Patent,no,0,0,27,33,0,G06F15/0233,G06F3/02;;G06F9/45;;G06F15/02,,0,0,,,,EXPIRED
211,EP,A1,EP 4271345 A1,170-990-734-087-687,2023-11-08,2023,EP 21914797 A,2021-12-07,US 202063132437 P;;IB 2021061420 W,2020-12-30,PENDANT FOR MOBILE MEDICAL PLATFORMS,,AURIS HEALTH INC,SCHMITT FABIEN Y;;NORKOSKI CHRISTOPHER MICHAEL;;COVINGTON TRAVIS C;;DOISNEAU ANNE DONAHUE;;HASSAN ALEXANDER TAREK;;LE ROUX ELOI,,https://lens.org/170-990-734-087-687,Patent Application,yes,0,0,4,4,0,A61B90/57;;A61B34/30;;A61G13/02;;A61G13/04;;A61G13/08;;A61B2090/376;;A61B90/361;;A61B2034/2051;;A61B2034/2059;;A61B2034/2061;;A61B2034/2065;;A61B2017/00477;;A61B34/74;;A61B34/37;;A61B90/50;;A61B2090/571;;A61B50/13;;A61B2034/301;;A61B34/25;;A61G13/104;;A61G7/08;;A61G13/06;;A61G13/0018;;A61G13/104;;A61G2203/14;;A61G2203/20;;A61G2203/30;;A61G2203/70,A61G13/02;;A61B34/00;;A61B34/30;;A61B90/57;;A61G13/10,,0,0,,,,PENDING
212,WO,A1,WO 2022/144641 A1,074-851-806-874-672,2022-07-07,2022,IB 2021061420 W,2021-12-07,US 202063132437 P,2020-12-30,PENDANT FOR MOBILE MEDICAL PLATFORMS,"Certain aspects relate to systems and techniques for operating a medical platform that may include a table with a base and table top, one or more robotic arms that are coupled to the table, one or more wheel assemblies coupled to the base to support and move the base in a physical environment, and an input device configured to receive user inputs of a first type. The mobile medical platform may be configured to receive a first user input of the first input type via the input device. The mobile medical platform may be configured to, in response to receiving the first user input of the first input type and in accordance with a determination that the first user input meets first criteria, initiate first movement of the at least one motorized wheel in accordance with the first user input of the first input type.",AURIS HEALTH INC,SCHMITT FABIEN Y;;NORKOSKI CHRISTOPHER MICHAEL;;COVINGTON TRAVIS C;;DOISNEAU ANNE DONAHUE;;HASSAN ALEXANDER TAREK;;LE ROUX ELOI,,https://lens.org/074-851-806-874-672,Patent Application,yes,5,0,4,4,0,A61B90/57;;A61B34/30;;A61G13/02;;A61G13/04;;A61G13/08;;A61B2090/376;;A61B90/361;;A61B2034/2051;;A61B2034/2059;;A61B2034/2061;;A61B2034/2065;;A61B2017/00477;;A61B34/74;;A61B34/37;;A61B90/50;;A61B2090/571;;A61B50/13;;A61B2034/301;;A61B34/25;;A61G13/104;;A61G7/08;;A61G13/06;;A61G13/0018;;A61G13/104;;A61G2203/14;;A61G2203/20;;A61G2203/30;;A61G2203/70,A61G13/02;;A61B34/00;;A61B34/30;;A61B90/57;;A61G13/10,,0,0,,,,PENDING
213,CN,A,CN 114375182 A,078-706-943-221-808,2022-04-19,2022,CN 202080064052 A,2020-09-02,US 201962898472 P;;IB 2020058182 W,2019-09-10,Systems and methods for kinematic optimization using shared robot degrees of freedom,"Systems and methods for kinematic optimization with shared robot degrees of freedom are provided. In one aspect, a robotic medical system includes a base, an adjustable arm support coupled to the base, and at least one robotic arm coupled to the adjustable arm support. The at least one robotic arm is further configured to couple to a medical tool configured to be delivered through an incision or natural orifice of the patient. The system further includes a processor configured to adjust a position of the adjustable arm support and the at least one robotic arm while maintaining a remote center of movement of the tool.",ORIUS HEALTH COMPANY,EYRE NICHOLAS J;;KELLY SEAN PATRICK;;WEHRMANN STEFAN;;DAN YUVAL;;COVINGTON THOMAS CHRISTOPHER;;HUANG YANAN;;MINTZ DAVID S,,https://lens.org/078-706-943-221-808,Patent Application,no,0,2,8,8,0,A61B34/30;;A61B34/74;;A61B34/37;;A61B34/35;;B25J9/06;;B25J9/16;;B25J9/1689;;B25J5/007;;B25J9/1666;;B25J15/0019;;B25J9/0087;;B25J9/1643;;B25J15/0052;;A61B2034/302;;A61B2034/301;;A61B2034/303;;A61B2090/066;;G05B2219/40202;;G05B2219/40201;;A61B2034/2059;;A61B34/30;;B25J9/16;;B25J9/0087;;G05B2219/40202;;G05B2219/40201;;A61B34/37;;A61B34/74;;A61B2034/303;;A61B2034/2059;;A61B2090/066;;B25J5/007;;A61B34/30;;A61B2034/301;;A61B2034/302;;A61B34/35;;B25J9/06;;B25J9/1643;;B25J9/1666;;B25J9/1689;;B25J15/0019;;B25J15/0052,A61B34/00;;A61B34/20;;A61B34/30;;A61B34/35;;A61B34/37;;A61B90/00;;B25J5/00;;B25J9/00;;B25J9/06;;B25J9/16;;B25J15/00,,0,0,,,,PENDING
214,US,A,US 4126898 A,160-586-510-357-88X,1978-11-21,1978,US 76080277 A,1977-01-19,US 76080277 A,1977-01-19,Programmable calculator including terminal control means,"An adaptable programmable calculator is provided by employing a modular read-write and read-only memory unit capable of being expanded to provide the calculator with additional program and data storage functions oriented towards the environment of the user, a central processing unit capable of performing both serial binary and parallel binary-coded-decimal arithmetic, and an input-output control unit capable of bidirectionally transferring information between the memory or central processing units and a number of input and output units. The memory, central processor, and input-output control units are controlled by a microprocessor included in the central processing unit. The input and output units include a keyboard input unit with a plurality of alphanumeric keys, a magnetic tape cassette reading and recording unit capable of bidirectionally transferring programs and data between a magnetic tape and the calculator and, a solid state output display unit capable of displaying every alphabetic and numeric character and many other symbols individually or in combination. All of these input and output units are included within the calculator itself. An output printer, an X-Y plotter, a typewriter, a teletypewriter, a magnetic or paper tape reading and recording unit, an extended read-write memory unit, a magnetic disc reading and recording unit, a modem for connecting the calculator via telephone lines to a remotely located computer, and many other peripheral input and output units may also be employed with the calculator. The calculator may be operated manually by the user from the keyboard input unit or automatically by a program stored within the memory unit to perform calculations and provide an output indication of the results thereof. It may also be employed to load programs into the memory unit from the keyboard input unit, to separately or collectively transfer data and programs bidirectionally between the memory unit and an external magnetic tape and to code programs or sections thereof stored in the memory unit as being secure when they are transferred to an external magnetic tape, thereby preventing users of the calculator from again transferring them to an external magnetic tape or obtaining any indication of the individual program steps once they are reloaded into the calculator. In addition, the calculator may be employed to edit programs stored in the memory unit and to print out program lists, labels, and messages. The calculator employs an extended version of BASIC computer language and allows the user to enter a line comprising an alphanumeric statement into the calculator from the keyboard input unit while visually observing an alphanumeric display of that line to check for errors therein, permitting the user to cause the entered lines to be immediately executed by the calculator or stored as part of a program within the memory unit, and permitting the user to subsequently recall the executed or stored line so that it may be reinspected, reevaluated, and, if necessary, edited and executed and re-executed, or restored in edited form. Any entered or recalled information may be edited by employing the keyboard input unit to selectively delete or replace incorrect or undesired portions of the information or to selectively insert corrected or previously omitted portions thereof on a line-by-line or character-by-character basis. Syntax errors are automatically detected by the calculator when the entered statement is terminated, and execution errors are automatically detected upon attempted execution of the statement or statements. Both types of errors are indicated to the user via error messages displayed by the output display unit. In the event the calculator is being used in combination with an external printer unit indications of syntax or execution errors may, if desired, be printed. The calculator employs a compiler for converting each statement entered into the calculator in BASIC language into an internal stored format. It also employs an uncompiler for regenerating in the BASIC language statement any entered line converted to the internal stored format. The compiler and uncompiler operate on a line-by-line basis. The magnetic tape cassette reading and recording unit employed in the calculator allows the user to chain together several program segments and allows program manipulation of several blocks of data on an individual basis, thereby providing more efficient utilization of the available calculator memory. An interrupt feature of the cassette unit facilitates searching for a particular file located on a magnetic tape at the same time the calculator is performing other functions.",HEWLETT PACKARD CO,WATSON R;;CADA F;;SIMCOE K;;WENNINGER F;;JUDD M;;SPANGLER R;;COVINGTON W;;BURMEISTER E;;CHRISTOPHER C,,https://lens.org/160-586-510-357-88X,Granted Patent,yes,15,11,1,1,0,G06F15/02;;G06F15/02,G06F15/02,364900;;364706;;364709;;364715,1,0,,,"""Computer Programming Fundamentals: Based on the IBM System/360"", H. D. Leeds & G. M. Weinberg, McGraw-Hill, 1970, pp. 166-170, 490-537, 584.",EXPIRED
215,US,A1,US 2023/0355456 A1,139-765-319-510-551,2023-11-09,2023,US 202318342096 A,2023-06-27,US 202318342096 A;;IB 2021061420 W;;US 202063132437 P,2020-12-30,PENDANT FOR MOBILE MEDICAL PLATFORMS,"Certain aspects relate to systems and techniques for operating a medical platform that may include a table with a base and table top, one or more robotic arms that are coupled to the table, one or more wheel assemblies coupled to the base to support and move the base in a physical environment, and an input device configured to receive user inputs of a first type. The mobile medical platform may be configured to receive a first user input of the first input type via the input device. The mobile medical platform may be configured to, in response to receiving the first user input of the first input type and in accordance with a determination that the first user input meets first criteria, initiate first movement of the at least one motorized wheel in accordance with the first user input of the first input type.",AURIS HEALTH INC,SCHMITT FABIEN Y;;NORKOSKI CHRISTOPHER MICHAEL;;COVINGTON TRAVIS C;;DOISNEAU ANNE DONAHUE;;HASSAN ALEXANDER TAREK;;LE ROUX ELOI,AURIS HEALTH INC (2023-08-25),https://lens.org/139-765-319-510-551,Patent Application,yes,0,1,4,4,0,A61B90/57;;A61B34/30;;A61G13/02;;A61G13/04;;A61G13/08;;A61B2090/376;;A61B90/361;;A61B2034/2051;;A61B2034/2059;;A61B2034/2061;;A61B2034/2065;;A61B2017/00477;;A61B34/74;;A61B34/37;;A61B90/50;;A61B2090/571;;A61B50/13;;A61B2034/301;;A61B34/25;;A61G13/104;;A61G7/08;;A61G13/06;;A61G13/0018;;A61G13/104;;A61G2203/14;;A61G2203/20;;A61G2203/30;;A61G2203/70,A61G13/10;;A61G13/00,,0,0,,,,PENDING
216,US,A1,US 2007/0005634 A1,173-979-528-607-524,2007-01-04,2007,US 23126005 A,2005-09-20,US 23126005 A;;US 16985605 A,2005-06-29,Templates in a schema editor,"A schema editor allows for definition, distribution, and use of schema templates. The schema editor allows schema to be edited and then saved in such a way that the saved file can be reimported into the schema editor.",MICROSOFT CORP,SELCA VITORE;;BRYANT CHRISTOPHER W;;COVINGTON CLINTON D;;HOUGH DAN;;KROUT KELLY M;;GROFF SHANE L;;GETSCH TIMOTHY E,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2005-09-20),https://lens.org/173-979-528-607-524,Patent Application,yes,86,55,2,9,0,G06F16/211;;G06F16/252;;G06F16/211;;G06F16/252,G06F7/00,707/102,0,0,,,,INACTIVE
217,US,B2,US 7484180 B2,146-820-045-874-149,2009-01-27,2009,US 26868605 A,2005-11-07,US 26868605 A,2005-11-07,Getting started experience,"A one-screen entry point to a document management program (“program”) is provided to allow a user to browse templates associated with the program. The templates can be local templates and/or online templates provided by one or more Web services. The one-screen entry point allows a user to search, browse, or download online templates, and/or create documents using the templates. Each template is identified with a template category and displayed together with templates identified with the same template category. Local templates are presented along with online templates if the local templates and the online templates are identified with the same online template category. A user or an administrator of the program can create and/or customize local templates and local template categories. A blank template is provided so a user can create custom documents for the program.",MICROSOFT CORP,MCCORMACK MICHAEL J;;BRYANT CHRISTOPHER W;;FORDHAM GEORGE;;MCPHERSON JONATHAN A;;GARDNER SCOTT T;;COVINGTON CLINTON DEE;;HOUGH DANIEL,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2005-12-14),https://lens.org/146-820-045-874-149,Granted Patent,yes,11,30,2,2,0,G06F40/186;;G06F40/186,G06F3/00,715/764;;715/765;;715/738;;715/744;;715/825;;715/826,1,0,,,"Sue Dickinson, From Office XP to Office 2003, May 2005.",INACTIVE
218,US,B2,US 8135755 B2,139-880-673-294-402,2012-03-13,2012,US 23126005 A,2005-09-20,US 23126005 A;;US 16985605 A,2005-06-29,Templates in a schema editor,"A schema editor allows for definition, distribution, and use of schema templates. The schema editor allows schema to be edited and then saved in such a way that the saved file can be reimported into the schema editor.",SELCA VITORE;;BRYANT CHRISTOPHER W;;COVINGTON CLINTON D;;HOUGH DAN;;KROUT KELLY M;;GROFF SHANE L;;GETSCH TIMOTHY E;;MICROSOFT CORP,SELCA VITORE;;BRYANT CHRISTOPHER W;;COVINGTON CLINTON D;;HOUGH DAN;;KROUT KELLY M;;GROFF SHANE L;;GETSCH TIMOTHY E,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2005-09-20),https://lens.org/139-880-673-294-402,Granted Patent,yes,117,7,2,9,0,G06F16/211;;G06F16/252;;G06F16/211;;G06F16/252,G06F17/30,707/803,31,2,015-718-706-880-87X;;040-393-580-637-973,10.1109/dsn.2004.1311926;;10.1016/j.diin.2005.07.003,"Louis Davidson; ""Profesional SQLServer 2000 Database Design""; Wrox Press Ltd., 464 pgs.;;Anonymous, ""Method and Apparatus for Automatic Character Line Fill of Decimal Fields."" IBM Technical Disclosure Bulletin vol. 36, No. 10, pp. 155-156, Oct. 1993.;;Miastkowski, S. ""Excel 5.0-a Quick-start Guide to Using Excel's Powerful New Features."" Macworld vol. 11, No. 10, pp. 146-151,0ct. 1994.;;Microsoft Corp. Help File on 'Series' 'Repeated Entries', and 'Auto Fill' (screen shot) of Microsoft Excel 97 (1996), taken Mar. 2001, 6 pp.;;Crew, Ed, ed. ""Lesson in Excel 97: Lesson One . . . "", Web page tutorial on Excel 97 downloaded from pathways.uwe.ac.uk/Edict/Excel/Excel-01.asp on Mar. 29, 2002, 6 pp.;;Sonic.net. ""Microsoft Excel 5.0 (Tips on Using MS Excel 5.0 Repeat Entries)"" downloaded from www.sonic.net/aboutsbaumann/excel.html on Apr. 2, 2002, 5 pp.;;Microsoft Office 2000/Visual Basic Programmer's Guide, ""Creating Dynamic Reports with Query Tables in Excel"", http://msdn.microsoft.com/library/en-us/odeopg/html/deconcreatingdynamicreportswithq . . . , downloaded May 16, 2006, 2 pp.;;Khor, ""Microsoft Office Excel 2003 Preview"", Jun. 2003, http://msdn.microsoft.com/library/en-us/odc-x12003-ta/html/odc-xlov.asp?frame=true, downloaded May 16, 2006, 19 pp.;;U.S. Appl. No. 10/667,543, filed Sep. 22, 2003 entitled ""Extension of Formulas and Formatting in an Electronic Spreadsheet"".;;U.S. Appl. No. 10/782,074, filed Feb. 19, 2004 entitled ""Data Source Write back and Offline Data Editing and Storage in a Spreadsheet"".;;U.S. Application No. 11/169,856, filed Jun. 29, 2005 entitled ""Modifying Table Definitions Within a Database Application"".;;U.S. Appl. No. 11/317,648, filed Dec. 22, 2005 entitled ""Data Source Task Pane"".;;U.S. Appl. No. 11/300,728, filed Dec. 15, 2005 entitled ""Offline Multi-Table Data Editing and Storage System"".;;Official Action in U.S. Appl. No. 10/667,543 mailed Feb. 15, 2006. .;;Official Action in U.S. Appl. No. 10/667,543 mailed Aug. 2, 2006.;;U.S. Official Action in U.S. Appl. No. 11/300,728 mailed Jan. 9, 2008.;;U.S. Official Action in U.S. Appl. No. 11/343,957 mailed Jan. 15, 2008.;;U.S. Official Action in U.S. Appl. No. 11/317,648 mailed Apr. 17, 2008, 33 pgs.;;U.S. Official Action in U.S. Appl. No. 11/169,856 mailed Jul. 21, 2008, 7 pgs.;;EP Search Report in 07763001.0/2201/1984839 mailed May 29, 2009., pp. 1-7.;;EP Examination Report in 07763001.0/2201/1984839 mailed Aug. 7, 2009, pp. 1-4.;;Ganapathi, et al., ""Why PCs Are Fragile and What We Can Do About It: A Study of Windows Registry Problems"", Proceedings of the 2004 International Conference on Dependable Systems and Networks, 2004, 6 pp.;;Carvey, ""The Windows Registry as a Forensic Resource"", Digital Investigation, 2005, pp. 201-205.;;EP Summons to Attend Oral Hearing in 07763001.0-2201/1984839 mailed Oct. 29, 2009, pp. 1-9.;;EP Decision on Oral Hearing in 07763001.0-2201/1984839 mailed Mar. 3, 2010, pp. 1-29.;;Davidson, ""Professional SQL Server 2000 Database Design"", Wrox Press Ltd., 2001, 464 pp.;;""Mapping Windows XP Professional to Your Business Needs"", Microsoft: Windows XP Resource Kits, http://www.microsoft.com/resources/documentation/Windows/XP/all/reskit/en-us/Default.asp?url=/resources/documentation/Windows/XP/all/reskit/en-us/prba-dwp-tnvo.asp, printed Dec. 15, 2005, 8 pp.;;Strong, Craeg, ""Release Information"", http://www.zope.org/Members/arielpartners/CVSFile/readme/document-view, Apr. 2003, 6 pp.;;Onion, Fritz, ""Understanding Paths in ASP.NET"", Informit.com, http://www.informit.com/articles/article.asp?p=101145&redir=1, Sep. 2003, 4 pp.;;U.S. Official Action in U.S. Appl. No. 11/169,856 mailed Oct. 3, 2007.;;PCT International Search Report in PCT/US2007/002662 mailed Jul. 5, 2007.",INACTIVE
219,US,A1,US 2007/0106951 A1,003-484-933-569-702,2007-05-10,2007,US 26868605 A,2005-11-07,US 26868605 A,2005-11-07,Getting started experience,"A one-screen entry point to a document management program (“program”) is provided to allow a user to browse templates associated with the program. The templates can be local templates and/or online templates provided by one or more Web services. The one-screen entry point allows a user to search, browse, or download online templates, and/or create documents using the templates. Each template is identified with a template category and displayed together with templates identified with the same template category. Local templates are presented along with online templates if the local templates and the online templates are identified with the same online template category. A user or an administrator of the program can create and/or customize local templates and local template categories. A blank template is provided so a user can create custom documents for the program.",MICROSOFT CORP,MCCORMACK MICHAEL J;;BRYANT CHRISTOPHER W;;FORDHAM GEORGE R;;MCPHERSON JONATHAN A;;GARDNER SCOTT T;;COVINGTON CLINTON D;;HOUGH DANIEL,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2005-12-14),https://lens.org/003-484-933-569-702,Patent Application,yes,11,38,2,2,0,G06F40/186;;G06F40/186,G06F9/00,715/764;;715/810;;715/835,0,0,,,,INACTIVE
220,US,B2,US 10042597 B2,056-733-502-040-054,2018-08-07,2018,US 201514725628 A,2015-05-29,US 201514725628 A,2015-05-29,Redundant display system using emissive display,"Redundant display systems and methods for providing display redundancy are disclosed. A display system may include a primary display and at least one secondary display. The primary display and the at least one secondary display may be stacked in series relative to a line of sight of a user, and the at least one secondary display may be configured to serve as a backup to the primary display upon a failure of the primary display.",BARNIDGE TRACY J;;TCHON JOSEPH L;;COVINGTON BLAKE P;;MOSIER DONALD E;;JOHNSON NEIL C;;CHAPMAN CHRISTOPHER R;;APPEL MARIA A;;ROCKWELL COLLINS INC,BARNIDGE TRACY J;;TCHON JOSEPH L;;COVINGTON BLAKE P;;MOSIER DONALD E;;JOHNSON NEIL C;;CHAPMAN CHRISTOPHER R;;APPEL MARIA A,ROCKWELL COLLINS INC (2015-05-28),https://lens.org/056-733-502-040-054,Granted Patent,yes,12,0,4,4,0,B64D43/00;;B64D43/00;;G06F3/1423;;G06F3/1423;;G09F9/30;;G06F3/1438;;G06F3/1438;;G06F3/147;;G06F3/147;;G09G2300/023;;G09G2300/023;;G09G2330/08;;G09G2330/08;;G09G2380/12;;G09G2380/12,G09G5/00;;B64D43/00;;G06F3/14;;G06F3/147,,0,0,,,,ACTIVE
221,CN,A,CN 106205387 A,101-597-313-438-625,2016-12-07,2016,CN 201510564901 A,2015-09-07,US 201514725628 A,2015-05-29,Redundant display system using emissive display,"Redundant display systems and methods for providing display redundancy are disclosed. A display system may include a primary display and at least one secondary display. The primary display and the at least one secondary display may be stacked in series relative to a line of sight of a user, and the at least one secondary display may be configured to serve as a backup to the primary display upon a failure of the primary display.",ROCKWELL COLLINS INC,MARIA A APPEL;;DONALD E MOSIER;;JOSEPH L TCHON;;BLAKE P COVINGTON;;NEIL C JOHNSON;;TRACY J BARNIDGE;;CHRISTOPHER R CHAPMAN,,https://lens.org/101-597-313-438-625,Patent Application,no,7,2,4,4,0,B64D43/00;;B64D43/00;;G06F3/1423;;G06F3/1423;;G09F9/30;;G06F3/1438;;G06F3/1438;;G06F3/147;;G06F3/147;;G09G2300/023;;G09G2300/023;;G09G2330/08;;G09G2330/08;;G09G2380/12;;G09G2380/12,G09F9/30,,0,0,,,,INACTIVE
222,US,A1,US 2016/0350049 A1,142-545-498-453-866,2016-12-01,2016,US 201514725628 A,2015-05-29,US 201514725628 A,2015-05-29,Redundant Display System Using Emissive Display,"Redundant display systems and methods for providing display redundancy are disclosed. A display system may include a primary display and at least one secondary display. The primary display and the at least one secondary display may be stacked in series relative to a line of sight of a user, and the at least one secondary display may be configured to serve as a backup to the primary display upon a failure of the primary display.",BARNIDGE TRACY J;;TCHON JOSEPH L;;COVINGTON BLAKE P;;MOSIER DONALD E;;JOHNSON NEIL C;;CHAPMAN CHRISTOPHER R;;APPEL MARIA A;;ROCKWELL COLLINS INC,BARNIDGE TRACY J;;TCHON JOSEPH L;;COVINGTON BLAKE P;;MOSIER DONALD E;;JOHNSON NEIL C;;CHAPMAN CHRISTOPHER R;;APPEL MARIA A,ROCKWELL COLLINS INC (2015-05-28),https://lens.org/142-545-498-453-866,Patent Application,yes,9,20,4,4,0,B64D43/00;;B64D43/00;;G06F3/1423;;G06F3/1423;;G09F9/30;;G06F3/1438;;G06F3/1438;;G06F3/147;;G06F3/147;;G09G2300/023;;G09G2300/023;;G09G2330/08;;G09G2330/08;;G09G2380/12;;G09G2380/12,G06F3/14;;B64D43/00;;G09G5/00,,0,0,,,,ACTIVE
223,US,A1,US 2012/0268846 A1,179-292-382-683-491,2012-10-25,2012,US 201113093536 A,2011-04-25,US 201113093536 A,2011-04-25,Magnetic Element With Enhanced Coupling Portion,An apparatus and associated method may be used to produce a magnetic element capable of detecting changes in magnetic states. Various embodiments of the present invention are generally directed to a magnetically responsive lamination of layers with a first portion and a laterally adjacent second portion. The second portion having a predetermined roughness between at least two layers capable of producing orange-peel coupling.,GADBOIS JASON BRYCE;;KAUTZKY MICHAEL CHRISTOPHER;;COVINGTON MARK WILLIAM;;SONG DIAN;;DIMITROV DIMITAR VELIKOV;;HE QING;;TIAN WEI;;BOONSTRA THOMAS;;GANGOPADHYAY SUNITA;;SEAGATE TECHNOLOGY LLC,GADBOIS JASON BRYCE;;KAUTZKY MICHAEL CHRISTOPHER;;COVINGTON MARK WILLIAM;;SONG DIAN;;DIMITROV DIMITAR VELIKOV;;HE QING;;TIAN WEI;;BOONSTRA THOMAS;;GANGOPADHYAY SUNITA,SEAGATE TECHNOLOGY LLC (2011-04-12),https://lens.org/179-292-382-683-491,Patent Application,yes,16,13,2,2,0,G01R33/093;;G01R33/098;;G11B5/398;;H01F10/325;;H01F10/3254;;H01F41/303;;B82Y40/00;;G11B5/3912;;Y10T29/49021;;Y10T29/49034;;Y10T29/49021;;Y10T29/49034;;G11B5/398;;G01R33/093;;G01R33/098;;H01F10/3254;;H01F10/325;;H01F41/303;;B82Y40/00;;G11B5/3912,H04R31/00;;G11B5/39,360/319;;360/313;;29/603.01;;XG9B  5113,0,0,,,,ACTIVE
224,US,B2,US 8705212 B2,097-639-322-363-047,2014-04-22,2014,US 201113093536 A,2011-04-25,US 201113093536 A,2011-04-25,Magnetic element with enhanced coupling portion,An apparatus and associated method may be used to produce a magnetic element capable of detecting changes in magnetic states. Various embodiments of the present invention are generally directed to a magnetically responsive lamination of layers with a first portion and a laterally adjacent second portion. The second portion having a predetermined roughness between at least two layers capable of producing orange-peel coupling.,GADBOIS JASON BRYCE;;KAUTZKY MICHAEL CHRISTOPHER;;COVINGTON MARK WILLIAM;;SONG DIAN;;DIMITROV DIMITAR VELIKOV;;HE QING;;TIAN WEI;;BOONSTRA THOMAS;;GANGOPADHYAY SUNITA;;SEAGATE TECHNOLOGY LLC,GADBOIS JASON BRYCE;;KAUTZKY MICHAEL CHRISTOPHER;;COVINGTON MARK WILLIAM;;SONG DIAN;;DIMITROV DIMITAR VELIKOV;;HE QING;;TIAN WEI;;BOONSTRA THOMAS;;GANGOPADHYAY SUNITA,SEAGATE TECHNOLOGY LLC (2011-04-12),https://lens.org/097-639-322-363-047,Granted Patent,yes,26,1,2,2,0,G01R33/093;;G01R33/098;;G11B5/398;;H01F10/325;;H01F10/3254;;H01F41/303;;B82Y40/00;;G11B5/3912;;Y10T29/49021;;Y10T29/49034;;Y10T29/49021;;Y10T29/49034;;G11B5/398;;G01R33/093;;G01R33/098;;H01F10/3254;;H01F10/325;;H01F41/303;;B82Y40/00;;G11B5/3912,G11B5/33;;H01L29/82,360/313;;360/324.12;;29/603.08;;257/421,7,7,010-844-740-236-776;;095-977-116-133-258;;019-867-317-114-471;;160-695-126-112-012;;019-761-664-300-791;;086-540-395-193-318;;140-200-760-406-613,10.1063/1.2794420;;10.1063/1.2840188;;10.1063/1.2740351;;10.1016/j.mee.2008.05.019;;10.1109/ted.2002.802617;;10.1088/0953-8984/14/35/301;;10.1149/1.2952432,"Aram Amassian, Kate Kaminska, Motofumi Suzuki, Ludvik Martinu and Kevin Robbie, ""Onset of shadowing-dominated growth in glancing angle deposition,"" Applied Physics Letters 91, 2007, pp. 1-3, American Institute of Physics.;;J. Dufourcq, G. Gay, D. Lafond, P. Mur, G. Molas, J. P. Nieto, L. Vandroux, L. Jodin, F. Gustavo and TH. Baron, ""High density platinum nanocrystals for non-volatile memory applications,"" Applied Physics Letters 92, 2008, pp. 1-3, American Institute of Physics.;;Damon B. Farmer and Roy G. Gordon, ""High density Ru nanocrystal deposition for nonvolatile memory applications,"" Journal of Applied Physics 101, 2007, pp. 1-5, American Institute of Physics.;;Ralf Hofmann and Nety Krishna, ""Self-assembled metallic nanocrystal structures for advanced non-volatile memory applications,"" Microelectronic Engineering 85, 2008, pp. 1975-1978, Elsevier B. V.;;Zengtao Liu, Venkat Narayanan, Gen Pei and Edwin Chihchuan Kan, ""Metal Nanocrystal Memories-Part I: Device Design and Fabrication,"" IEEE Transactions on Electron Devices, Sep. 2002, vol. 49, No. 9, pp. 1606-1613, IEEE.;;U. Valbusa, C. Boragno and F. Buatier de Mongeot, ""Nanostructuring surfaces by ion sputtering,"" Journal of Physics Condensed Matter 14, 2002, pp. 8153-8175, IOP Publishing Ltd., UK.;;Sung-Soo Yim, Do-Joong Lee, Ki-Su Kim, Moon-Sang Lee, Soo-Hyun Kim and Ki-Bum Kim, ""Atomic Layer Deposition of Ru Nanocrystals with a Tunable Density and Size for Charge Storage Memory Device Application,"" Electrochemical and Solid-State Letters 11, 2008, pp. K89-K92, The Electrochemical Society.",ACTIVE
225,US,B2,US 7774755 B2,036-843-889-582-342,2010-08-10,2010,US 21802405 A,2005-08-31,US 21802405 A,2005-08-31,Quick-creating objects in an application,"A palette of representations that can be generated by an application for database, spreadsheet, word processing, and the like, is provided in response to a request for a new object within the application. If the application already has one or more objects open at the time of the request, the representations are also determined based on the context of the data such as from any currently open object(s). The new object is then generated based on the selected representation from the palette, the context of the data, and a structure of data consumed by the application. The layout parameters for the new object are automatically set based on the current context, the structure of the data, and the selected representation.",MICROSOFT CORP,WOODALL ZACHARY P;;HOUGH DAN;;SRINIVASAMURTHY KUMAR;;KUMAR NISHANT;;KARIMOV PAVEL R;;LESSER STEPHEN I;;COVINGTON CLINTON;;MCCORMACK MICHAEL J;;BRYANT CHRISTOPHER W,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2005-08-30),https://lens.org/036-843-889-582-342,Granted Patent,yes,5,3,4,4,0,G06F40/103;;G06F40/18;;G06F3/0481;;G06F3/0482;;G06F9/451;;G06F9/451;;G06F16/252;;G06F16/252;;G06F40/103;;G06F40/18,G06F9/44;;G06F7/00;;G06F17/00;;G06F17/50,717/121;;717/168;;707/102;;703/13,1,0,,,"Habraken, Joe, ""Microsoft Office 2003 All in One"", Nov. 2003, Que Publishing, 58 pages.",INACTIVE
226,US,A1,US 2006/0149768 A1,042-603-973-846-528,2006-07-06,2006,US 2730104 A,2004-12-30,US 2730104 A,2004-12-30,Database interaction,"Database interaction is facilitated by graphically presenting database objects in groups that are not necessarily dictated by object types of the database objects. In an example implementation, database navigation is facilitated by determining object dependency groups for a database in which each object dependency group corresponds to a database source object and includes at least those database objects that depend directly or indirectly from the corresponding database source object. When these data source object-based dependency groups are graphically displayed, selecting a database object thereof provides access thereto. In another example implementation, a user can designate an attribute associated with database objects by which the database objects are to be grouped. Thus, the database objects are grouped by various values that the user-designated associated attribute takes. These designated attribute-based value-driven groups may also be graphically displayed to enable navigation of and access to the different database objects assigned to them.",MICROSOFT CORP,MCCORMACK MICHAEL J;;BRYANT CHRISTOPHER W;;COGGINS ROBERT E;;GARDNER SCOTT T;;NARAMORE THERESA A;;HOUGH DANIEL;;KROUT KELLY M;;COVINGTON CLINTON D,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2005-03-17),https://lens.org/042-603-973-846-528,Patent Application,yes,41,15,2,2,0,G06F3/0482;;G06F16/242;;G06F16/248;;G06F16/954;;G06F3/0482;;G06F16/248;;G06F16/954;;G06F16/242,G06F17/00,707/101,0,0,,,,INACTIVE
227,US,B2,US 8832645 B2,105-384-610-685-741,2014-09-09,2014,US 64009609 A,2009-12-17,US 64009609 A;;US 21802405 A,2005-08-31,Quick-creating objects in an application,"A palette of representations that can be generated by an application for database, spreadsheet, word processing, and the like, is provided in response to a request for a new object within the application. If the application already has one or more objects open at the time of the request, the representations are also determined based on the context of the data such as from any currently open object(s). The new object is then generated based on the selected representation from the palette, the context of the data, and a structure of data consumed by the application. The layout parameters for the new object are automatically set based on the current context, the structure of the data, and the selected representation.",WOODALL ZACHARY P;;HOUGH DAN;;SRINIVASAMURTHY KUMAR;;KUMAR NISHANT;;KARIMOV PAVEL R;;LESSER STEPHEN I;;COVINGTON CLINTON;;MCCORMACK MICHAEL J;;BRYANT CHRISTOPHER W;;MICROSOFT CORP,WOODALL ZACHARY P;;HOUGH DAN;;SRINIVASAMURTHY KUMAR;;KUMAR NISHANT;;KARIMOV PAVEL R;;LESSER STEPHEN I;;COVINGTON CLINTON;;MCCORMACK MICHAEL J;;BRYANT CHRISTOPHER W,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14),https://lens.org/105-384-610-685-741,Granted Patent,yes,6,3,4,4,0,G06F40/103;;G06F40/18;;G06F3/0481;;G06F3/0482;;G06F9/451;;G06F9/451;;G06F16/252;;G06F16/252;;G06F40/103;;G06F40/18,G06F9/44;;G06F3/0481;;G06F3/0482;;G06F9/45;;G06F17/21;;G06F17/24;;G06F17/30,717/109;;703/13;;717/121;;717/168,1,0,,,"Habraken, Joe, ""Microsoft Office 2003 All in One""; ch. 10-11; Nov. 2003, Que Publishing, 17pg.",INACTIVE
228,US,B2,US 7730067 B2,185-204-850-030-665,2010-06-01,2010,US 2730104 A,2004-12-30,US 2730104 A,2004-12-30,Database interaction,"Database interaction is facilitated by graphically presenting database objects in groups that are not necessarily dictated by object types of the database objects. In an example implementation, database navigation is facilitated by determining object dependency groups for a database in which each object dependency group corresponds to a database source object and includes at least those database objects that depend directly or indirectly from the corresponding database source object. When these data source object-based dependency groups are graphically displayed, selecting a database object thereof provides access thereto. In another example implementation, a user can designate an attribute associated with database objects by which the database objects are to be grouped. Thus, the database objects are grouped by various values that the user-designated associated attribute takes. These designated attribute-based value-driven groups may also be graphically displayed to enable navigation of and access to the different database objects assigned to them.",MICROSOFT CORP,MCCORMACK MICHAEL J;;BRYANT CHRISTOPHER W;;COGGINS ROBERT E;;GARDNER SCOTT T;;NARAMORE THERESA A;;HOUGH DANIEL;;KROUT KELLY M;;COVINGTON CLINTON D,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2005-03-17),https://lens.org/185-204-850-030-665,Granted Patent,yes,40,8,2,2,0,G06F3/0482;;G06F16/242;;G06F16/248;;G06F16/954;;G06F3/0482;;G06F16/248;;G06F16/954;;G06F16/242,G06F17/30,707/737;;707/758;;707/802,0,0,,,,INACTIVE
229,US,A1,US 2007/0050752 A1,059-716-516-371-510,2007-03-01,2007,US 21802405 A,2005-08-31,US 21802405 A,2005-08-31,Quick-creating objects in an application,"A palette of representations that can be generated by an application for database, spreadsheet, word processing, and the like, is provided in response to a request for a new object within the application. If the application already has one or more objects open at the time of the request, the representations are also determined based on the context of the data such as from any currently open object(s). The new object is then generated based on the selected representation from the palette, the context of the data, and a structure of data consumed by the application. The layout parameters for the new object are automatically set based on the current context, the structure of the data, and the selected representation.",MICROSOFT CORP,WOODALL ZACHARY P;;HOUGH DAN;;SRINIVASAMURTHY KUMAR;;KUMAR NISHANT;;KARIMOV PAVEL R;;LESSER STEPHEN I;;COVINGTON CLINTON;;MCCORMACK MICHAEL J;;BRYANT CHRISTOPHER W,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2005-08-30),https://lens.org/059-716-516-371-510,Patent Application,yes,5,4,4,4,0,G06F40/103;;G06F40/18;;G06F3/0481;;G06F3/0482;;G06F9/451;;G06F9/451;;G06F16/252;;G06F16/252;;G06F40/103;;G06F40/18,G06F9/44,717/105,0,0,,,,INACTIVE
230,US,A1,US 2010/0094915 A1,134-705-431-069-085,2010-04-15,2010,US 64009609 A,2009-12-17,US 64009609 A;;US 21802405 A,2005-08-31,Quick-Creating Objects in an Application,"A palette of representations that can be generated by an application for database, spreadsheet, word processing, and the like, is provided in response to a request for a new object within the application. If the application already has one or more objects open at the time of the request, the representations are also determined based on the context of the data such as from any currently open object(s). The new object is then generated based on the selected representation from the palette, the context of the data, and a structure of data consumed by the application. The layout parameters for the new object are automatically set based on the current context, the structure of the data, and the selected representation.",MICROSOFT CORP,WOODALL ZACHARY P;;HOUGH DAN;;SRINIVASAMURTHY KUMAR;;KUMAR NISHANT;;KARIMOV PAVEL R;;LESSER STEPHEN I;;COVINGTON CLINTON;;MCCORMACK MICHAEL J;;BRYANT CHRISTOPHER W,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14),https://lens.org/134-705-431-069-085,Patent Application,yes,6,3,4,4,0,G06F40/103;;G06F40/18;;G06F3/0481;;G06F3/0482;;G06F9/451;;G06F9/451;;G06F16/252;;G06F16/252;;G06F40/103;;G06F40/18,G06F17/30;;G06F3/048,707/805;;X707E17009,1,0,,,"Habraken, Joe, ""Microsoft Office 2003 All in One""; ch. 10-11; Nov. 2003, Que Publishing, 17pg.",INACTIVE
231,CA,A,CA 1080851 A,192-392-821-926-096,1980-07-01,1980,CA 264637 A,1976-10-29,US 63838175 A,1975-12-08,PROGRAMMABLE CALCULATOR,SUBSTITUTE REMPLACEMENT SECTION is not Present Cette Section est Absente,HEWLETT PACKARD CO,CHRISTOPHER CHRIS J;;WENNINGER FRED W;;MORRIS DONALD E;;COVINGTON WAYNE F;;FOLSOM JERRY B;;BEYERS JOSEPH W;;NAIRN JOHN H;;OSBORNE JEFFREY C,,https://lens.org/192-392-821-926-096,Granted Patent,no,0,0,7,8,0,G06F15/02;;G06F15/02,G06F15/02,354-215,0,0,,,,EXPIRED
232,US,A,US 4437156 A,072-789-197-966-91X,1984-03-13,1984,US 22701981 A,1981-01-21,US 22701981 A;;US 3134179 A;;US 63838175 A,1975-12-08,Programmable calculator,"An adaptable programmable calculator employs modular read-write and read-only memories separately expandable to provide additional program and data storage functions within the calculator oriented toward the environment of the user, and an LSI NMOS central processing unit, which includes the capability of bidirectionally transferring information between itself and various input/output units. The input/output units include a keyboard input unit having a full complement of alphanumeric keys, a magnetic tape cassette reading and recording unit capable of bidirectionally transferring programs and data between the calculator and a magnetic tape, a 32-character solid state output display unit capable of displaying every alphabetic and numeric character. The calculator employs a natural algebraic program language that allows the user to enter lines of one or more alphanumeric algebraic statements into the calculator from the keyboard input unit while visually observing each line as it is entered to check for errors therein. The user may immediately execute each entered line or store that line as part of a program in the read-write memory, may subsequently recall the executed or stored line so that it may be reinspected, and, if necessary, edited and re-executed or re-stored, thereby automatically replacing the previously stored line. The program language of the calculator is contained within a plug-in language read-only memory and may be changed by inserting a different language read-only memory.",HEWLETT PACKARD CO,CHRISTOPHER CHRIS J;;WENNINGER FRED W;;MORRIS DONALD E;;COVINGTON WAYNE F;;FOLSOM JERRY B;;BEYERS JOSEPH W;;NAIRN JOHN H;;OSBORNE JEFFREY C,HEWLETT-PACKARD COMPANY (1998-05-20),https://lens.org/072-789-197-966-91X,Granted Patent,yes,4,16,1,8,0,G06F15/02;;G06F15/02,G06F15/02,364/200,0,0,,,,EXPIRED
233,US,A,US 4075679 A,168-568-428-637-657,1978-02-21,1978,US 63838175 A,1975-12-08,US 63838175 A,1975-12-08,PROGRAMMABLE CALCULATOR,"An adaptable programmable calculator employs modular read-write and read-only memories separately expandable to provide additional program and data storage functions within the calculator oriented toward the environment of the user, and an LSI NMOS central processing unit, capable of handling sixteen-bit parallel binary operations, binary-coded-decimal arithmetic, sixteen-bit parallel input/output operations, two-level interrupt from up to sixteen input/output devices, and a direct memory access channel. The input/output units include a keyboard input unit having a full complement of alphanumeric keys, a magnetic tape cassette reading and recording unit capable of bidirectionally transferring programs and data between the calculator and a magnetic tape, a 32-character solid state output display unit capable of displaying every alphabetic and numeric character and many other symbols individually or in combination, and a sixteen-column alphanumeric thermal printer for printing results of computations, program listings, messages generated by the user and the calculator itself, and error conditions encountered during use of the calculator. All of these input/output units are included within the calculator itself. Many other external input/output units may be employed with the calculator. The calculator may be operated manually by the user from the keyboard input unit or automatically through a program stored within the read-write memory to perform calculations and to provide an output indication of the results thereof. While a program stored within the read-write memory is being executed, the user can perform calculations manually from the keyboard. Execution of the program is temporarily suspended at convenient points within the program to allow execution of the calculations manually selected by the user. If desired, the user may be prevented from manually selecting calculations from the keyboard input unit by disabling the keyboard input unit during program execution. The calculator employs a natural algebraic program language that allows the user to enter lines of one or more alphanumeric algebraic statements into the calculator from the keyboard input unit while visually observing each line as it is entered to check for errors therein. The user may immediately execute each entered line or store that line as part of a program in the read-write memory, may subsequently recall the executed or stored line so that it may be reinspected, and, if necessary, edited and re-executed or re-stored, thereby automatically replacing the previously stored line. The program language of the calculator is contained within a plug-in language read-only memory and may be changed by inserting a different language read-only memory.",HEWLETT PACKARD CO,CHRISTOPHER CHRIS J;;WENNINGER FRED W;;MORRIS DONALD E;;COVINGTON WAYNE F;;FOLSOM JERRY B;;BEYERS JOSEPH W;;NAIRN JOHN H;;OSBORNE JEFFREY C,,https://lens.org/168-568-428-637-657,Granted Patent,yes,9,41,7,8,0,G06F15/02;;G06F15/02,G06F15/02,G4A AKB           KB,0,0,,,,EXPIRED
234,DE,A1,DE 2655241 A1,175-595-162-672-371,1977-06-30,1977,DE 2655241 A,1976-12-07,US 63838175 A,1975-12-08,PROGRAMMIERBARER RECHNER,,HEWLETT PACKARD CO,CHRISTOPHER CHRIS J;;WENNINGER FRED W;;MORRIS DONALD E;;COVINGTON WAYNE F;;FOLSOM JERRY B;;BEYERS JOSEPH W;;NAIRN JOHN H;;OSBORNE JEFFREY C,,https://lens.org/175-595-162-672-371,Patent Application,no,3,3,7,8,0,G06F15/02;;G06F15/02,G06F15/02,,0,0,,,,DISCONTINUED
235,US,A1,US 2021/0329058 A1,040-118-469-796-531,2021-10-21,2021,US 202016849574 A,2020-04-15,US 202016849574 A,2020-04-15,"SYSTEMS AND METHODS FOR ESTABLISHING, USING, AND RECOVERING UNIVERSAL DIGITAL IDENTIFIERS","Disclosed herein are systems and methods for establishing, using, and recovering universal digital identifiers. In an embodiment, a system establishes a universal identifier (ID) associated with a user and a device of the user. The universal ID is universal with respect to a plurality of distinct entities, has at least a suspended state and an unsuspended state, and initially is in the unsuspended state. The system transmits the universal ID to the device of the user. Thereafter, the system detects an ID-suspension event in connection with the universal ID, and responsively suspends the universal ID, including placing the universal ID in the suspended state. After suspending the universal ID, the system completes an ID-recovery process for the universal ID, and responsively unsuspends the universal ID, including placing the universal ID in the unsuspended state.",WELLS FARGO BANK NA,ADAMS CHAD E;;CARICATO DANIEL ROBERT;;COVINGTON KAHLIDAH B;;GODFREY ASHLEY BROOK;;HOWSER CHRISTOPHER WAYNE;;MAIORANA NICOLA A;;PATEL NIRALI J;;SCHROEDER RICHARD JOSEPH;;WHITE ROGER DARYLL,WELLS FARGO BANK N.A (2020-05-04),https://lens.org/040-118-469-796-531,Patent Application,yes,0,0,3,3,0,H04L63/08;;H04W12/06;;H04W12/72;;H04W4/80;;G06Q20/3821;;G06Q20/4014;;G06Q20/409;;G06Q20/405;;G06Q20/3674;;H04L2101/365;;H04L67/02;;H04L63/08;;H04L63/0428;;G06Q20/20;;H04W76/11;;H04W48/16;;H04W12/06,H04L29/08;;G06Q20/20;;H04L29/06;;H04W12/06;;H04W48/16;;H04W76/11,,0,0,,,,ACTIVE
236,US,B2,US 11848943 B2,135-552-762-944-499,2023-12-19,2023,US 202217811710 A,2022-07-11,US 202217811710 A;;US 202016868194 A,2020-05-06,Centralized threat intelligence,Systems and techniques for centralized threat intelligence are described herein. A connection may be established to a plurality of threat data sources. An anonymized set of threat data may be obtained by application of a set of privacy rules to the threat data from the plurality of threat data. A threat database may be populated with the anonymized set of threat data. A registration request may be received for a user of a device. A unique user identifier may be assigned for the user and a unique device identifier may be assigned for the device. A threat model may be generated based on a set of the characteristics from the threat database. A set of data access attributes may be received for a data access request. The data access request may be blocked based on an evaluation of the data access attributes using the threat model.,WELLS FARGO BANK NA,ADAMS CHAD E;;CARICATO DANIEL ROBERT;;COVINGTON KAHLIDAH B;;GODFREY ASHLEY BROOK;;HOWSER CHRISTOPHER WAYNE;;MAIORANA NICOLA A;;PATEL NIRALI J;;SCHROEDER RICHARD JOSEPH;;WHITE ROGER DARYLL,WELLS FARGO BANK N.A (2020-05-12),https://lens.org/135-552-762-944-499,Granted Patent,yes,18,0,5,5,0,G06F21/6254;;G06F21/604;;H04L63/1433;;H04L63/0245;;H04L63/0421;;H04L63/08;;H04L63/1416;;G06F21/44;;H04L63/0876,G06F21/44;;H04L9/40,,7,0,,,"“AlienVault Threat Intelligence”, [Online]. Retrieved from the Internet: <URL: https://www.alienvault.com/solutions/threat-intelligence>, (Accessed Mar. 23, 2021), 5 pgs.;;“U.S. Appl. No. 16/868,194, Non Final Office Action dated Nov. 17, 2021”, 10 pgs.;;“U.S. Appl. No. 16/868,194, Notice of Allowance dated Mar. 11, 2022”, 7 pgs.;;“U.S. Appl. No. 16/868,194, Response filed Feb. 17, 2022 to Non Final Office Action dated Nov. 17, 2021”, 12 pgs.;;“Consortium Networks Announces General Availability of Consortium Z Threat Intelligence Platform”, Consortium Networks, LLC, [Online]. Retrieved from the Internet: <URL: https://www.globenewswire.com/news-release/2019/03/26/1768410/0/en/Consortium-Networks-Announces-General-Availability-of-Consortium-Z-Threat-Intelligence-Platform.html>, (Mar. 26, 2019), 2 pgs.;;“Microsoft uses threat intelligence to protect, detect, and respond to threats”, Microsoft Corporation, (Sep. 2018), 11 pgs.;;Zrahia, Aviram, “Threat intelligence sharing between cybersecurity vendors: Network, dyadic, and agent views”, Journal of Cybersecurtiy, vol. 0, No. 0, [Online]. Retrieved from the Internet: <URL: https://academic.oup.com/cybersecurity/article/4/1/tyy008/5245383>, (Dec. 13, 2018), 1-16.",ACTIVE
237,US,B2,US 11388179 B2,017-966-323-088-725,2022-07-12,2022,US 202016868194 A,2020-05-06,US 202016868194 A,2020-05-06,Centralized threat intelligence,Systems and techniques for centralized threat intelligence are described herein. A connection may be established to a plurality of threat data sources. An anonymized set of threat data may be obtained by application of a set of privacy rules to the threat data from the plurality of threat data. A threat database may be populated with the anonymized set of threat data. A registration request may be received for a user of a device. A unique user identifier may be assigned for the user and a unique device identifier may be assigned for the device. A threat model may be generated based on a set of the characteristics from the threat database. A set of data access attributes may be received for a data access request. The data access request may be blocked based on an evaluation of the data access attributes using the threat model.,WELLS FARGO BANK NA,ADAMS CHAD E;;CARICATO DANIEL ROBERT;;COVINGTON KAHLIDAH B;;GODFREY ASHLEY BROOK;;HOWSER CHRISTOPHER WAYNE;;MAIORANA NICOLA A;;PATEL NIRALI J;;SCHROEDER RICHARD JOSEPH;;WHITE ROGER DARYLL,WELLS FARGO BANK N.A (2020-05-12),https://lens.org/017-966-323-088-725,Granted Patent,yes,15,1,5,5,0,G06F21/6254;;G06F21/604;;H04L63/1433;;H04L63/0245;;H04L63/0421;;H04L63/08;;H04L63/1416;;G06F21/44;;H04L63/0876,G06F21/44;;H04L9/40,,4,1,110-546-633-822-294,10.1093/cybsec/tyy008,"“AlienVault Threat Intelligence”, [Online]. Retrieved from the Internet: <URL: https://www.alienvault.com/solutions/threat-intelligence>, (Accessed Mar. 23, 2021), 5 pgs.;;“Consortium Networks Announces General Availability of Consortium Z Threat Intelligence Platform”, Consortium Networks, LLC, [Online], Retrieved from the Internet: <URL: https://www.globenewswire.com/news-release/2019/03/26/1768410/0/en/Consortium-Networks-Announces-General-Availability-of-Consortium-Z-Threat-Intelligence-Platform.html>, (Mar. 26, 2019), 2 pgs.;;“Microsoft uses threat intelligence to protect, detect, and respond to threats”, Microsoft Corporation, (Sep. 2018), 11 pgs.;;Zrahia, Aviram, “Threat intelligence sharing between cybersecurity vendors: Network, dyadic, and agent views”, Journal of Cybersecurtiy, vol. 0, No. 0, [Online], Retrieved from the Internet: <URL: https://academic.oup.eom/cybersecurity/article/4/1/tyy008/5245383>, (Dec. 13, 2018), 1-16.",ACTIVE
238,US,B2,US 11394766 B2,021-382-954-391-224,2022-07-19,2022,US 202016849574 A,2020-04-15,US 202016849574 A,2020-04-15,"Systems and methods for establishing, using, and recovering universal digital identifiers","Disclosed herein are systems and methods for establishing, using, and recovering universal digital identifiers. In an embodiment, a system establishes a universal identifier (ID) associated with a user and a device of the user. The universal ID is universal with respect to a plurality of distinct entities, has at least a suspended state and an unsuspended state, and initially is in the unsuspended state. The system transmits the universal ID to the device of the user. Thereafter, the system detects an ID-suspension event in connection with the universal ID, and responsively suspends the universal ID, including placing the universal ID in the suspended state. After suspending the universal ID, the system completes an ID-recovery process for the universal ID, and responsively unsuspends the universal ID, including placing the universal ID in the unsuspended state.",WELLS FARGO BANK NA,ADAMS CHAD E;;CARICATO DANIEL ROBERT;;COVINGTON KAHLIDAH B;;GODFREY ASHLEY BROOK;;HOWSER CHRISTOPHER WAYNE;;MAIORANA NICOLA A;;PATEL NIRALI J;;SCHROEDER RICHARD JOSEPH;;WHITE ROGER DARYLL,WELLS FARGO BANK N.A (2020-05-04),https://lens.org/021-382-954-391-224,Granted Patent,yes,27,0,3,3,0,H04L63/08;;H04W12/06;;H04W12/72;;H04W4/80;;G06Q20/3821;;G06Q20/4014;;G06Q20/409;;G06Q20/405;;G06Q20/3674;;H04L2101/365;;H04L67/02;;H04L63/08;;H04L63/0428;;G06Q20/20;;H04W76/11;;H04W48/16;;H04W12/06,H04L67/02;;G06Q20/20;;G06Q20/36;;G06Q20/40;;H04L9/40;;H04W12/06;;H04W12/72;;H04W48/16;;H04W76/11,,4,0,,,"“Combining Frictionless Risk-based Authentication with Comprehensive Strong Customer Authentication for an Enhanced Customer Experience”, ThreatMetrix, (2019), 2 pgs.;;“Empowering Smarter Authentication and Fraud Decisioning”, ThreatMetrix, (2017), 2 pgs.;;Kozak, Aron, “Biometrics and digital identity—Is that really you?”, Signacat, [Online]. Retrieved from the Internet: <URL: https://www.signicat.com/resources/biometrics-and-digital-identity-is-that-really-you>, (Mar. 13, 2019), 4 pgs.;;Muppidi, Sridhar, “Threat-aware Identity and Access Management”, IBM Security Systems, (2014), 27 pgs.",ACTIVE
239,US,A,US 4546448 A,017-391-134-107-451,1985-10-08,1985,US 42159182 A,1982-09-22,US 42159182 A;;US 20028180 A,1980-10-24,Programmable calculator including program variable initialization means and definition means array,"A programmable calculator utilizes an initialization key for setting all program variables, including array variables that are stored as part of a program in the calculator memory, to a predetermined initial value.",HEWLETT PACKARD CO,SPANGLER RICHARD M;;BURMEISTER EUGENE V;;CADA FRANK E;;CHRISTOPHER CHRIS J;;COVINGTON WAYNE F;;JUDD MYLES A;;WENNINGER FREDDIE W;;WATSON ROBERT E;;SIMCOE KENT W,HEWLETT-PACKARD COMPANY (1998-05-20),https://lens.org/017-391-134-107-451,Granted Patent,yes,11,0,1,33,0,G06F15/02;;G06F15/02,G06F15/02,364/900,0,0,,,,EXPIRED
240,DE,A1,DE 2365543 A1,053-974-080-266-691,1975-04-30,1975,DE 2365543 A,1973-07-04,US 26989972 A,1972-07-07,ELEKTRONISCHER RECHNER,,HEWLETT PACKARD CO,SPANGLER RICHARD M;;BURMEISTER EUGENE V;;CADA FRANK E;;COVINGTON WAYNE F;;CHRISTOPHER CHRIS J;;JUDD MYLES A;;WENNINGER FREDDIE W;;SIMCOE KENT W;;WATSON ROBERT E,,https://lens.org/053-974-080-266-691,Patent Application,no,0,0,27,33,0,G06F15/0233,G06F3/02;;G06F9/45;;G06F15/02,,0,0,,,,DISCONTINUED
241,US,A,US 4012725 A,099-719-048-333-840,1977-03-15,1977,US 46972774 A,1974-05-30,US 46972774 A;;US 26989972 A,1972-07-07,Programmable calculator,"An adaptable programmable calculator is provided by employing a modular read-write and read-only memory unit capable of being expanded to provide the calculator with additional program and data storage functions oriented towards the environment of the user, a central processing unit capable of performing both serial binary and parallel binary-coded-decimal arithmetic, and an input-output control unit capable of bidirectionally transferring information between the memory or central processing units and a number of input and output units. The memory, central processor, and input-output control units are controlled by a microprocessor included in the central processing unit. The input and output units include a keyboard input unit with a plurality of alphanumeric keys, a magnetic tape cassette reading and recording unit capable of bidirectionally transferring programs and data between a magnetic tape and the calculator and, a solid state output display unit capable of displaying every alphabetic and numeric character and many other symbols individually or in combination. All of these input and output units are included within the calculator itself. An output printer, an X-Y plotter, a typewriter, a teletypewriter, a magnetic or paper tape reading and recording unit, an extended read-write memory unit, a magnetic disc reading and recording unit, a modem for connecting the calculator via telephone lines to a remotely located computer, and many other peripheral input and output units may also be employed with the calculator. The calculator may be operated manually by the user from the keyboard input unit or automatically by a program stored within the memory unit to perform calculations and provide an output indication of the results thereof. It may also be employed to load programs into the memory unit from the keyboard input unit, to separately or collectively transfer data and programs bidirectionally between the memory unit and an external magnetic tape and to code programs or sections thereof stored in the memory unit as being secure when they are transferred to an external magnetic tape, thereby preventing users of the calculator from again transferring them to an external magnetic tape or obtaining any indication of the individual program steps once they are reloaded into the calculator. In addition, the calculator may be employed to edit programs stored in the memory unit and to print out program lists, labels, and messages. The calculator employs an extended version of BASIC computer language and allows the user to enter a line comprising an alphanumeric statement into the calculator from the keyboard input unit while visually observing an alphanumeric display of that line to check for errors therein, permitting the user to cause the entered lines to be immediately executed by the calculator or stored as part of a program within the memory unit, and permitting the user to subsequently recall the executed or stored line so that it may be reinspected, reevaluated, and, if necessary, edited and executed or re-executed, or restored in edited form. Any entered or recalled information may be edited by employing the keyboard input unit to selectively delete or replace incorrect or undesired portions of the information or to selectively insert corrected or previously omitted portions thereof on a line-by-line or character-by-character basis. Syntax errors are automatically detected by the calculator when the entered statement is terminated, and execution errors are automatically detected upon attempted execution of the statement or statements. Both types of errors are indicated to the user via error messages displayed by the output display unit. In the event the calculator is being used in combination with an external printer, unit indications of syntax or execution errors may, if desired, be printed. The calculator employs a compiler for converting each statement entered into the calculator in BASIC language into an internal stored format. It also employs an uncompiler for generating in the BASIC language statement any entered line converted to the internal stored format. The compiler and uncompiler operate on a line-by-line basis. The magnetic tape cassette reading and recording unit employed in the calculator allows the user to chain together several program segments and allows program manipulation of several blocks of data on an individual basis, thereby providing more efficient utilization of the available calculator memory. An interrupt feature of the cassette unit facilitates searching for a particular file located on a magnetic tape at the same time the calculator is performing other functions.",HEWLETT PACKARD CO,SPANGLER RICHARD M;;BURMEISTER EUGENE V;;CADA FRANK E;;COVINGTON WAYNE F;;CHRISTOPHER CHRIS J;;JUDD MYLES A;;WENNINGER FREDDIE W;;WATSON ROBERT E;;SIMCOE KENT W,,https://lens.org/099-719-048-333-840,Granted Patent,yes,13,33,1,33,0,G06F15/02;;G06F15/0233;;G06F15/0233;;G06F15/02,G06F15/02,G4A AKB           -,0,0,,,,EXPIRED
242,CA,A,CA 1099020 A,117-415-283-089-356,1981-04-07,1981,CA 316026 A,1978-11-09,CA 316026 A;;CA 174483 A;;US 26989972 A,1972-07-07,PROGRAMMABLE CALCULATOR,"An adaptable programmable calculator is provided by employing a modular read-write and read-only memory unit, a central processing unit, and an input-output control unit capable of bidirectionally transferring information between the memory or central processing units and a number of input and output units. These input and output units include an alphanumeric keyboard input unit, a magnetic tape cassette reading and recording unit, an alphanumeric solid state output display unit, an output printer, an X-Y plotter, a magnetic or paper tape reading and recording unit, a magnetic disc reading and recording unit, and a modem for connecting the calculator via telephone lines to a remotely located computer. The calculator employs an extended version of BASIC computer language and allows the user to enter a line comprising one or more alphanumeric statements into the calculator from the keyboard input unit while visually observing an alphanumeric display of the line to check for errors therein. Syntax errors are automatically detected by the calculator when an entered statement is terminated, and execution errors are automatically detected upon attempted execution of a statement or statements. Both types of errors are indicated to the user via error messages displayed by the output display unit. The calculator employs a compiler for converting each statement entered into the calculator in BASIC language into an internal stored format. It also employs an uncompiler for regenerating in BASIC language any entered line converted to the internal stored format. The magnetic tape cassette reading and recording unit employed in the calculator allows the user to chain together several program segments and allows program manipulation of several blocks of data on an individual basis. An interrupt feature of the cassette unit facilitates searching for a particular file located on a magnetic tape at the same time the calculator is performing other functions.",HEWLETT PACKARD CO,SPANGLER RICHARD M;;BURMEISTER EUGENE V;;CADA FRANK E;;COVINGTON WAYNE F;;CHRISTOPHER CHRIS J;;JUDD MYLES A;;WENNINGER FREDDIE W;;SIMCOE KENT W;;WATSON ROBERT E,,https://lens.org/117-415-283-089-356,Granted Patent,no,0,1,1,33,0,,G06F3/14;;G06F7/38;;G06F15/02,354-215,0,0,,,,EXPIRED
243,US,A,US 4322816 A,004-002-941-951-321,1982-03-30,1982,US 15867580 A,1980-06-12,US 15867580 A;;US 26989972 A;;US 46972774 A,1972-07-07,Programmable calculator having structure for controlling an x-y plotter,"An adaptable programmable calculator is provided by employing a modular read-write and read-only memory unit capable of being expanded to provide the calculator with additional program and data storage functions oriented towards the environment of the user, a central processing unit capable of performing both serial binary and parallel binary-coded-decimal arithmetic, and an input-output control unit capable of bidirectionally transferring information between the memory or central processing units and a number of input and output units. The memory, central processor, and input-output control units are controlled by a microprocessor included in the central processing unit. The input and output units include a keyboard input unit with a plurality of alphanumeric keys, a magnetic tape cassette reading and recording unit capable of bidirectionally transferring programs and data between a magnetic tape and the calculator, and a solid state output display unit capable of displaying every alphabetic and numeric character and many other symbols individually or in combination. All of these input and output units are included within the calculator itself. An output printer, an X-Y plotter, a typewriter, a teletypewriter, a magnetic or paper tape reading and recording unit, an extended read-write memory unit, a magnetic disc reading and recording unit, a modem for connecting the calculator via telephone lines to a remotely located computer, and many other peripheral input and output units may also be employed with the calculator. The calculator may be operated manually by the user from the keyboard input unit or automatically by a program stored within the memory unit to perform calculations and provide an output indication of the results thereof. It may also be employed to load programs into the memory unit from the keyboard input unit, to separately or collectively transfer data and programs bidirectionally between the memory unit and an external magnetic tape and to code programs or sections thereof stored in the memory unit as being secure when they are transferred to an external magnetic tape, whereby preventing users of the calculator from again transferring them to an external magnetic tape or obtaining any indication of the individual program steps once they are reloaded into the calculator. In addition, the calculator may be employed to edit programs stored in the memory unit and to print out program lists, labels, and messages. The calculator employs an extended version of BASIC computer language and allows the user to enter a line comprising an alphanumeric statement into the calculator from the keyboard input unit while visually observing an alphanumeric display of that line to check for errors therein, permitting the user to cause the entered lines to be immediately executed by the calculator or stored as part of a program within the memory unit, and permitting the user to subsequently recall the executed or stored line so that it may be reinspected, reevaluated, and, if necessary edited and executed or re-executed, or restored in edited form. Any entered or recalled information may be edited by employing the keyboard input unit to selectively delete or replace incorrect or undesired portions of the information or to selectively insert corrected or previously omitted portions thereof on a line-by-line or character-by-character basis. Syntax errors are automatically detected by the calculator when the entered statement is terminated, and execution errors are automatically detected upon attempted execution of the statement or statements. Both types of errors are indicated to the user via error messages displayed by the output display unit. In the event the calculator is being used in combination with an external printer unit indications of syntax or execution errors may, if desired, be printed. The calculator employs a compiler for converting each statement entered into the calculator in BASIC language into an internal stored format. It also employs an uncompiler for regenerating in the BASIC language statement any entered line converted to the internal stored format. The compiler and uncompiler operate on a line-by-line basis. The magnetic tape cassette reading and recording unit employed in the calculator allows the user to chain together several program segments and allows program manipulation of several blocks of data on an individual basis, thereby providing more efficient utilization of the available calculator memory. An interrupt feature of the cassette unit facilitates searching for a particular file located on a magnetic tape at the same time the calculator is performing other functions.",HEWLETT PACKARD CO,SPANGLER RICHARD M;;BURMEISTER EUGENE V;;CADA FRANK E;;COVINGTON WAYNE F;;CHRISTOPHER CHRIS J;;JUDD MYLES A;;WENNINGER FREDDIE W;;WATSON ROBERT E;;SIMCOE KENT W,,https://lens.org/004-002-941-951-321,Granted Patent,yes,20,8,1,33,0,G06F3/147;;G06F15/0233;;G06F15/0233;;G06F3/147,G06F3/147;;G06F15/02,G4A AU            U;;G4A AUX           UX;;G4A AUXX          UXX,10,5,002-863-283-222-777;;037-330-264-447-549;;102-999-677-125-257;;020-166-022-739-531;;102-772-209-696-319,10.1093/comjnl/10.3.278;;10.1145/366349.366436;;10.1145/365170.365200;;10.1147/sj.41.0025;;10.1093/comjnl/10.3.282,"""A Program for the Construction of Pert Flow Charts"", Howden, The Computer Journal, vol. 10, Issue 3, Nov. 1967, pp. 278-281, Doc #L7140-1513.;;""Algorithm 162, Xymove Plotting"", Stockton, Collected Algorithms from Cacm, p. 162-P1, Doc #L7140-1735.;;""Algorithm 278, Graph Plotter"", Lloyd, Collected Algorithms from Cacm, 278-P1, Doc #L7140-1851.;;""Algorithm for Computer Control of a Digital Plotter"", Bresenham, IBM Systems Journal, vol. 4, No. 1, 1965, pp. 25-30, Doc. #L7140-1611.;;A Machine-Aided Drafting System"", Lerman, Datamation, vol. 13, Issue 1, Jan. 1967, pp. 49-54, Doc. #L7140-1075.;;""A Mathematical Method for the Automatic Scaling of a Function"", Giammo, Journal of the Association for Computing Machinery, vol. 11, Issue 1, Jan. 64, pp. 79-83, Doc. #L7140-0399.;;""Algorithm for Drawing Ellipses for Hyperbolae with a Digital Plotter"", Pitteway, The Computer Journal, vol. 10, Issue 3, Nov. 67, pp. 282-289, Doc. #L7140-1514.;;""Note on the Computer as an Aid to the Architect"", Fair et al., The Computer Journal, vol. 9, Issue 1, May 66, pp. 16-20, Doc. #L7140-1383.;;""Automated Plotting of Flow-Charts on a Small Computer"", Anderson, Communications of the ACM, vol. 8, Issue 1, Jan. 65, pp. 38-39, Doc. #L7140-0671.;;""The Choice of Origin and Scale for Graphs"", Dixon et al., Journal of ACM, vol. 12, Issue 2, Apr. 65, pp. 259-261, Doc. #L7140-0450.",EXPIRED
244,CH,A5,CH 597649 A5,103-407-428-688-002,1978-04-14,1978,CH 977473 A,1973-07-05,US 26989972 A,1972-07-07,CH 597649 A5,,HEWLETT PACKARD CO,SPANGLER RICHARD M;;BURMEISTER EUGENE V;;CADA FRANK E;;COVINGTON EAYNE F;;CHRISTOPHER CHRIS J;;JUDD MYLES A;;WENNINGER FREDDIE W;;SIMCOE KENT W;;WATSON ROBERT E,,https://lens.org/103-407-428-688-002,Granted Patent,no,0,0,27,33,0,G06F15/0233,G06F3/02;;G06F9/45;;G06F15/02,,0,0,,,,EXPIRED
245,CA,A,CA 1046644 A,156-369-200-957-016,1979-01-16,1979,CA 174483 A,1973-06-19,US 26989972 A,1972-07-07,PROGRAMMABLE CALCULATOR,"Procédé perfectionné de soudage de deux pièces, formées d'un même matériau, par faisceau d'électrons, dans lequel on introduit un matériau d'insertion dans une région soumise à une refusion lors d'une opération de soudage des deux pièces par faisceau d'électrons. Ce matériau d'insertion est obtenu en appliquant à un acier doux ou faiblement allié un procédé de soudage à l'arc ou de refusion sous laitier afin que le matériau d'insertion contienne de 100 à 800 p.p.m. d'oxygène, de sorte que la microstructure de la soudure ainsi réalisée est améliorée. Un dispositif de mise en oeuvre du procédé décrit ci-haut pour un soudage bout à bout de deux pièces cylindriques par faisceau d'électrons où le matériau d'insertion a la forme d'un fil, comprend une enceinte étanche en forme générale de tore dans laquelle règne un vide poussé, cette enceinte recevant au moins un canon à électrons et délimitant un espace radialement interne dans lequel sont placées les pièces cylindriques à souder, et une gaine recevant intérieurement le fil constituant le matériau d'insertion. La gaine s'étend à l'intérieur de l'enceinte depuis un premier joint d'étanchéité lié à la gaine et disposé sur une paroi externe de l'enceinte pour former une entrée du fil, jusqu'à un deuxième joint d'étanchéité lié à la gaine et disposé sur une paroi radialement interne de l'enceinte pour former une sortie du fil.",HEWLETT PACKARD CO,SPANGLER RICHARD M;;BURMEISTER EUGENE V;;CADA FRANK E;;COVINGTON WAYNE F;;CHRISTOPHER CHRIS J;;JUDD MYLES A;;WENNINGER FREDDIE W;;SIMCOE KENT W;;WATSON ROBERT E,,https://lens.org/156-369-200-957-016,Granted Patent,no,0,0,27,33,0,G06F15/0233,G06F3/02;;G06F9/45;;G06F15/02,354-215,0,0,,,,EXPIRED
246,US,B1,US 11914719 B1,018-351-881-073-953,2024-02-27,2024,US 202016849589 A,2020-04-15,US 202016849589 A,2020-04-15,Systems and methods for cyberthreat-risk education and awareness,"A system determines a baseline cyberthreat-risk score for a user, and displays the baseline cyberthreat-risk score via a user interface. The system presents at least one cyberthreat-education activity via the user interface, and receives, via the user interface, at least one user input associated with the presented at least one cyberthreat-education activity. The system generates an updated cyberthreat-risk score at least in part by updating the baseline cyberthreat-risk score based at least in part on the user input, and displays the updated cyberthreat-risk score via the user interface.",WELLS FARGO BANK NA,ADAMS CHAD E;;CARICATO DANIEL ROBERT;;COVINGTON KAHLIDAH B;;GODFREY ASHLEY BROOK;;HOWSER CHRISTOPHER WAYNE;;MAIORANA NICOLA A;;PATEL NIRALI J;;SCHROEDER RICHARD JOSEPH;;WHITE ROGER DARYLL,WELLS FARGO BANK N.A (2020-05-04),https://lens.org/018-351-881-073-953,Granted Patent,yes,81,0,1,1,0,G06F21/577;;G06Q50/265;;G06Q10/107;;G06F16/9535;;H04L67/306;;G09B7/00;;H04L63/1483;;G06F2221/034;;G06F3/0482;;G09B19/0053,G06F21/57;;G06F3/0482;;G06F16/9535;;G06Q10/107;;G06Q50/26;;G09B7/00;;G09B19/00;;H04L9/40;;H04L67/306,,8,0,,,"Phising Tackle Limited, Running a Baseline Phising Test, Published Aug. 2022 via Phising Tackle Limited, pp. 1-6 (pdf).;;Sophos, Sophos Phish Threat, Published Jul. 11, 2022 by Sophos, pp. 1-2 (pdf).;;NIST, The Phish Scale: NIST-Developed Method Helps IT Staff See Why Users Click on Fraudulent Emails, Published Sep. 17, 2020 by National Institute of Standards and Technology, pp. 1-4 (pdf).;;Caitlin Jones, The Top 11 Phising Awarness Training Solutions, Published Mar. 14, 2023 via Expert Insights, pp. 1-17 (pdf).;;KnowBe4, Recommendations for the Most Effective Baseline Phising Test, Published 2018 via wayback archive, pp. 1-2 (pdf).;;“Enterprise Threat Simulation”, AIS Network, [Online]. Retrieved from the Internet: <URL: https://www.aisn.net/enterprise-threat-simulation/>, (2019), 9 pgs.;;“Risk Mitigation Planning, Implementation, and Progress Monitoring”, The MITRE Corporation, [Online]. Retrieved from the Internet: <URL: https://www.mitre.org/publications/systems-engineering-guide/acquisition-systems-engineering/risk-management/risk-mitigation-planning-implementation-and-progress- monitoring>, (Accessed Sep. 19, 2019), 7 pgs.;;Legg, Philip, “Visualizing the Insider Threat: Challenges and tools for identifying malicious user activity”, IEEE Symposium on Visualization for Cyber Security (VIZSEC), [Online]. Retrieved from the Internet: <URL: http://eprints.uwe.ac.uk/27441/1/2015-VizSec_preprint.pdf>, (2015), 7 pgs.",ACTIVE
247,DE,A1,DE 2333908 A1,025-104-929-245-183,1974-01-24,1974,DE 2333908 A,1973-07-04,US 26989972 A,1972-07-07,PROGRAMMIERBARER RECHNER,,HEWLETT PACKARD CO,SPANGLER RICHARD M;;BURGMEISTER EUGENE V;;CADA FRANK E;;COVINGTON WAYNE F;;CHRISTOPHER CHRIS J;;JUDD MYLES A;;WENNINGER FREDDIE W;;SIMCOE KENT W;;WATSON ROBERT E,,https://lens.org/025-104-929-245-183,Patent Application,no,0,0,27,33,0,G06F15/0233,G06F3/02;;G06F9/45;;G06F15/02,,0,0,,,,DISCONTINUED
248,DE,A1,DE 2365568 A1,027-259-883-017-722,1975-07-17,1975,DE 2365568 A,1973-07-04,US 26989972 A,1972-07-07,ELEKTRONISCHER RECHNER,,HEWLETT PACKARD CO,SPANGLER RICHARD M;;BURMEISTER EUGENE V;;CADA FRANK E;;COVINGTON WAYNE F;;CHRISTOPHER CHRIS J;;JUDD MYLES A;;WENNINGER FREDDIE W;;SIMCOE KENT W;;WATSON ROBERT E,,https://lens.org/027-259-883-017-722,Patent Application,no,0,0,27,33,0,G06F15/0233,G06F3/02;;G06F9/45;;G06F15/02,,0,0,,,,DISCONTINUED
249,DE,A1,DE 2365570 A1,015-784-414-999-209,1975-05-22,1975,DE 2365570 A,1973-07-04,US 26989972 A,1972-07-07,ELEKTRONISCHER RECHNER,,HEWLETT PACKARD CO,SPANGLER RICHARD M;;BURMEISTER EUGENE V;;CADA FRANK E;;COVINGTON WAYNE F;;CHRISTOPHER CHRIS J;;JUDD MYLES A;;WENNINGER FREDDIE W;;SIMCOE KENT W;;WATSON ROBERT E,,https://lens.org/015-784-414-999-209,Patent Application,no,0,0,27,33,0,G06F15/0233,G06F3/02;;G06F9/45;;G06F15/02,,0,0,,,,PENDING
250,US,A,US 4366553 A,095-139-348-480-344,1982-12-28,1982,US 20028180 A,1980-10-24,US 20028180 A;;US 26989972 A,1972-07-07,Electronic computing apparatus employing basic language,"An adaptable programmable calculator is provided by employing a modular read-write and read-only memory unit capable of being expanded to provide the calculator with additional program and data storage functions oriented towards the environment of the user, a central processing unit capable of performing both serial binary and parallel binary-coded-decimal arithmetic, and an input-output control unit capable of bidirectionally transferring information between the memory or central processing units and a number of input and output units. The memory, central processor, and input-output control units are controlled by a microprocessor included in the central processing unit. Also the calculator may be operated manually by the user from an alphanumeric keyboard input unit or automatically by a program stored within the memory unit to perform calculations and provide an output indication of the results thereof. It may also be employed to load programs into the memory unit from the keyboard input unit. Also, the computer language allows the user to enter a line comprising an alphanumeric statement into the calculator from the keyboard input unit while visually observing an alphanumeric display of that line to check for errors therein, permitting the user to cause the entered lines to be immediately executed by the calculator or stored as part of a program within the memory unit, and permitting the user to subsequently recall the executed or stored line so that it may be reinspected, reevaluated, and, if necessary, edited and executed or re-executed, or restored in edited form. The calculator employs a compiler for converting each statement entered into the calculator in BASIC language into an internal stored format. It also employs an uncompiler for regenerating in the BASIC language statement any entered line converted to the internal stored format. The compiler and uncompiler operate on a line-by-line basis.",HEWLETT PACKARD CO,SPANGLER RICHARD M;;BURMEISTER EUGENE V;;CADA FRANK E;;COVINGTON WAYNE F;;CHRISTOPHER CHRIS J;;JUDD MYLES A;;WENNINGER FREDDIE W;;WATSON ROBERT E;;SIMCOE KENT W,,https://lens.org/095-139-348-480-344,Granted Patent,yes,10,7,1,33,0,G06F15/0233;;G06F15/0233;;G06F15/02;;G06F15/02,G06F15/02,364/900,6,0,,,"""Programming Languages: History and Fundamentals"", Sammet, 1969, pp. 215-217, 229-232, 755, 305.;;""Computer Programming Fundamentals"", Leeds & Weinberg, 1970, pp. 166-170, 490-537, 584.;;""PDP10 Timesharing Handbook"", Digital Equipment Corp., 1970, pp. I to III, 1-1 to 1-14, 2-1 to 2-20, 3-1 to 3-78, back cover.;;A Manual for BASIC, Kemeny et al., Jun. 1965, Trustees of Dartmouth College, printed by G. E., pp. 1,3-14.;;""Introduction to Programming"", vol. I, PDP-8 Handbook, Digital Equipment Corp., 1969, pp. I to VIII, 1-31 to 1-33, 2-4 to 2-8, 6-1 to 6-43, 9-2 to 9-5, 9-23 to 9-24, 9-45 to 9-71, 10-1 to 10-15.;;""Introduction to Programming"", vol. II, PDP-8 Handbook, Digital Equipment Corp., 1970, pp. I to XIV, 12-1 to 12-67.",EXPIRED
251,US,A,US 4127897 A,120-140-108-755-700,1978-11-28,1978,US 76080177 A,1977-01-19,US 46972774 A,1974-05-30,Programmable calculator having extended input/output capability,"An adaptable programmable calculator is provided by employing a modular read-write and read-only memory unit capable of being expanded to provide the calculator with additional program and data storage functions oriented towards the environment of the user, a central processing unit capable of performing both serial binary and parallel binary-coded-decimal arithmetic, and an input-output control unit capable of bidirectionally transferring information between the memory or central processing units and a number of input and output units. The memory, central processor, and input-output control units are controlled by a microprocessor included in the central processing unit. The input and output units include a keyboard input unit with a plurality of alphanumeric keys, a magnetic tape cassette reading and recording unit capable of bidirectionally transferring programs and data between a magnetic tape and the calculator, and a solid state output display unit capable of displaying every alphabetic and numeric character and many other symbols individually or in combination. All of these input and output units are included within the calculator itself. An output printer, and X-Y plotter, a typewriter, a teletypewriter, a magnetic or paper tape reading and recording unit, an extended read-write memory unit, a magnetic disc reading and recording unit, a modem for connecting the calculator via telephone lines to a remotely located computer, and many other peripheral input and output units may also be employed with the calculator. The calculator may be operated manually by the user from the keyboard input unit or automatically by a program stored within the memory unit to perform calculations and provide an output indication of the results thereof. It may also be employed to load programs into the memory unit from the keyboard input unit, to separately or collectively transfer data and programs bidirectionally between the memory unit and an external magnetic tape and to code programs or sections thereof stored in the memory unit as being secure when they are transferred to an external magnetic tape, thereby preventing users of the calculator from again transferring them to an external magnetic tape or obtaining any indication of the individual program steps once they are reloaded into the calculator. In addition, the calculator may be employed to edit programs stored in the memory unit and to print out program lists, labels, and messages. The calculator employs an extended version of BASIC computer language and allows the user to enter a line comprising an alphanumeric statement into the calculator from the keyboard input unit while visually observing an alphanumeric display of that line to check for errors therein, permitting the user to cause the entered lines to be immediately executed by the calculator or stored as part of a program within the memory unit, and permitting the user to subsequently recall the executed or stored line so that it may be reinspected, reevaluated, and, if necessary, edited and executed or re-executed, or restored in edited form. Any entered or recalled information may be edited by employing the keyboard input unit to selectively delete or replace incorrect or undesired portions of the information or to selectively insert corrected or previously omitted portions thereof on a line-by-line or character-by-character basis. Syntax errors are automatically detected by the calculator when the entered statement is terminated, and execution errors are automatically detected upon attempted execution of the statement or statements. Both types of errors are indicated to the user via error messages displayed by the output display unit. In the event the calculator is being used in combination with an external printer unit indications of syntax or execution errors may, if desired, be printed. The calculator employs a compiler for converting each statement entered into the calculator in BASIC language into an internal stored format. It also employs an uncompiler for regenerating in the BASIC language statement any entered line converted to the internal stored format. The compiler and uncompiler operate on a line-by-line basis. The magnetic tape cassette reading and recording unit employed in the calculator allows the user to chain together several program segments and allows program manipulation of several blocks of data on an individual basis, thereby providing more efficient utilization of the available calculator memory. An interrupt feature of the cassette unit facilitates searching for a particular file located on a magnetic tape at the same time the calculator is performing other functions.",HEWLETT PACKARD CO,SPANGLER RICHARD M;;BURMEISTER EUGENE V;;CADA FRANK E;;COVINGTON WAYNE F;;CHRISTOPHER CHRIS J;;JUDD MYLES A;;WENNINGER FREDDIE W;;WATSON ROBERT E;;SIMCOE KENT W,,https://lens.org/120-140-108-755-700,Granted Patent,yes,13,4,1,33,0,G06F15/0233;;G06F15/0233,G06F15/02,364/900,4,0,,,"""Computer Dictionary and Handbook"", Sippl & Sippl, Howard W. Sams & Co., 1966, pp. 665-674.;;""IBM Data Processing Glossary"", IBM, Aug. 1971, p. 9.;;""PDP 11 Peripherals and Interfacing Handbook"", Digital Equipment Corp., 1971, pp. 1-11, 109-115, 122-131.;;""Introduction to Data Communication"", Murphy & Kallis, Digital Equipment Corp., 1971, pp. 44-52, 77.",EXPIRED
252,DE,A1,DE 2365542 A1,099-043-033-088-507,1975-05-22,1975,DE 2365542 A,1973-07-04,US 26989972 A,1972-07-07,ELEKTRONISCHER RECHNER,,HEWLETT PACKARD CO,SPANGLER RICHARD M;;BURMEISTER EUGENE V;;CADA FRANK E;;COVINGTON WAYNE F;;CHRISTOPHER CHRIS J;;JUDD MYLES A;;WENNINGER FREDDIE W;;SIMCOE KENT W;;WATSON ROBERT E,,https://lens.org/099-043-033-088-507,Patent Application,no,0,0,27,33,0,G06F15/0233,G06F3/02;;G06F9/45;;G06F15/02,,0,0,,,,DISCONTINUED
253,DE,A1,DE 2365569 A1,103-122-369-370-66X,1975-06-12,1975,DE 2365569 A,1973-07-04,US 26989972 A,1972-07-07,ELEKTRONISCHER RECHNER,,HEWLETT PACKARD CO,SPANGLER RICHARD M;;BURMEISTER EUGENE V;;CADA FRANK E;;COVINGTON WAYNE F;;CHRISTOPHER CHRIS J;;JUDD MYLES A;;WENNINGER FREDDIE W;;SIMCOE KENT W;;WATSON ROBERT E,,https://lens.org/103-122-369-370-66X,Patent Application,no,0,2,27,33,0,G06F15/0233,G06F3/02;;G06F9/45;;G06F15/02,,0,0,,,,DISCONTINUED
254,DE,A1,DE 2365567 A1,179-192-834-065-11X,1975-06-12,1975,DE 2365567 A,1973-07-04,US 26989972 A,1972-07-07,ELEKTRONISCHER RECHNER,,HEWLETT PACKARD CO,SPANGLER RICHARD M;;BURMEISTER EUGENE V;;CADA FRANK E;;COVINGTON WAYNE F;;CHRISTOPHER CHRIS J;;JUDD MYLES A;;WENNINGER FREDDIE W;;SIMCOE KENT W;;WATSON ROBERT E,,https://lens.org/179-192-834-065-11X,Patent Application,no,0,0,27,33,0,G06F15/0233,G06F3/02;;G06F9/45;;G06F15/02,,0,0,,,,DISCONTINUED
255,CA,A1,CA 3106936 A1,025-150-669-274-558,2021-11-06,2021,CA 3106936 A,2021-01-25,US 202016868194 A,2020-05-06,CENTRALIZED THREAT INTELLIGENCE,Systems and techniques for centralized threat intelligence are described herein. A connection may be established to a plurality of threat data sources. An anonymized set of threat data may be obtained by application of a set of privacy rules to the threat data from the plurality of threat data. A threat database may be populated with the anonyinized set of threat data. A registration request inay be received for a user of a device. A unique user identifier may be assigned for the user and a unique device identifier may be assigned for the device. A threat model may be generated based on a set of the characteristics frorn the threat database. A set of data access attributes may be received for a data access request. The data access request rnay be blocked based on an evaluation of the data access attributes using the threat model.,TORONTO DOMINION BANK,ADAMS CHAD E;;CARICATO DANIEL ROBERT;;COVINGTON KAHILDAH B;;GODFREY ASHLEY BROOK;;HOWSER CHRISTOPHER WAYNE;;MAIORANA NICOLA A;;PATEL NIRALI J;;SCHROEDER RICHARD JOSEPH;;WHITE ROGER DARYLL,,https://lens.org/025-150-669-274-558,Patent Application,no,0,0,5,5,0,G06F21/6254;;G06F21/604;;H04L63/1433;;H04L63/0245;;H04L63/0421;;H04L63/08;;H04L63/1416;;G06F21/44;;H04L63/0876,G06F21/55;;G06F21/57,,0,0,,,,PENDING
256,US,A1,US 2022/0353281 A1,034-878-327-631-12X,2022-11-03,2022,US 202217811710 A,2022-07-11,US 202217811710 A;;US 202016868194 A,2020-05-06,CENTRALIZED THREAT INTELLIGENCE,Systems and techniques for centralized threat intelligence are described herein. A connection may be established to a plurality of threat data sources. An anonymized set of threat data may be obtained by application of a set of privacy rules to the threat data from the plurality of threat data. A threat database may be populated with the anonymized set of threat data. A registration request may be received for a user of a device. A unique user identifier may be assigned for the user and a unique device identifier may be assigned for the device. A threat model may be generated based on a set of the characteristics from the threat database. A set of data access attributes may be received for a data access request. The data access request may be blocked based on an evaluation of the data access attributes using the threat model.,WELLS FARGO BANK NA,ADAMS CHAD E;;CARICATO DANIEL ROBERT;;COVINGTON KAHLIDAH B;;GODFREY ASHLEY BROOK;;HOWSER CHRISTOPHER WAYNE;;MAIORANA NICOLA A;;PATEL NIRALI J;;SCHROEDER RICHARD JOSEPH;;WHITE ROGER DARYLL,WELLS FARGO BANK N.A (2020-05-12),https://lens.org/034-878-327-631-12X,Patent Application,yes,4,0,5,5,0,G06F21/6254;;G06F21/604;;H04L63/1433;;H04L63/0245;;H04L63/0421;;H04L63/08;;H04L63/1416;;G06F21/44;;H04L63/0876,H04L9/40;;G06F21/44,,0,0,,,,ACTIVE
257,US,A1,US 2021/0352088 A1,042-122-312-827-357,2021-11-11,2021,US 202016868194 A,2020-05-06,US 202016868194 A,2020-05-06,CENTRALIZED THREAT INTELLIGENCE,Systems and techniques for centralized threat intelligence are described herein. A connection may be established to a plurality of threat data sources. An anonymized set of threat data may be obtained by application of a set of privacy rules to the threat data from the plurality of threat data. A threat database may be populated with the anonymized set of threat data. A registration request may be received for a user of a device. A unique user identifier may be assigned for the user and a unique device identifier may be assigned for the device. A threat model may be generated based on a set of the characteristics from the threat database. A set of data access attributes may be received for a data access request. The data access request may be blocked based on an evaluation of the data access attributes using the threat model.,WELLS FARGO BANK NA,ADAMS CHAD E;;CARICATO DANIEL ROBERT;;COVINGTON KAHLIDAH B;;GODFREY ASHLEY BROOK;;HOWSER CHRISTOPHER WAYNE;;MAIORANA NICOLA A;;PATEL NIRALI J;;SCHROEDER RICHARD JOSEPH;;WHITE ROGER DARYLL,WELLS FARGO BANK N.A (2020-05-12),https://lens.org/042-122-312-827-357,Patent Application,yes,0,7,5,5,0,G06F21/6254;;G06F21/604;;H04L63/1433;;H04L63/0245;;H04L63/0421;;H04L63/08;;H04L63/1416;;G06F21/44;;H04L63/0876,H04L29/06;;G06F21/44,,0,0,,,,ACTIVE
258,CA,A1,CA 3105849 A1,182-624-844-870-969,2021-10-15,2021,CA 3105849 A,2021-01-15,US 202016849574 A,2020-04-15,"SYSTEMS AND METHODS FOR ESTABLISHING, USING, AND RECOVERING UNIVERSAL DIGITAL IDENTIFIERS","Disclosed herein are systems and methods for establishing, using, and recovering universal digital identifiers. In an embodiment, a system establishes a universal identifier (ID) associated with a user and a device of the user. The universal ID is universal with respect to a plurality of distinct entities, has at least a suspended state and an unsuspended state, and initially is in the unsuspended state. The system transmits the universal ID to the device of the user. Thereafter, the system detects an ID-suspension event in connection with the universal ID, and responsively suspends the universal ID, including placing the universal ID in the suspended state. After suspending the universal ID, the system completes an ID-recovery process for the universal ID, and responsively unsuspends the universal ID, including placing the universal ID in the unsuspended state.",TORONTO DOMINION BANK,ADAMS CHAD E;;CARICATO DANIEL ROBERT;;COVINGTON KAHLIDAH B;;GODFREY ASHLEY BROOK;;HOWSER CHRISTOPHER WAYNE;;MAIORANA NICOLA A;;PATEL NIRALI J;;SCHROEDER RICHARD JOSEPH;;WHITE ROGER DARYLL,,https://lens.org/182-624-844-870-969,Patent Application,no,0,0,3,3,0,H04L63/08;;H04W12/06;;H04W12/72;;H04W4/80;;G06Q20/3821;;G06Q20/4014;;G06Q20/409;;G06Q20/405;;G06Q20/3674;;H04L2101/365;;H04L67/02;;H04L63/08;;H04L63/0428;;G06Q20/20;;H04W76/11;;H04W48/16;;H04W12/06,G06F21/00;;G06Q40/02;;H04L12/22,,0,0,,,,PENDING
259,US,B2,US 8689137 B2,104-220-815-670-52X,2014-04-01,2014,US 40147006 A,2006-04-10,US 40147006 A;;US 71462205 P,2005-09-07,Command user interface for displaying selectable functionality controls in a database application,"An improved user interface is provided for displaying selectable software functionality controls of a database application. When a task-based functionality tab is selected from the user interface, selectable functionality controls provided by the associated database application for performing aspects of a task related to the selected tab are presented in a ribbon-shaped user interface above a workspace in which a user is entering or editing data. Upon selection of a different task-based functionality tab, the presentation of functionality controls associated with the first task is removed, and selectable functionality controls associated with the second selected task-based functionality tab are presented in the user interface. The selectable functionality controls presented in the user interface are grouped into logical groupings for more efficient utilization. An extensibility model is provided for allowing users to develop and use customized user interfaces and to allow utilization of legacy user interfaces.",MCCORMACK MICHAEL J;;KENNEY ADAM RUSSELL;;BRYANT CHRISTOPHER W;;COVINGTON CLINTON DEE;;DICKINSON RICHARD L;;COGGINS ROBERT E;;KROUT KELLY MICHAEL;;SELCA VITORE;;WOODALL ZACHARY P;;HOUGH DAN JACOB;;MICROSOFT CORP,MCCORMACK MICHAEL J;;KENNEY ADAM RUSSELL;;BRYANT CHRISTOPHER W;;COVINGTON CLINTON DEE;;DICKINSON RICHARD L;;COGGINS ROBERT E;;KROUT KELLY MICHAEL;;SELCA VITORE;;WOODALL ZACHARY P;;HOUGH DAN JACOB,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2006-04-10),https://lens.org/104-220-815-670-52X,Granted Patent,yes,108,44,13,13,0,G06F3/0481;;G06F3/0481;;G06F3/0481,G06F3/048,715/810,99,8,030-185-319-944-137;;006-973-672-738-921;;116-986-833-248-765;;065-216-601-524-514;;095-840-153-289-000;;009-946-190-370-680;;129-561-705-550-917;;104-484-357-593-596,10.1145/642611.642674;;10.1145/238218.238222;;10.1145/99370.99407;;10.1145/237091.237094;;10.1016/s0169-7552(97)00065-2;;10.1145/138859.138867;;10.1109/69.790816;;10.1145/342009.335432,"Microsoft Office Word 2003, Part of Microsoft Office Professional Edition 2003, 1983-2003 Microsoft Corporation, screen shot 1, 1 pp.;;Microsoft Office 2003, Microsoft Office Professional Edition 2003, Microsoft Corporation, 10 pages.;;Screendumps-Microsoft Office, Microsoft Office Professional Edition 2003, Microsoft Corporation, 10 pages.;;Screendumps-Microsoft Office Outlook, Microsoft Office Outlook Professional Edition 2003, Microsoft Corporation, 2 pages.;;Chinese Second Office Action dated Nov. 21, 2008 cited in Appln No. 200510089514.X.;;U.S. Official Action dated Jun. 19, 2008 cited in U.S. Appl. No. 10/851,506.;;U.S. Official Action dated Jun. 20, 2008 cited in U.S. Appl. No. 10/955,928.;;U.S. Official Action dated Jul. 17, 2008 cited in U.S. Appl. No. 10/955,940.;;U.S. Official Action dated Dec. 23, 2008 in U.S. Appl. No. 10/955,942.;;U.S. Official Action dated Dec. 24, 2008 in U.S. Appl. No. 10/955,967.;;U.S. Official Action dated Jan. 6, 2009 in U.S. Appl. No. 10/955,941.;;U.S. Office Action dated Jan. 28, 2008 cited in U.S. Appl. No. 10/836,154.;;Chilean Office Action dated Nov. 27, 2008 cited in Appln No. 1768-2005.;;Chilean Office Action dated Sep. 23, 2008 cited in Appln No. 1770-2005.;;Chilean Office Action dated Nov. 27, 2008 cited in Appln No. 1769-2005.;;U.S. Appl. No. 12/028,797, filed Feb. 9, 2008 entitled ""Side-by-Side Shared Calendars"".;;U.S. Office Action dated Feb. 20, 2008 cited in U.S. Appl. No. 10/848,774.;;U.S. Office Action dated Feb. 21, 2008 cited in U.S. Appl. No. 10/851,442.;;Marshall School of Business, Workshop 1-Introduction to Outlook & E-mail, Apr. 6, 2000, pp. 1-11.;;Jane Dorothy Calabria Burke, Ten Minute Guide to Lotus Notes 4.6, Publication date: Dec. 23, 1997, 2 pgs.;;Bill Dyszel, Microsoft Outlook 2000 for Windows for Dummies, Copyright 1999, pp. 82-86, 102-103, 141,143.;;Gina Danielle Venolia et al., Understanding Sequence and Reply Relationships within Email Conversations: A Mixed-Model Visualization, CHI 2003, Apr. 5-10, 2003, vol. No. 5, Issue No. 1, pp. 361-368.;;Charles Rich, Candace L. Sidner, ""Segmented Interaction History in a Collaborative Interface Agent,"" 1997 ACM, pp. 23-30.;;Andrew Dwelly, ""Functions and Dynamic User Interfaces,"" 1989 ACM, pp. 371-381.;;Alias I. Wavefront, ""The Hotbox: Efficient Access to a Large Number of Menu-items,"" ACM 1999, pp. 231-237.;;Charles Rich, Candace L. Sidner, ""Adding a Collaborative Agent to Graphical User Interfaces,"" 1996 ACM, pp. 21-30.;;U.S. Official Action mailed Dec. 23, 2003 in U.S. Appl. No. 09/896,384.;;U.S. Official Action mailed Aug. 24, 2004 in U.S. Appl. No. 09/896,384.;;U.S. Appl. No. 10/982,073, filed Nov. 5, 2004, entitled ""Gallery User Interface Controls"".;;U.S. Appl. No. 10/836,154, filed Apr. 30, 2004, entitled ""Combined Content Selection and Display User Interface"".;;U.S. Appl. No. 10/848,774, filed May 19, 2004, entitled ""Automatic Grouping of Electronic Mail"".;;Boyce, ""Microsoft Outlook Inside Out,"" 2001, pp. 67, 68, 109, 110, 230, 231, 310, 316-318, 798.;;Halvorson and Young, ""Microsoft Office XP Inside Out,"" 2001, pp. 1005-1009, 1015, 1023-1028, 1036-1039, 1093.;;Riggsby, McCoy, Haberman and Falciani, ""Mastering Lotus Notes and Domino 6,"" 2003, pp. 135-139.;;U.S. Appl. No. 10/851,442, filed May 21, 2004, entitled ""Conversation Grouping of Electronic Mail Records"".;;Riggsby, McCoy, Haberman and Falciani, ""Mastering Lotus Notes and Domino 6,"" 2003, pp. 135-138, 607-612.;;U.S. Appl. No. 10/851,506, filed May 21, 2004, entitled ""Adaptive Multi-Line View User Interface"".;;Examination Report, Jul. 25, 2005.;;Search Report, Danish Patent and Trademark Office, Sep. 18, 2006.;;Written Opinion, Danish Patent and Trademark Office, Sep. 18, 2006.;;Search Report, Danish Patent and Trademark Office, Sep. 19, 2006.;;U.S. Appl. No. 10/955,940, filed Sep. 30, 2004, entitled ""User Interface for Displaying Selectable Software Functionality Controls that are Contextually Relevant to a Selected Object"".;;U.S. Appl. No. 10/955,967, filed Sep. 30, 2004, entitled ""Command User Interface for Displaying Selectable Software Functionality Controls"".;;U.S. Appl. No. 10/955,942, filed Sep. 30, 2004, entitled ""User Interface for Displaying a Gallery of Formatting Options Applicable to a Selected Object"".;;U.S. Appl. No. 10/955,928, filed Sep. 30, 2004, entitled ""User Interface for Providing Task Management and Calendar Information"".;;U.S. Official Action mailed Apr. 27, 2006 in U.S. Appl. No. 10/800,056.;;Amendment to Office Action of Apr. 27, 2006, dated Jul. 27, 2006 in U.S. Appl. No. 10/800,056.;;U.S. Official Action mailed Oct. 19, 2006 in U.S. Appl. No. 10/800,056.;;Amendment to Office Action of Oct. 19, 2006, dated Jan. 19, 2007 in U.S. Appl. No. 10/800,056.;;U.S. Appl. No. 10/800,056, filed Mar. 12, 2004, entitled ""Method and System for Data Binding in a Block Structured User Interface Scripting Language"".;;Khare and Rifkin, ""The Origin of (Document) Species,"" University of California, 1998 (9 pages).;;""Separate Structure and Presentation,"" http://www.webreference.com/html/tutorial5/l.html, Aug. 20, 1998 (4 pages).;;""The Style Attribute and CSS Declarations,"" http://www.webreference.com/html/tutorial5/2, Aug. 20, 1998 (4 pages).;;""What's Hot in Internet Services?,"" http://www.webreference.com/html/tutorial5/3, Aug. 20, 1998 (3 pages).;;""The Style Element & CSS Selectors,"" http://www.webreference.com/html/tutorial5/4.html, Aug. 20, 1998 (e pages).;;http://www/webreference.com/html/tutorial5/5.html, Aug. 20, 1998 (3 pages.;;""ID & Class Selectors, Pseudoclasses,"" http://www.webreference.com/html/tutorial5/6.html, Aug. 20, 1998 (3 pages).;;http://www.webreference.com/html/tutorial5/7.html, Aug. 20, 1998 (3 pages).;;http://www.webreference.com/html/tutorial5/8.html, Aug. 20, 1998 (2 pages).;;""External Style Sheets,"" http://www.webreference.com/html/tutorial5/10.html, Aug. 20, 1998 (3 pages).;;Raman, ""Cascaded Speech Style Sheets,"" 1997 (9 pages).;;""Primary Windows,"" http://www-03.ibm.com/servers/eserver/iseries/navigator/guidelines/primary.html, , (23 pages).;;""User Interface Standards,"" http://msdn2.microsoftt.com/en-us/library/aa217660(office.11,d=printer).aspx, Sep. 2001 (5 pages).;;""WebSphere Studio Overview,"" http://researchweb.watson.ibm.com/journal/sj/432/budinsky.html, May 6, 2004 (25 page).;;U.S. Official Action mailed Feb. 14, 2007 in U.S. Appl. No. 10/800,056.;;U.S. Final Office Action dated Apr. 15, 2008 cited in U.S. Appl. No. 10/955,942.;;Screendumps Microsoft Corporation, Microsoft Office Professional Edition 2003, 5 pgs.;;U.S. Final Office Action dated Apr. 16, 2008 cited in U.S. Appl. No. 10/955,967.;;Screendumps Microsoft Corporation, Microsoft Office Professional Edition 2003, 4 pgs.;;U.S. Final Office Action dated May 28, 2008 cited in U.S. Appl. No. 10/982,073.;;Chinese Official Action dated Mar. 21, 2008 cited in Chinese Application No. 200510092146.4.;;Chinese Official Action dated Mar. 21, 2008 cited in Chinese Application No. 200510092139.4.;;Philippine Official Action dated Apr. 21, 2008 cited in Philippine Application No. 1-2005-000405.;;Philippine Official Action dated Apr. 21, 2008 cited in Philippine Application No. 1-2005-000406.;;U.S. Final Office Action dated Apr. 29, 2008 cited in U.S. Appl. No. 10/955,941.;;Habraken, Microsoft Office XP 8 in 1, published Jun. 5, 2001, http://proquest.safaribooksonline.com/0789725096/, 12 pgs.;;Word 2002, Chapter 14; Paradigm Publishing Inc., copyright 2002; http://www.emcp.com/tech-tutorials/sig-irc/Signature-Word-Chapter-14.ppt, 21 pgs.;;Chilean Office Action dated Mar. 28, 2008 cited in Application No. 1770-05, no English Translation.;;Chinese First Office Action dated Apr. 11, 2008 cited in Application No. 200510092141.1.;;Chinese Office Action dated Apr. 18, 2008 cited in Application No. 200510092142.6.;;U.S. Final Office Action dated Jul. 24, 2008 cited in U.S. Appl. No. 11/151,686.;;Microsoft Office Word 2003. Part of Microsoft Office Professional Edition 2003. Copyright 1983-2003 Microsoft Corporation.;;Chinese Office Action dated May 23, 2008 cited in Application No. 200510089514.X.;;Philippine Official Action dated Jul. 31, 2008 cited in Philippine Application No. 12005000495.;;European Communication dated Jun. 23, 2008 cited in European Application No. 04102463.9-2211/1517239.;;U.S. Appl. No. 11/154,278, filed Jun. 16, 2005 entitled ""Cross Version and Cross Product User Interface Compatibility"".;;U.S. Appl. No. 11/151,686, filed Jun. 13, 2005 entitled ""Floating Command Object"".;;U.S. Appl. No. 10/607,020, filed Jun. 26, 2003 entitled ""Side-by-Side Shared Calendars"".;;U.S. Appl. No. 10/741,407, filed Dec. 19, 2003 entitled ""Methods, Systems, and Computer-Readable Mediums for Providing Persisting and Continuously Updating Search Folders"".;;U.S. Appl. No. 11/782,059, filed Jul. 24, 2007 entitled ""Methods, Systems, and Computer-Readable Mediums for Providing Persisting and Continuously Updating Search Folders"".;;U.S. Appl. No. 10/955,941, filed Sep. 30, 2004 entitled ""An Improved User Interface for Displaying Selectable Software Functionality Controls that are Relevant to a Selected Object"".;;Gordon Padwick, Using Microsoft Outlook 2000, Que, Sp. Ed., May 1999.;;Becker et al., ""Virtual Folders: Database Support for Electronic Messages Classification,"" Pontificia Universidade Catolica do Rio Grande do Sul, Porto Alegre, Brazil, pp. 163-170.;;Goldberg et al., ""Using Collaborative Filtering to Weave an Information Tapestry,"" Communication of the ACM, vol. 35, No. 12, pp. 61-70, Dec. 1992.;;Liu et al., ""Continual Queries for Internet Scale Event-Driven Information Delivery,"" IEEE Transactions on Knowledge and Data Engineering, vol. 11, Issue 1, pp. 610-628, 1999.;;Chen et al., ""NiagaraCQ: A Scalable Continuous Query System for Internet Databases,"" Int. Conf. On Management of Data, Proc. Of the 2000 ACM SIGMOD Int. Conf. On Management of Data, pp. 379-390, 2000.;;Marshall School of Business: ""Workshop IV-Calendar,"" http://www.marshall.usc.edu/computing/PDF-Files/Outlook/Workshop4, PDF, Apr. 10, 2000, pp. 1-4.;;M. Williams, ""Programming Windows NT4: Unleashed,"" Sams Publishing, Indianapolis, 1996, pp. index & 167-185.;;""Microsoft Outlook 2000: Introduction to Calendar,"" Version Mar. 25, 2002, http://www.uakron.edu/its/learning/training/docs/Calendar032502.pdf, Mar. 25, 2002, pp. 1-52.",INACTIVE
260,KR,A,KR 20080041234 A,144-504-552-604-576,2008-05-09,2008,KR 20087005366 A,2006-09-07,US 40147006 A;;US 71462205 P;;US 2006/0034993 W,2005-09-07,COMMAND USER INTERFACE FOR DISPLAYING SELECTABLE FUNCTIONALITY CONTROLS IN A DATABASE APPLICATION,"An improved user interface is provided for displaying selectable software functionality controls of a database application. When a task-based functionality tab is selected from the user interface, selectable functionality controls provided by the associated database application for performing aspects of a task related to the selected tab are presented in a ribbon-shaped user interface above a workspace in which a user is entering or editing data. Upon selection of a different task-based functionality tab, the presentation of functionality controls associated with the first task is removed, and selectable functionality controls associated with the second selected task-based functionality tab are presented in the user interface. The selectable functionality controls presented in the user interface are grouped into logical groupings for more efficient utilization. An extensibility model is provided for allowing users to develop and use customized user interfaces and to allow utilization of legacy user interfaces.",MICROSOFT CORP,MCCORMACK MICHAEL J;;KENNEY ADAM RUSSELL;;BRYANT CHRISTOPHER W;;COVINGTON CLINTON DEE;;DICKINSON RICHARD L;;COGGINS ROBERT E;;KROUT KELLY MICHAEL;;SELCA VICTORE;;WOODALL ZACHARY P;;HOUGH DAN JACOB,,https://lens.org/144-504-552-604-576,Patent Application,no,0,20,13,13,0,G06F3/0481;;G06F3/0481;;G06F3/0481,G06F3/048;;G06F17/30,,0,0,,,,ACTIVE
261,CN,B,CN 101278252 B,038-382-944-086-055,2011-03-23,2011,CN 200680032564 A,2006-09-07,US 2006/0034993 W;;US 71462205 P;;US 40147006 A,2005-09-07,Method for providing function for user interface for a database application and the interface deployment method,"An improved user interface is provided for displaying selectable software functionality controls of a database application. When a task-based functionality tab is selected from the user interface, selectable functionality controls provided by the associated database application for performing aspects of a task related to the selected tab are presented in a ribbon-shaped user interface above a workspace in which a user is entering or editing data. Upon selection of a different task-based functionality tab, the presentation of functionality controls associated with the first task is removed, and selectable functionality controls associated with the second selected task-based functionality tab are presented in the user interface. The selectable functionality controls presented in the user interface are grouped into logical groupings for more efficient utilization. An extensibility model is provided for allowing users to develop and use customized user interfaces and to allow utilization of legacy user interfaces.",MICROSOFT CORP,COGGINS ROBERT E;;JACOB HOUGH DAN;;BRYANT CHRISTOPHER W;;DICKINSON RICHARD L;;MICHAEL KROUT KELLY;;RUSSELL KENNEY ADAM;;DEE COVINGTON CLINTON;;VICTORE SELCA;;WOODALL ZACHARY P;;MCCORMACK MICHAEL J,MICROSOFT TECHNOLOGY LICENSING LLC (2015-04-30),https://lens.org/038-382-944-086-055,Granted Patent,no,0,0,13,13,0,G06F3/0481;;G06F3/0481;;G06F3/0481,G06F3/048,,0,0,,,,INACTIVE
262,US,A1,US 2007/0055943 A1,001-049-599-066-050,2007-03-08,2007,US 40147006 A,2006-04-10,US 40147006 A;;US 71462205 P,2005-09-07,Command user interface for displaying selectable functionality controls in a database applicaiton,"An improved user interface is provided for displaying selectable software functionality controls of a database application. When a task-based functionality tab is selected from the user interface, selectable functionality controls provided by the associated database application for performing aspects of a task related to the selected tab are presented in a ribbon-shaped user interface above a workspace in which a user is entering or editing data. Upon selection of a different task-based functionality tab, the presentation of functionality controls associated with the first task is removed, and selectable functionality controls associated with the second selected task-based functionality tab are presented in the user interface. The selectable functionality controls presented in the user interface are grouped into logical groupings for more efficient utilization. An extensibility model is provided for allowing users to develop and use customized user interfaces and to allow utilization of legacy user interfaces.",MICROSOFT CORP,MCCORMACK MICHAEL J;;KENNEY ADAM R;;BRYANT CHRISTOPHER W;;COVINGTON CLINTON D;;DICKINSON RICHARD L;;COGGINS ROBERT E;;KROUT KELLY M;;SELCA VITORE;;WOODALL ZACHARY P;;HOUGH DAN J,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2006-04-10),https://lens.org/001-049-599-066-050,Patent Application,yes,198,122,13,13,0,G06F3/0481;;G06F3/0481;;G06F3/0481,G06F17/30,715/746;;707/10,0,0,,,,INACTIVE
263,US,A1,US 2006/0149769 A1,152-006-493-791-110,2006-07-06,2006,US 2750204 A,2004-12-30,US 2750204 A,2004-12-30,Database navigation,"Database interaction is facilitated by graphically presenting database objects in groups that are not necessarily dictated by object types of the database objects. In an example implementation, database navigation is facilitated by determining object dependency groups for a database in which each object dependency group corresponds to a database source object and includes at least those database objects that depend directly or indirectly from the corresponding database source object. When these data source object-based dependency groups are graphically displayed, selecting a database object thereof provides access thereto. In another example implementation, a user can designate an attribute associated with database objects by which the database objects are to be grouped. Thus, the database objects are grouped by various values that the user-designated associated attribute takes. These designated-attribute-based value-driven groups may also be graphically displayed to enable navigation of and access to the different database objects assigned to them.",MICROSOFT CORP,MCCORMACK MICHAEL J;;MILLER ANDREW R;;BRYANT CHRISTOPHER W;;SIGLER JONATHAN M;;COGGINS ROBERT E;;GARDNER SCOTT T;;NARAMORE THERESA A;;HOUGH DANIEL;;KROUT KELLY M;;COVINGTON CLINTON D,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2005-05-02),https://lens.org/152-006-493-791-110,Patent Application,yes,24,21,2,2,0,G06F16/284;;G06F16/284,G06F17/00,707/101,0,0,,,,INACTIVE
264,WO,A3,WO 2007/030696 A3,080-778-081-796-441,2007-05-03,2007,US 2006/0034993 W,2006-09-07,US 71462205 P;;US 40147006 A,2005-09-07,COMMAND USER INTERFACE FOR DISPLAYING SELECTABLE FUNCTIONALITY CONTROLS IN A DATABASE APPLICATION,"An improved user interface is provided for displaying selectable software functionality controls of a database application. When a task-based functionality tab is selected from the user interface, selectable functionality controls provided by the associated database application for performing aspects of a task related to the selected tab are presented in a ribbon-shaped user interface above a workspace in which a user is entering or editing data. Upon selection of a different task-based functionality tab, the presentation of functionality controls associated with the first task is removed, and selectable functionality controls associated with the second selected task-based functionality tab are presented in the user interface. The selectable functionality controls presented in the user interface are grouped into logical groupings for more efficient utilization. An extensibility model is provided for allowing users to develop and use customized user interfaces and to allow utilization of legacy user interfaces.",MICROSOFT CORP,MCCORMACK MICHAEL J;;KENNEY ADAM RUSSELL;;BRYANT CHRISTOPHER W;;COVINGTON CLINTON DEE;;DICKINSON RICHARD L;;COGGINS ROBERT E;;KROUT KELLY MICHAEL;;SELCA VICTORE;;WOODALL ZACHARY P;;HOUGH DAN JACOB,,https://lens.org/080-778-081-796-441,Search Report,yes,4,0,13,13,0,G06F3/0481;;G06F3/0481;;G06F3/0481,G06F3/048,,0,0,,,,PENDING
265,EP,A4,EP 1922604 A4,051-191-017-396-641,2012-10-24,2012,EP 06814334 A,2006-09-07,US 2006/0034993 W;;US 71462205 P;;US 40147006 A,2005-09-07,COMMAND USER INTERFACE FOR DISPLAYING SELECTABLE FUNCTIONALITY CONTROLS IN A DATABASE APPLICATION,,MICROSOFT CORP,MCCORMACK MICHAEL J;;KENNEY ADAM RUSSELL;;BRYANT CHRISTOPHER W;;COVINGTON CLINTON DEE;;DICKINSON RICHARD L;;COGGINS ROBERT E;;KROUT KELLY MICHAEL;;SELCA VICTORE;;WOODALL ZACHARY P;;HOUGH DAN JACOB,"MICROSOFT TECHNOLOGY LICENSING, LLC (2015-03-18)",https://lens.org/051-191-017-396-641,Search Report,no,5,0,13,13,0,G06F3/0481;;G06F3/0481;;G06F3/0481,G06F3/048,,1,0,,,See also references of WO 2007030696A2,ACTIVE
266,EP,A2,EP 1922604 A2,097-281-801-293-046,2008-05-21,2008,EP 06814334 A,2006-09-07,US 2006/0034993 W;;US 71462205 P;;US 40147006 A,2005-09-07,COMMAND USER INTERFACE FOR DISPLAYING SELECTABLE FUNCTIONALITY CONTROLS IN A DATABASE APPLICATION,,MICROSOFT CORP,MCCORMACK MICHAEL J;;KENNEY ADAM RUSSELL;;BRYANT CHRISTOPHER W;;COVINGTON CLINTON DEE;;DICKINSON RICHARD L;;COGGINS ROBERT E;;KROUT KELLY MICHAEL;;SELCA VICTORE;;WOODALL ZACHARY P;;HOUGH DAN JACOB,"MICROSOFT TECHNOLOGY LICENSING, LLC (2015-03-18)",https://lens.org/097-281-801-293-046,Patent Application,yes,0,0,13,13,0,G06F3/0481;;G06F3/0481;;G06F3/0481,G06F3/048,,0,0,,,,ACTIVE
267,WO,A2,WO 2007/030696 A2,043-653-846-649-128,2007-03-15,2007,US 2006/0034993 W,2006-09-07,US 71462205 P;;US 40147006 A,2005-09-07,COMMAND USER INTERFACE FOR DISPLAYING SELECTABLE FUNCTIONALITY CONTROLS IN A DATABASE APPLICATION,"An improved user interface is provided for displaying selectable software functionality controls of a database application. When a task-based functionality tab is selected from the user interface, selectable functionality controls provided by the associated database application for performing aspects of a task related to the selected tab are presented in a ribbon-shaped user interface above a workspace in which a user is entering or editing data. Upon selection of a different task-based functionality tab, the presentation of functionality controls associated with the first task is removed, and selectable functionality controls associated with the second selected task-based functionality tab are presented in the user interface. The selectable functionality controls presented in the user interface are grouped into logical groupings for more efficient utilization. An extensibility model is provided for allowing users to develop and use customized user interfaces and to allow utilization of legacy user interfaces.",MICROSOFT CORP,MCCORMACK MICHAEL J;;KENNEY ADAM RUSSELL;;BRYANT CHRISTOPHER W;;COVINGTON CLINTON DEE;;DICKINSON RICHARD L;;COGGINS ROBERT E;;KROUT KELLY MICHAEL;;SELCA VICTORE;;WOODALL ZACHARY P;;HOUGH DAN JACOB,,https://lens.org/043-653-846-649-128,Patent Application,yes,1,18,13,13,0,G06F3/0481;;G06F3/0481;;G06F3/0481,,,1,0,,,See also references of EP 1922604A4,PENDING
268,US,B2,US 7720887 B2,032-821-764-432-081,2010-05-18,2010,US 2750204 A,2004-12-30,US 2750204 A,2004-12-30,Database navigation,"Database interaction is facilitated by graphically presenting database objects in groups that are not necessarily dictated by object types of the database objects. In an example implementation, database navigation is facilitated by determining object dependency groups for a database in which each object dependency group corresponds to a database source object and includes at least those database objects that depend directly or indirectly from the corresponding database source object. When these data source object-based dependency groups are graphically displayed, selecting a database object thereof provides access thereto. In another example implementation, a user can designate an attribute associated with database objects by which the database objects are to be grouped. Thus, the database objects are grouped by various values that the user-designated associated attribute takes. These designated-attribute-based value-driven groups may also be graphically displayed to enable navigation of and access to the different database objects assigned to them.",MICROSOFT CORP,MCCORMACK MICHAEL J;;MILLER ANDREW R;;BRYANT CHRISTOPHER W;;SIGLER JONATHAN M;;COGGINS ROBERT E;;GARDNER SCOTT T;;NARAMORE THERESA A;;HOUGH DANIEL;;KROUT KELLY M;;COVINGTON CLINTON D,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2005-05-02),https://lens.org/032-821-764-432-081,Granted Patent,yes,39,23,2,2,0,G06F16/284;;G06F16/284,G06F3/048;;G06F7/00,707/805;;715/810,0,0,,,,INACTIVE
269,EP,B1,EP 1922604 B1,110-103-286-810-113,2019-06-12,2019,EP 06814334 A,2006-09-07,US 2006/0034993 W;;US 71462205 P;;US 40147006 A,2005-09-07,COMMAND USER INTERFACE FOR DISPLAYING SELECTABLE FUNCTIONALITY CONTROLS IN A DATABASE APPLICATION,,MICROSOFT TECHNOLOGY LICENSING LLC,MCCORMACK MICHAEL J;;KENNEY ADAM RUSSELL;;BRYANT CHRISTOPHER W;;COVINGTON CLINTON DEE;;DICKINSON RICHARD L;;COGGINS ROBERT E;;KROUT KELLY MICHAEL;;SELCA VICTORE;;WOODALL ZACHARY P;;HOUGH DAN JACOB,"MICROSOFT TECHNOLOGY LICENSING, LLC (2015-03-18)",https://lens.org/110-103-286-810-113,Granted Patent,yes,9,0,13,13,0,G06F3/0481;;G06F3/0481;;G06F3/0481,G06F3/0481,,0,0,,,,ACTIVE
270,WO,A3,WO 2018/157171 A3,197-655-995-449-350,2018-11-29,2018,US 2018/0020054 W,2018-02-27,US 201762464371 P;;US 201762465817 P;;US 201762470180 P;;US 201762527002 P;;US 201762580416 P;;US 201762584740 P;;US 201762596703 P,2017-02-27,"COMPOSITIONS, ARTICLES OF MANUFACTURE AND METHODS RELATED TO DOSING IN CELL THERAPY","Provided herein are methods, compositions and articles of manufacture for use in connection with cell therapy involving the administration of one or more doses of a therapeutic T cell composition. The cells of the T cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the provided embodiments, including the numbers of cells or units of cells administered and/or the potency of administered cells, provide various advantages, such as lower risk of toxicity in subjects administered the T cell compositions.",JUNO THERAPEUTICS INC,CHRISTIN BRIAN;;COVINGTON MICHAEL;;DAVE KEDAR;;GETTO RICHARD;;KOWSKI TOM;;LARSON RYAN;;RAMSBORG CHRISTOPHER;;TREDE NIKOLAUS;;WEBER CLINTON;;WHITMORE JAMES;;YEE NATHAN;;BEAUCHESNE PASCAL;;BECKETT TRAVIS;;BLACKMAN SAMUEL;;CHARTRAND NATHANIEL;;DAVIS-PICKETT MEL;;GILBERT MARK;;LAMBERT NATHANIEL;;LI HE;;MALLANEY MARY;;POLLOCK KATHRYN;;ODEGARD VALERIE;;SMITH JEFF;;SUTHERLAND CLAIRE;;WALKER ANDREW,,https://lens.org/197-655-995-449-350,Search Report,yes,1,0,16,16,0,C07K14/7051;;C12N5/0636;;C07K2319/03;;C07K2319/33;;A61P35/00;;A61P35/02;;A61K39/4611;;A61K39/4631;;A61K39/464412;;A61K2239/48;;A61K35/17;;A61P35/00;;A61P35/02;;C07K14/7051;;C12N5/0636;;C07K2319/03;;C07K2319/33;;A61K35/17;;C12N5/0636;;C12N2510/00;;G01N33/5091;;G01N33/6869;;G01N2800/28;;G01N2800/42,A61K35/17,,3,3,072-204-681-901-652;;031-329-155-540-561;;120-714-957-074-096,10.2217/imt.15.23;;26065477;;10.1182/blood-2016-04-703751;;pmc4929924;;27207799;;10.1126/scitranslmed.aac5415;;pmc5909068;;26333935,"KLAVER YARNE ET AL: ""Adoptive T-cell therapy: a need for standard immune monitoring."", IMMUNOTHERAPY 2015, vol. 7, no. 5, 2015, pages 513 - 533, XP009506029, ISSN: 1750-7448;;JENNIFER N. BRUDNO ET AL: ""Toxicities of chimeric antigen receptor T cells: recognition and management"", BLOOD, vol. 127, no. 26, 20 May 2016 (2016-05-20), US, pages 3321 - 3330, XP055442400, ISSN: 0006-4971, DOI: 10.1182/blood-2016-04-703751;;D. L. PORTER ET AL: ""Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia"", SCIENCE TRANSLATIONAL MEDICINE, vol. 7, no. 303, 2 September 2015 (2015-09-02), US, pages 1 - 13, XP055411906, ISSN: 1946-6234, DOI: 10.1126/scitranslmed.aac5415",PENDING
271,WO,A2,WO 2018/157171 A2,038-089-024-412-441,2018-08-30,2018,US 2018/0020054 W,2018-02-27,US 201762464371 P;;US 201762465817 P;;US 201762470180 P;;US 201762527002 P;;US 201762580416 P;;US 201762584740 P;;US 201762596703 P,2017-02-27,"COMPOSITIONS, ARTICLES OF MANUFACTURE AND METHODS RELATED TO DOSING IN CELL THERAPY","Provided herein are methods, compositions and articles of manufacture for use in connection with cell therapy involving the administration of one or more doses of a therapeutic T cell composition. The cells of the T cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the provided embodiments, including the numbers of cells or units of cells administered and/or the potency of administered cells, provide various advantages, such as lower risk of toxicity in subjects administered the T cell compositions.",JUNO THERAPEUTICS INC,CHRISTIN BRIAN;;COVINGTON MICHAEL GERARD;;DAVE KEDAR HIMANSHU;;GETTO RICHARD JAMES;;KOWSKI TOM;;LARSON RYAN P;;RAMSBORG CHRISTOPHER GLEN;;TREDE NIKOLAUS SEBASTIAN;;WEBER CLINTON;;WHITMORE JAMES BOYD;;YEE NATHAN;;BEAUCHESNE PASCAL;;BECKETT TRAVIS;;BLACKMAN SAMUEL CHARLES;;CHARTRAND NATHANIEL;;DAVIS-PICKETT MEL;;GILBERT MARK;;LAMBERT NATHANIEL;;LI HE;;MALLANEY MARY;;POLLOCK KATHRYN LINDSAY;;ODEGARD VALERIE;;SMITH JEFF;;SUTHERLAND CLAIRE;;WALKER ANDREW W,,https://lens.org/038-089-024-412-441,Patent Application,yes,81,10,16,16,58,C07K14/7051;;C12N5/0636;;C07K2319/03;;C07K2319/33;;A61P35/00;;A61P35/02;;A61K39/4611;;A61K39/4631;;A61K39/464412;;A61K2239/48;;A61K35/17;;A61P35/00;;A61P35/02;;C07K14/7051;;C12N5/0636;;C07K2319/03;;C07K2319/33;;A61K35/17;;C12N5/0636;;C12N2510/00;;G01N33/5091;;G01N33/6869;;G01N2800/28;;G01N2800/42,A61K35/17,,118,84,015-135-965-483-866;;003-965-481-653-512;;060-589-636-791-858;;063-433-217-012-045;;036-008-552-768-222;;015-135-965-483-866;;067-335-002-036-302;;023-650-948-525-282;;020-080-307-999-663;;014-955-178-957-687;;117-444-872-566-432;;045-219-219-367-333;;020-536-198-725-040;;056-563-230-206-145;;116-382-497-517-69X;;120-738-288-740-114;;015-472-454-332-748;;023-461-951-501-916;;108-450-768-747-000;;000-971-368-458-960;;031-606-974-183-150;;039-718-974-716-276;;023-719-373-138-419;;032-942-121-304-562;;002-280-663-279-666;;028-522-520-525-965;;015-089-932-644-040;;066-607-688-825-938;;000-874-901-888-607;;027-222-971-280-580;;027-552-012-139-76X;;016-566-211-770-835;;162-839-071-431-907;;003-965-481-653-512;;007-538-000-443-231;;003-562-221-195-045;;017-660-065-337-845;;015-239-659-590-870;;098-491-388-193-819;;024-754-476-881-467;;081-128-682-009-468;;039-515-794-348-090;;016-859-592-443-49X;;061-715-232-537-360;;025-352-538-084-346;;081-384-558-962-246;;086-559-027-032-916;;054-614-759-223-919;;086-559-027-032-916;;054-614-759-223-919;;021-446-361-160-551;;006-251-195-332-050;;002-162-465-889-925;;086-745-238-331-392;;016-228-040-726-191;;076-025-924-474-213;;087-228-441-640-087;;049-812-244-268-065;;045-728-526-507-231;;138-776-221-550-51X;;015-381-062-986-351;;002-067-583-917-127;;026-091-110-742-639;;061-020-387-423-869;;027-957-562-781-859;;021-131-907-979-811;;037-679-506-850-982;;040-956-856-442-787;;098-513-039-752-103;;053-943-855-504-164;;013-047-051-959-239;;040-956-856-442-787;;115-905-641-952-818;;001-597-332-396-330;;045-962-320-146-915;;034-059-954-686-42X;;120-217-115-116-942;;048-250-796-277-615;;129-739-702-826-549;;020-423-721-980-230;;063-086-322-407-483;;036-537-002-834-639;;009-462-801-686-545;;030-993-115-650-407,10.1016/s1525-0016(16)35779-3;;23515080;;pmc3742551;;10.1126/scitranslmed.3005930;;10.1056/nejmoa1215134;;23527958;;pmc4058440;;pmc3327450;;10.1182/blood-2011-10-384388;;22160384;;24141191;;10.1016/j.canlet.2013.10.004;;10.1016/s1525-0016(16)35779-3;;10.1182/blood-2014-05-552729;;24876563;;pmc4093680;;21060341;;10.1038/nrneurol.2010.160;;pmc2901998;;10.1038/nature09204;;20562859;;pmc2990190;;10.1002/path.2697;;20225336;;21808266;;pmc6292196;;10.1038/nrclinonc.2011.116;;23934177;;pmc5722218;;10.1038/nbt.2678;;10.1016/j.bbrc.2013.07.030;;23872144;;pmc5554955;;pmc3621858;;10.1371/journal.pone.0061338;;23585892;;10.1002/pbc.26039;;27149049;;19097774;;10.1016/j.ejca.2008.10.026;;pmc4180491;;23155265;;25207766;;10.1056/nejmoa1403088;;pmc4191900;;22897847;;10.1016/j.ccr.2012.06.005;;pmc3422513;;10.1038/ng.2803;;pmc4039076;;24141364;;10.1080/10428194.2016.1219902;;27855558;;pmc6077981;;pmc5455698;;27870571;;10.1200/jco.2016.69.0073;;10.1182/blood-2009-08-239681;;pmc3321747;;20699438;;pmc2747302;;19561539;;10.1097/cji.0b013e3181ac6138;;10.1038/343336a0;;2137200;;9207007;;pmc2198969;;10.1084/jem.186.1.131;;10.4049/jimmunol.180.5.3447;;18292571;;7720078;;10.1016/0008-8749(95)80026-f;;8454850;;15905584;;10.4049/jimmunol.174.11.7368;;pmc3667586;;23550147;;10.1158/2159-8290.cd-12-0548;;10.1038/nrclinonc.2013.46;;pmc6322669;;23546520;;pmc3525345;;23090078;;10.1097/cji.0b013e318270dec7;;23515080;;pmc3742551;;10.1126/scitranslmed.3005930;;pmc3319867;;22315351;;10.1158/0008-5472.can-11-3890;;10.1158/1078-0432.ccr-12-1449;;23032741;;10.1002/jmr.640;;14523945;;10.4049/jimmunol.150.3.880;;8423344;;23620405;;pmc3804130;;10.1158/1078-0432.ccr-13-0330;;10.1073/pnas.87.23.9138;;2251255;;pmc55119;;pmc454949;;3208747;;10.1002/j.1460-2075.1988.tb03258.x;;10.1016/s0145-305x(02)00039-3;;12477501;;7553574;;10.1128/cmr.8.3.411-426.1995;;pmc174633;;10.1128/cmr.8.3.411;;10.1038/ni863;;12469116;;10.1073/pnas.080078297;;pmc25838;;10779548;;pmc2680719;;10.1016/j.jim.2008.09.016;;18854190;;10.1093/bioinformatics/17.12.1236;;11751237;;10.1007/978-1-60327-118-9_5;;18449993;;10.1093/bioinformatics/17.12.1236;;11751237;;10.1007/978-1-60327-118-9_5;;18449993;;10.1073/pnas.89.10.4759;;1584815;;pmc49163;;7932722;;10.1006/jmbi.1994.1615;;pmc46399;;8387198;;10.1073/pnas.90.9.3830;;8601837;;10.1006/jmbi.1996.0132;;pmc4238416;;10.1126/scitranslmed.3006597;;24337479;;23090074;;10.1097/cji.0b013e31827806e6;;pmc3501135;;10.1039/c000136h;;pmc3118392;;20379604;;10.1002/jbio.200810018;;pmc2746115;;19343660;;12393484;;10.1182/blood-2002-07-1989;;19110622;;10.1007/978-1-59745-409-4_8;;10.1182/blood-2003-01-0297;;12649146;;1729703;;pmc48169;;10.1073/pnas.89.1.33;;10.1016/s0301-472x(00)00526-9;;11027832;;10.1016/j.tibtech.2011.04.009;;pmc3193849;;21663987;;16632409;;10.1016/j.ymthe.2006.03.007;;20736930;;pmc2951569;;10.1038/mt.2010.178;;20104209;;10.1038/mt.2010.2;;pmc2862530;;15363111;;pmc521497;;10.1186/1479-0556-2-13;;15260831;;10.1111/j.1398-9219.2004.00205.x;;10.1128/jvi.69.2.748-755.1995;;pmc188638;;7815539;;1643151;;10.1089/hum.1992.3.3-319;;15363111;;pmc521497;;10.1186/1479-0556-2-13;;2081186;;10.1089/hum.1990.1.1-5;;10.1016/0042-6822(91)90105-k;;1989392;;pmc47282;;10.1073/pnas.90.17.8033;;8396259;;8453267;;10.1016/s0959-437x(05)80349-1;;23555950;;10.1371/journal.pone.0060298;;pmc3608570;;10.1038/sj.gt.3301252;;10981672;;10.1089/hum.2009.114;;pmc2938363;;19905893;;19110623;;10.1007/978-1-59745-409-4_9;;2201923;;10.1038/346776a0;;pmc365315;;3037341;;10.1128/mcb.7.5.2031-2034.1987;;10.1128/mcb.7.5.2031;;22907378;;10.1007/978-1-61779-974-7_36;;10.1146/annurev-med-060512-150254;;24274181;;pmc4120077,"SENTMAN, IMMUNOTHERAPY, vol. 5, 2013, pages 10;;DAVILA ET AL., SCI TRANSL MED, vol. 6, 2014, pages 224ra25;;BRENTJENS ET AL., SCI. TRANSL. MED., vol. 5, 2013, pages 177ra38;;GRUPP ET AL., N. ENGL. J. MED., vol. 368, 2013, pages 1509 - 1518;;KOCHENDERFER ET AL., BLOOD, vol. 119, 2012, pages 2709 - 2720;;XU ET AL., CANCER LETTERS, vol. 343, 2014, pages 172 - 78;;DAVILLA ET AL., SCIENCE TRANSLATIONAL MEDICINE, vol. 6, no. 224, 2014, pages 224ra25;;LEE ET AL., BLOOD, vol. 124, no. 2, 2014, pages 188 - 95;;GUIDO CAVALETTI; PAOLA MARMIROLI, NATURE REVIEWS NEUROLOGY, vol. 6, December 2010 (2010-12-01), pages 657 - 666;;J. PAUL ROBINSON ET AL.: ""Current Protocols in Cytometry"", 2007, WILEY-LISS PUB, article ""Flow Cytometry in Clinical Diagnosis"";;""Flow Cytometry -A practical approach"", 2000, OXFORD UNIVERSITY PRESS;;ORMEROD, M.G.: ""Flow Cytometry"", 1999, BIOS SCIENTIFIC PUBLISHERS;;MICHAEL G. ORMEROD, FLOW CYTOMETRY -A BASIC INTRODUCTION, 2008;;BEHRENDS, NATURE, vol. 466, no. 7302, 1 July 2010 (2010-07-01), pages 68 - 76;;GLICK ET AL., J PATHOL., vol. 221, no. l, May 2010 (2010-05-01), pages 3 - 12;;ROSENBERG, NAT REV CLIN ONCOL, vol. 8, no. 10, 2011, pages 577 - 85;;THEMELI ET AL., NAT BIOTECHNOL., vol. 31, no. 10, 2013, pages 928 - 933;;TSUKAHARA ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 438, no. 1, 2013, pages 84 - 9;;DAVILA ET AL., PLOS ONE, vol. 8, no. 4, 2013, pages e61338;;CARCELLER ET AL., PEDIATR BLOOD CANCER, vol. 63, no. 8, 2016, pages 1400 - 1406;;EISENHAUER ET AL., EUR J CANCER, vol. 45, no. 2, 2009, pages 228 - 247;;MONSKY ET AL., ANTICANCER RES., vol. 32, no. 11, 2012, pages 4951 - 4961;;ROBERTS ET AL., N ENGL J MED, vol. 371, no. 11, 2014, pages 1005 - 1015;;ROBERTS ET AL., CANCER CELL, vol. 22, no. 2, 2012, pages 153 - 66;;PEREZ-ANDREU ET AL., NATURE GENETICS, vol. 45, no. 12, 2013, pages 1494 - 1498;;YAP ET AL., LEUK LYMPHOMA, vol. 58, no. 4, 2017, pages 950 - 958;;ROBERTS ET AL., J CLIN ONCOL, vol. 35, no. 4, 2017, pages 394 - 401;;HARVEY ET AL., BLOOD, vol. 122, 2013, pages 826;;HARVEY ET AL., BLOOD, vol. 116, no. 23, 2010, pages 4874 - 4884;;KOCHENDERFER ET AL., J. IMMUNOTHERAPY, vol. 32, no. 7, 2009, pages 689 - 702;;HERMAN ET AL., J. IMMUNOLOGICAL METHODS, vol. 285, no. 1, 2004, pages 25 - 40;;""Remington's Pharmaceutical Sciences"", 1980, MACK PUB. CO.;;HARMURN, C. H. ET AL., NATURE, vol. 343, 1990, pages 336 - 340;;GONG ET AL., J EXP MED., vol. 186, no. 1, 7 July 1997 (1997-07-07), pages 131 - 137;;SHAHRARA ET AL., J IMMUNOL, vol. 180, 2008, pages 3447 - 3456;;DOBBER ET AL., CELL IMMUNOL., vol. 160, no. 2, February 1995 (1995-02-01), pages 185 - 92;;OZMEN ET AL., J IMMUNOL., vol. 150, no. 7, 1 April 1993 (1993-04-01), pages 2698 - 705;;HUNTER ET AL., J IMMUNOL., vol. 174, no. 11, 1 June 2005 (2005-06-01), pages 7368 - 75;;SADELAIN ET AL., CANCER DISCOV., vol. 3, no. 4, 2013, pages 388 - 398;;TURTLE ET AL., CURR. OPIN. IMMUNOL., vol. 24, no. 5, 2012, pages 633 - 39;;WU ET AL., CANCER, vol. 18, no. 2, 2012, pages 160 - 75;;KOCHENDERFER ET AL., NATURE REVIEWS CLINICAL ONCOLOGY, vol. 10, 2013, pages 267 - 276;;WANG ET AL., J. IMMUNOTHER., vol. 35, no. 9, 2012, pages 689 - 701;;BRENTJENS ET AL., SCI TRANSLMED, vol. 5, no. 177, 2013;;LING, N. R. ET AL., LEUCOCYTE TYPING III, 1987, pages 302;;URBANSKA ET AL., CANCER RES, vol. 72, 2012, pages 1844 - 1852;;TAMADA ET AL., CLIN CANCER RES, vol. 18, 2012, pages 6436 - 6445;;COHEN CJ. ET AL., J MOL. RECOGN., vol. 16, 2003, pages 324 - 332;;KINDT ET AL.: ""Kuby Immunology"", 2007, W.H. FREEMAN AND CO., pages: 91;;PORTOLANO ET AL., J. IMMUNOL., vol. 150, 1993, pages 880 - 887;;CLARKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628;;HUDECEK ET AL., CLIN. CANCER RES., vol. 19, 2013, pages 3153;;JORES ET AL., PROC. NAT'L ACAD. SCI. U.S.A., vol. 87, 1990, pages 9138;;CHOTHIA ET AL., EMBO J., vol. 7, 1988, pages 3745;;LEFRANC ET AL., DEV. COMP. IMMUNOL., vol. 27, 2003, pages 55;;KOTB, CLINICAL MICROBIOLOGY REVIEWS, vol. 8, 1995, pages 411 - 426;;JANEWAY ET AL.: ""Immunobiology: The Immune System in Health and Disease"", 1997, CURRENT BIOLOGY PUBLICATIONS, pages: 4,33;;KABAT ET AL.: ""Sequences of Proteins of Immunological Interest"", 1991, US DEPT. HEALTH AND HUMAN SERVICES;;HOLLER ET AL., NAT IMMUNOL, vol. 4, 2003, pages 55 - 62;;HOLLER ET AL., PROC NATL ACAD SCI USA, vol. 97, 2000, pages 5387 - 92;;LI ET AL., NAT BIOTECHNOL, vol. 23, 2005, pages 349 - 54;;CHERVIN ET AL., J IMMUNOL METHODS, vol. 339, 2008, pages 175 - 84;;SINGH; RAGHAVA, BIOINFORMATICS, vol. 17, no. 12, 2001, pages 1236 - 1237;;SCHULER ET AL., IMMUNOINFORMATICS METHODS IN MOLECULAR BIOLOGY, vol. 409, no. 1, 2007, pages 75 - 93;;SINGH; RAGHAVA: ""ProPred: prediction of HLA-DR binding sites"", BIOINFORMATICS, vol. 17, no. 12, 2001, pages 1236 - 1237, XP002371461, DOI: doi:10.1093/bioinformatics/17.12.1236;;SCHULER ET AL.: ""SYFPEITHI, Database for Searching and T-Cell Epitope Prediction"", IMMUNOINFORMATICS METHODS IN MOLECULAR BIOLOGY, vol. 409, no. 1, 2007, pages 75 - 93;;HOO, W. F. ET AL., PNAS (USA, vol. 89, 1992, pages 4759;;WIILFING, C.; PLIICKTHUN, A., J. MOL. BIOL., vol. 242, 1994, pages 655;;KURUCZ, I. ET AL., PNAS (USA), vol. 90, 1993, pages 3830;;SCHLUETER, C. J. ET AL., J. MOL. BIOL., vol. 256, 1996, pages 859;;FEDOROV ET AL., SCI. TRANSL. MEDICINE, vol. 5, no. 215, 2013;;TERAKURAET, BLOOD, vol. 1, 2012, pages 72 - 82;;WANG ET AL., J IMMUNOTHER., vol. 35, no. 9, 2012, pages 689 - 701;;""Methods in Molecular Medicine"", vol. 58;;""Cell Behavior In Vitro and In Vivo"", vol. 2, HUMANA PRESS INC., article ""Metastasis Research Protocols"", pages: 17 - 25;;KLEBANOFF ET AL., J IMMUNOTHER., vol. 35, no. 9, 2012, pages 651 - 660;;WANG ET AL., J IMMUNOTHER, vol. 35, no. 9, 2012, pages 689 - 701;;CHO ET AL., LAB CHIP, vol. 10, 2010, pages 1567 - 1573;;GODIN ET AL., J BIOPHOTON, vol. 1, no. 5, 2008, pages 355 - 376;;KLEBANOFF ET AL., J IMMUNOTHER, vol. 35, no. 9, 2012, pages 651 - 660;;COOPER ET AL., BLOOD, vol. 101, 2003, pages 1637 - 1644;;VERHOEYEN ET AL., METHODS MOL BIOL., vol. 506, 2009, pages 97 - 114;;CAVALIERI ET AL., BLOOD, vol. 102, no. 2, 2003, pages 497 - 505;;WIGLER ET AL., CELL II, vol. 223, 1977;;MULLEN ET AL., PROC. NATL. ACAD. SCI. USA., vol. 89, 1992, pages 33;;KOSTE ET AL., GENE THERAPY, 3 April 2014 (2014-04-03);;CARLENS ET AL., EXP HEMATOL, vol. 28, no. 10, 2000, pages 1137 - 46;;ALONSO-CAMINO ET AL., MOL THER NUCL ACIDS, vol. 2, 2013, pages e93;;PARK ET AL., TRENDS BIOTECHNOL, vol. 11, 29 November 2011 (2011-11-29), pages 550 - 557;;BAUM ET AL., MOLECULAR THERAPY: THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, vol. 13, 2006, pages 1050 - 1063;;FRECHA ET AL., MOLECULAR THERAPY, vol. 18, 2010, pages 1748 - 1757;;HACKETT ET AL., MOLECULAR THERAPY, vol. 18, 2010, pages 674 - 683;;FELIPE, GENETIC VACCINES AND THER., vol. 2, 2004, pages 13;;DE FELIPE ET AL., TRAFFIC, vol. 5, 2004, pages 616 - 626;;CHALLITA ET AL., J. VIROL., vol. 69, no. 2, 1995, pages 748 - 755;;LUPTON S. D. ET AL., MOL. AND CELL BIOL., vol. 11, 1991, pages 6;;RIDDELL ET AL., HUMAN GENE THERAPY, vol. 3, 1992, pages 319 - 338;;DE FELIPE, GENETIC VACCINES AND THER., vol. 2, 2004, pages 13;;DEFELIPE ET AL., TRAFFIC, vol. 5, 2004, pages 616 - 626;;LIU ET AL., NATURE BIOTECH., vol. 34, no. 4, April 2016 (2016-04-01), pages 430 - 434;;MILLER; ROSMAN, BIOTECHNIQUES, vol. 7, 1989, pages 980 - 990;;MILLER, A. D., HUMAN GENE THERAPY, vol. 1, 1990, pages 5 - 14;;SCARPA ET AL., VIROLOGY, vol. 180, 1991, pages 849 - 852;;BURNS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 8033 - 8037;;BORIS-LAWRIE; TEMIN, CUR. OPIN. GENET. DEVELOP., vol. 3, 1993, pages 102 - 109;;CHICAYBAM ET AL., PLOS ONE, vol. 8, no. 3, 2013, pages e60298;;VAN TEDELOO ET AL., GENE THERAPY, vol. 7, no. 16, 2000, pages 1431 - 1437;;MANURI ET AL., HUM GENE THER, vol. 21, no. 4, 2010, pages 427 - 437;;SHARMA ET AL., MOLEC THER NUCL ACIDS, vol. 2, 2013, pages e74;;HUANG ET AL., METHODS MOL BIOL, vol. 506, 2009, pages 115 - 126;;""Current Protocols in Molecular Biology"", JOHN WILEY & SONS;;JOHNSTON, NATURE, vol. 346, 1990, pages 776 - 777;;BRASH ET AL., MOL. CELL BIOL., vol. 7, 1987, pages 2031 - 2034;;CHEADLE ET AL.: ""Chimeric antigen receptors for T-cell based therapy"", METHODS MOL BIOL., vol. 907, 2012, pages 645 - 66, XP009179541, DOI: doi:10.1007/978-1-61779-974-7_36;;BARRETT ET AL., CHIMERIC ANTIGEN RECEPTOR THERAPY FOR CANCER ANNUAL REVIEW OF MEDICINE, vol. 65, 2014, pages 333 - 347;;""Remington's Pharmaceutical Sciences"", 1980;;""Remington: The Science and Practice of Pharmacy"", 1 May 2005, LIPPINCOTT WILLIAMS & WILKINS;;""Common Terminology for Adverse Events (CTCAE"", vol. 4.03, 28 May 2009, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES",PENDING
272,AU,A1,AU 2018/224856 A1,117-947-635-900-745,2019-08-29,2019,AU 2018/224856 A,2018-02-27,US 201762580416 P;;US 201762470180 P;;US 201762527002 P;;US 201762464371 P;;US 201762465817 P;;US 201762584740 P;;US 201762596703 P;;US 2018/0020054 W,2017-02-27,"Compositions, articles of manufacture and methods related to dosing in cell therapy","Provided herein are methods, compositions and articles of manufacture for use in connection with cell therapy involving the administration of one or more doses of a therapeutic T cell composition. The cells of the T cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the provided embodiments, including the numbers of cells or units of cells administered and/or the potency of administered cells, provide various advantages, such as lower risk of toxicity in subjects administered the T cell compositions.",JUNO THERAPEUTICS INC,CHRISTIN BRIAN;;COVINGTON MICHAEL GERARD;;DAVE KEDAR HIMANSHU;;GETTO JR RICHARD JAMES;;KOWSKI TOM;;LARSON RYAN P;;RAMSBORG CHRISTOPHER GLEN;;TREDE NIKOLAUS SEBASTIAN;;WEBER CLINTON;;WHITMORE JAMES BOYD;;YEE NATHAN;;BEAUCHESNE PASCAL;;BECKETT TRAVIS;;BLACKMAN SAMUEL CHARLES;;CHARTRAND NATHANIEL;;DAVIS-PICKETT MEL;;GILBERT MARK;;LAMBERT NATHANIEL;;LI HE;;MALLANEY MARY;;POLLOCK KATHRYN LINDSAY;;ODEGARD VALERIE;;SMITH JEFF;;SUTHERLAND CLAIRE;;WALKER ANDREW W,,https://lens.org/117-947-635-900-745,Patent Application,no,0,0,16,16,0,C07K14/7051;;C12N5/0636;;C07K2319/03;;C07K2319/33;;A61P35/00;;A61P35/02;;A61K39/4611;;A61K39/4631;;A61K39/464412;;A61K2239/48;;A61K35/17;;A61P35/00;;A61P35/02;;C07K14/7051;;C12N5/0636;;C07K2319/03;;C07K2319/33;;A61K35/17;;C12N5/0636;;C12N2510/00;;G01N33/5091;;G01N33/6869;;G01N2800/28;;G01N2800/42,A61K35/17,,0,0,,,,PENDING
273,US,A1,US 2020/0191774 A1,127-971-301-514-134,2020-06-18,2020,US 201816488935 A,2018-02-27,US 201816488935 A;;US 201762464371 P;;US 201762465817 P;;US 201762470180 P;;US 201762527002 P;;US 201762580416 P;;US 201762584740 P;;US 201762596703 P;;US 2018/0020054 W,2017-02-27,"COMPOSITIONS, ARTICLES OF MANUFACTURE AND METHODS RELATED TO DOSING IN CELL THERAPY","Provided herein are methods, compositions and articles of manufacture for use in connection with cell therapy involving the administration of one or more doses of a therapeutic T cell composition. The cells of the T cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the provided embodiments, including the numbers of cells or units of cells administered and/or the potency of administered cells, provide various advantages, such as lower risk of toxicity in subjects administered the T cell compositions.",JUNO THERAPEUTICS INC,CHRISTIN BRIAN;;COVINGTON MICHAEL GERARD;;DAVE KEDAR HIMANSHU;;GETTO JR RICHARD JAMES;;KOWSKI TOM;;LARSON RYAN P;;RAMSBORG CHRISTOPHER GLEN;;TREDE NIKOLAUS SEBASTIAN;;WEBER CLINTON;;WHITMORE JAMES BOYD;;YEE NATHAN;;BEAUCHESNE PASCAL;;BECKETT TRAVIS;;BLACKMAN SAMUEL CHARLES;;CHARTRAND NATHANIEL;;DAVIS-PICKETT MEL;;GILBERT MARK;;LAMBERT NATHANIEL;;LI HE;;MALLANEY MARY;;POLLOCK KATHRYN LINDSAY;;ODEGARD VALERIE;;SMITH JEFF;;SUTHERLAND CLAIRE;;WALKER ANDREW W,JUNO THERAPEUTICS INC (2019-10-03),https://lens.org/127-971-301-514-134,Patent Application,yes,0,3,16,16,58,C07K14/7051;;C12N5/0636;;C07K2319/03;;C07K2319/33;;A61P35/00;;A61P35/02;;A61K39/4611;;A61K39/4631;;A61K39/464412;;A61K2239/48;;A61K35/17;;A61P35/00;;A61P35/02;;C07K14/7051;;C12N5/0636;;C07K2319/03;;C07K2319/33;;A61K35/17;;C12N5/0636;;C12N2510/00;;G01N33/5091;;G01N33/6869;;G01N2800/28;;G01N2800/42,A61K35/17;;G01N33/50;;C12N5/0783;;G01N33/68,,4,4,140-283-171-635-609;;077-793-227-338-61X;;071-538-655-750-401;;066-686-648-408-054,10.1182/blood-2011-10-384362;;pmc3390963;;22496150;;32612263;;10.1038/s41573-020-0064-x;;31099694;;10.1200/edbk_238691;;10.1007/s11033-011-1205-4;;21769475,"Bergamaschi et al., Blood. 2012; 120(1): e1-e8 (Year: 2012);;Erin Kimbrel and Robert Lanza, Nature Reviews Drug Discovery, 2020; 19: 463-479 (Year: 2020);;Santomasso et al., Am Soc Clin Oncol Educ Book, 2019; 39: 433-444 (Year: 2019);;Tao et al., Mol Biol Rep (2012) 39:4201-4205 (Year: 2012)",PENDING
274,CA,A1,CA 3053539 A1,179-789-223-819-80X,2018-08-30,2018,CA 3053539 A,2018-02-27,US 201762464371 P;;US 201762465817 P;;US 201762470180 P;;US 201762527002 P;;US 201762580416 P;;US 201762584740 P;;US 201762596703 P;;US 2018/0020054 W,2017-02-27,"COMPOSITIONS, ARTICLES OF MANUFACTURE AND METHODS RELATED TO DOSING IN CELL THERAPY","Provided herein are methods, compositions and articles of manufacture for use in connection with cell therapy involving the administration of one or more doses of a therapeutic T cell composition. The cells of the T cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the provided embodiments, including the numbers of cells or units of cells administered and/or the potency of administered cells, provide various advantages, such as lower risk of toxicity in subjects administered the T cell compositions.",JUNO THERAPEUTICS INC,CHRISTIN BRIAN;;DAVE KEDAR HIMANSHU;;GETTO RICHARD JAMES;;KOWSKI TOM;;LARSON RYAN P;;RAMSBORG CHRISTOPHER GLEN;;TREDE NIKOLAUS SEBASTIAN;;WEBER CLINTON;;WHITMORE JAMES BOYD;;YEE NATHAN;;BEAUCHESNE PASCAL;;BECKETT TRAVIS;;CHARTRAND NATHANIEL;;DAVIS-PICKETT MEL;;GILBERT MARK;;LAMBERT NATHANIEL;;LI HE;;MALLANEY MARY;;POLLOCK KATHRYN LINDSAY;;ODEGARD VALERIE;;SMITH JEFF;;SUTHERLAND CLAIRE;;WALKER ANDREW W;;COVINGTON MICHAEL GERARD;;BLACKMAN SAMUEL CHARLES,,https://lens.org/179-789-223-819-80X,Patent Application,no,0,0,16,16,58,C07K14/7051;;C12N5/0636;;C07K2319/03;;C07K2319/33;;A61P35/00;;A61P35/02;;A61K39/4611;;A61K39/4631;;A61K39/464412;;A61K2239/48;;A61K35/17;;A61P35/00;;A61P35/02;;C07K14/7051;;C12N5/0636;;C07K2319/03;;C07K2319/33;;A61K35/17;;C12N5/0636;;C12N2510/00;;G01N33/5091;;G01N33/6869;;G01N2800/28;;G01N2800/42,A61K35/17,,0,0,,,,PENDING
275,EP,A2,EP 3585402 A2,139-671-069-466-65X,2020-01-01,2020,EP 18710284 A,2018-02-27,US 201762464371 P;;US 201762465817 P;;US 201762470180 P;;US 201762527002 P;;US 201762580416 P;;US 201762584740 P;;US 201762596703 P;;US 2018/0020054 W,2017-02-27,"COMPOSITIONS, ARTICLES OF MANUFACTURE AND METHODS RELATED TO DOSING IN CELL THERAPY",,JUNO THERAPEUTICS INC,CHRISTIN BRIAN;;COVINGTON MICHAEL GERARD;;DAVE KEDAR HIMANSHU;;GETTO RICHARD JAMES JR;;KOWSKI TOM;;LARSON RYAN P;;RAMSBORG CHRISTOPHER GLEN;;TREDE NIKOLAUS SEBASTIAN;;WEBER CLINTON;;WHITMORE JAMES BOYD;;YEE NATHAN;;BEAUCHESNE PASCAL;;BECKETT TRAVIS;;BLACKMAN SAMUEL CHARLES;;CHARTRAND NATHANIEL;;DAVIS-PICKETT MEL;;GILBERT MARK;;LAMBERT NATHANIEL;;LI HE;;MALLANEY MARY;;POLLOCK KATHRYN LINDSAY;;ODEGARD VALERIE;;SMITH JEFF;;SUTHERLAND CLAIRE;;WALKER ANDREW W,,https://lens.org/139-671-069-466-65X,Patent Application,yes,0,0,16,16,0,C07K14/7051;;C12N5/0636;;C07K2319/03;;C07K2319/33;;A61P35/00;;A61P35/02;;A61K39/4611;;A61K39/4631;;A61K39/464412;;A61K2239/48;;A61K35/17;;A61P35/00;;A61P35/02;;C07K14/7051;;C12N5/0636;;C07K2319/03;;C07K2319/33;;A61K35/17;;C12N5/0636;;C12N2510/00;;G01N33/5091;;G01N33/6869;;G01N2800/28;;G01N2800/42,A61K35/17,,0,0,,,,ACTIVE
276,MX,A,MX 2019010171 A,031-673-736-438-285,2019-10-15,2019,MX 2019010171 A,2018-02-27,US 201762464371 P;;US 201762465817 P;;US 201762470180 P;;US 201762527002 P;;US 201762580416 P;;US 201762584740 P;;US 201762596703 P;;US 2018/0020054 W,2017-02-27,"COMPOSITIONS, ARTICLES OF MANUFACTURE AND METHODS RELATED TO DOSING IN CELL THERAPY.","Provided herein are methods, compositions and articles of manufacture for use in connection with cell therapy involving the administration of one or more doses of a therapeutic T cell composition. The cells of the T cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the provided embodiments, including the numbers of cells or units of cells administered and/or the potency of administered cells, provide various advantages, such as lower risk of toxicity in subjects administered the T cell compositions.",JUNO THERAPEUTICS INC,PASCAL BEAUCHESNE;;VALERIE ODEGARD;;MARK GILBERT;;JEFF SMITH;;BRIAN CHRISTIN;;HE LI;;MICHAEL GERARD COVINGTON;;KEDAR HIMANSHU DAVE;;RICHARD JAMES JR GETTO;;TOM KOWSKI;;RYAN P LARSON;;CHRISTOPHER GLEN RAMSBORG;;NIKOLAUS SEBASTIAN TREDE;;CLINTON WEBER;;JAMES BOYD WHITMORE;;NATHAN YEE;;TRAVIS BECKETT;;SAMUEL CHARLES BLACKMAN;;NATHANIEL CHARTRAND;;MEL DAVIS-PICKETT;;NATHANIEL LAMBERT;;MARY MALLANEY;;KATHRYN LINDSAY POLLOCK;;CLAIRE SUTHERLAND;;ANDREW W WALKER,,https://lens.org/031-673-736-438-285,Patent Application,no,0,0,16,16,0,C07K14/7051;;C12N5/0636;;C07K2319/03;;C07K2319/33;;A61P35/00;;A61P35/02;;A61K39/4611;;A61K39/4631;;A61K39/464412;;A61K2239/48;;A61K35/17;;A61P35/00;;A61P35/02;;C07K14/7051;;C12N5/0636;;C07K2319/03;;C07K2319/33;;A61K35/17;;C12N5/0636;;C12N2510/00;;G01N33/5091;;G01N33/6869;;G01N2800/28;;G01N2800/42,A61K35/17,,0,0,,,,PENDING
277,BR,A2,BR 112019017767 A2,180-698-437-030-97X,2020-04-07,2020,BR 112019017767 A,2018-02-27,US 2018/0020054 W;;US 201762464371 P;;US 201762465817 P;;US 201762470180 P;;US 201762527002 P;;US 201762580416 P;;US 201762584740 P;;US 201762596703 P,2017-02-27,"composições, artigos de fabricação e métodos relacionados à dosagem em terapia celular","a presente invenção refere-se a métodos, composições e artigos de fabricação para uso em conexão com terapia celular envolvendo a administração de uma ou mais doses de uma composição terapêutica de célula t. as células da composição de célula t expressam receptores recombinantes tais como receptores quiméricos, por exemplo, receptores de antígenos quiméricos (cars) ou outros receptores transgênicos tal como receptores de célula t (tcrs). características das modalidades fornecidas, incluindo os números de células ou unidades de células administradas e/ou a potência de células administradas, fornecem várias vantagens, tal como menor risco de toxicidade em indivíduos administrados com composição de células t.",JUNO THERAPEUTICS INC,ANDREW W WALKER;;BRIAN CHRISTIN;;CHRISTOPHER GLEN RAMSBORG;;CLAIRE SUTHERLAND;;CLINTON WEBER;;HE LI;;JAMES BOYD WHITMORE;;JEFF SMITH;;KATHRYN LINDSAY POLLOCK;;KEDAR HIMANSHU DAVE;;MARK GILBERT;;MARY MALLANEY;;MEL DAVIS-PICKETT;;MICHAEL GERARD COVINGTON;;NATHAN YEE;;NATHANIEL CHARTRAND;;NATHANIEL LAMBERT;;NIKOLAUS SEBASTIAN TREDE;;PASCAL BEAUCHESNE;;RICHARD JAMES GETTO JR;;RYAN P LARSON;;SAMUEL CHARLES BLACKMAN;;TOM KOWSKI;;TRAVIS BECKETT;;VALERIE ODEGARD,,https://lens.org/180-698-437-030-97X,Patent Application,no,0,0,16,16,0,C07K14/7051;;C12N5/0636;;C07K2319/03;;C07K2319/33;;A61P35/00;;A61P35/02;;A61K39/4611;;A61K39/4631;;A61K39/464412;;A61K2239/48;;A61K35/17;;A61P35/00;;A61P35/02;;C07K14/7051;;C12N5/0636;;C07K2319/03;;C07K2319/33;;A61K35/17;;C12N5/0636;;C12N2510/00;;G01N33/5091;;G01N33/6869;;G01N2800/28;;G01N2800/42,A61K35/17,,0,0,,,,PENDING
278,KR,A,KR 20200010179 A,049-149-548-916-852,2020-01-30,2020,KR 20197028511 A,2018-02-27,US 201762464371 P;;US 201762465817 P;;US 201762470180 P;;US 201762527002 P;;US 201762580416 P;;US 201762584740 P;;US 201762596703 P;;US 2018/0020054 W,2017-02-27,"세포 요법에 있어서 투약과 관련된 조성물, 제조 물품 및 방법","본원에 따라 1 이상의 용량으로 치료용 T 세포 조성물을 투여하는 것과 관련된, 세포 요법과 관련하여 사용하기 위한 방법, 조성물들 및 제조 물품이 제공된다. T 세포 조성물의 세포는 재조합 수용체 이를테면 키메라 수용체, 예컨대 키메라 항원 수용체 (CARs) 또는 다른 트랜스제닉 수용체 이를테면 T 세포 수용체 (TCRs)를 발현한다. 투여된 세포 또는 세포 단위의 수 및/또는 투여된 세포의 효력을 비롯한, 제공된 구현예의 특성들은 T 세포 조성물이 투여된 대상체에 있어서 이를테면 독성 위험을 낮추는 것과 같은 다양한 이점을 제공한다.",JUNO THERAPEUTICS INC,CHRISTIN BRIAN;;COVINGTON MICHAEL GERARD;;DAVE KEDAR HIMANSHU;;GETTO RICHARD JAMES JR;;KOWSKI TOM;;LARSON RYAN P;;RAMSBORG CHRISTOPHER GLEN;;TREDE NIKOLAUS SEBASTIAN;;WEBER CLINTON;;WHITMORE JAMES BOYD;;YEE NATHAN;;BEAUCHESNE PASCAL;;BECKETT TRAVIS;;BLACKMAN SAMUEL CHARLES;;CHARTRAND NATHANIEL;;DAVIS PICKETT MEL;;GILBERT MARK;;LAMBERT NATHANIEL;;LI HE;;MALLANEY MARY;;POLLOCK KATHRYN LINDSAY;;ODEGARD VALERIE;;SMITH JEFF;;SUTHERLAND CLAIRE;;WALKER ANDREW W,,https://lens.org/049-149-548-916-852,Patent Application,no,0,0,16,16,0,C07K14/7051;;C12N5/0636;;C07K2319/03;;C07K2319/33;;A61P35/00;;A61P35/02;;A61K39/4611;;A61K39/4631;;A61K39/464412;;A61K2239/48;;A61K35/17;;A61P35/00;;A61P35/02;;C07K14/7051;;C12N5/0636;;C07K2319/03;;C07K2319/33;;A61K35/17;;C12N5/0636;;C12N2510/00;;G01N33/5091;;G01N33/6869;;G01N2800/28;;G01N2800/42,A61K35/17;;A61P35/00;;A61P35/02;;C07K14/725;;C12N5/0783,,0,0,,,,DISCONTINUED
279,EP,B1,EP 3585402 B1,095-125-789-415-444,2024-03-06,2024,EP 18710284 A,2018-02-27,US 201762464371 P;;US 201762465817 P;;US 201762470180 P;;US 201762527002 P;;US 201762580416 P;;US 201762584740 P;;US 201762596703 P;;US 2018/0020054 W,2017-02-27,"COMPOSITIONS, ARTICLES OF MANUFACTURE AND METHODS RELATED TO DOSING IN CELL THERAPY",,JUNO THERAPEUTICS INC,CHRISTIN BRIAN;;COVINGTON MICHAEL GERARD;;DAVE KEDAR HIMANSHU;;GETTO RICHARD JAMES JR;;KOWSKI TOM;;LARSON RYAN P;;RAMSBORG CHRISTOPHER GLEN;;TREDE NIKOLAUS SEBASTIAN;;WEBER CLINTON;;WHITMORE JAMES BOYD;;YEE NATHAN;;BEAUCHESNE PASCAL;;BECKETT TRAVIS;;BLACKMAN SAMUEL CHARLES;;CHARTRAND NATHANIEL;;DAVIS-PICKETT MEL;;GILBERT MARK;;LAMBERT NATHANIEL;;LI HE;;MALLANEY MARY;;POLLOCK KATHRYN LINDSAY;;ODEGARD VALERIE;;SMITH JEFF;;SUTHERLAND CLAIRE;;WALKER ANDREW W,,https://lens.org/095-125-789-415-444,Granted Patent,yes,1,0,16,16,0,C07K14/7051;;C12N5/0636;;C07K2319/03;;C07K2319/33;;A61P35/00;;A61P35/02;;A61K39/4611;;A61K39/4631;;A61K39/464412;;A61K2239/48;;A61K35/17;;A61P35/00;;A61P35/02;;C07K14/7051;;C12N5/0636;;C07K2319/03;;C07K2319/33;;A61K35/17;;C12N5/0636;;C12N2510/00;;G01N33/5091;;G01N33/6869;;G01N2800/28;;G01N2800/42,A61P35/00;;A61K39/00;;A61P35/02;;C07K14/725;;C12N5/0783,,3,0,,,"KLAVER YARNE ET AL: ""Adoptive T-cell therapy: a need for standard immune monitoring."", IMMUNOTHERAPY 2015, vol. 7, no. 5, 2015, pages 513-533, XP9506029, ISSN: 1750-7448;;JENNIFER N. BRUDNO ET AL: ""Toxicities of chimeric antigen receptor T cells: recognition and management"", BLOOD, vol. 127, no. 26, 20 May 2016 (2016-05-20) , pages 3321-3330, XP055442400, US ISSN: 0006-4971, DOI: 10.1182/blood-2016-04-703751;;D. L. PORTER ET AL: ""Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia"", SCIENCE TRANSLATIONAL MEDICINE, vol. 7, no. 303, 2 September 2015 (2015-09-02), pages 1-13, XP055411906, US ISSN: 1946-6234, DOI: 10.1126/scitranslmed.aac5415",ACTIVE
